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 Recent evidence suggests that 18 - 29% of eukaryotic genomes encode 
enzymes which are critical to the vital functioning of living system. However, only a 
limited proportion of these enzymes have thus far been studied, characterized, and 
little is understood about the physiological roles, substrate specificity and downstream 
targets of the vast majority of these important proteins. A key step towards the 
biological characterization of enzymes, as well as in their adoption as drug targets, is 
the development of global solutions that bridge the gap in understanding proteins and 
their interactions, especially in complex environments. This thesis examines and 
addresses these challenges by integration a series of technologies that span various 
analytical modes, effectively expanding current capabilities in protein profiling by 
leveraging on throughput. These include small molecule microarray (Chapter 2 and 3) 
and microplate (Chapters 4 & 5) platforms. Chapter 2 describes a novel peptide 
aldehyde microarray for rapid differentiation of infection stages in cellular level, and 
characterized the potential enzyme targets of identified compounds. Chapter 3 
presents a novel hybrid small molecule library that enables the development of 
inhibitor targeting 14-3-3 protein interaction in vivo. Chapter 4 shows a robust 
screening and analysis of inhibitor library against various protein tyrosine 
phosphatase. Chapter 5 demonstrates an oriented library designed targeting caspases. 
Cohesively, the approaches are applied (but not limited) to investigations of certain 
classes of enzymes or proteins, but also provide functional insight into complex 
biological dynamics that orchestrate the remarkable enigma of life. 
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 Microarrays have carved an impressive niche for high-throughput research 
over the last two decades. DNA microarrays, for instance, originally invented and 
applied in the 1990s, have now become one of the most dominant research tools for 
genetics and genomics, specifically in the areas of expression profiling, genotyping 
and copy number variation (CNV) analysis. The turn of the century witnessed the 
development of small molecule, protein, cell and tissue microarrays, heralding a new 
era of discovery-driven research using a host of different chemical libraries, 
biomolecules and tissue types. This chapter takes stock of this first decade of small 
molecule microarrays (SMMs) and describes how the technology has matured into a 
robust screening platform over these recent years. We also highlight the many 
interesting and unique applications appearing using small molecule microarrays, in 
order to project forward to possible areas in which SMMs could dominate, perhaps 





1.2 Small Molecule Microarrays: The First Decade and Beyond 
 Microarrays are miniaturized assemblies of molecules organized across a 
planar surface.1,2 The precise physical position of each spot (or feature) on the array 
encodes its molecular identity. Libraries ranging anywhere from the hundreds to tens 
of thousands of different compounds may be densely gridded on planar surfaces, 
typically glass slides. Immobilization using a variety of covalent and non-covalent 
chemical ligation methods has become the dominant way in which SMMs are 
fabricated, but several sophisticated methods using in situ synthesis and selective 
deposition have also been developed.3-5 Fluorescence imaging remains the preferred 
way in which interactions are measured on microarrays, with several alternative 
imaging modalities also developed.6-8 The beauty of having so many different 
molecules available within a compact surface (which may be conveniently mass 
produced), is that it provides an unprecedented means for massively parallel screening 
against multiple targets of choice, while consuming low quantities of both precious 
samples and analytes (Figure 1.1). Throughput and scalability are the core features of 
microarray technology, key drivers that have expanded its application envelope. This 
review describes the journey of SMMs, and highlights the most interesting recent 
applications that could chart its future. 
 The first class of molecules that successfully capitalized on the throughput 
offered by microarrays was DNA.9 This breakthrough happened in the mid-1990s, to 
the credit of Fodor et al.10 and Brown and colleagues,11,12 and has led to the DNA 
microarray revolution. DNA microarrays are pervasively used today in a wide range 
of applications, spanning both research and industry, from cancer gene discovery to 
direct-to-consumer genetics.13 (A search in ISI Web of Science in Aug 2010 revealed 




Figure 1.1 Small molecule microarray based screening. (A) Small molecules from a 
variety of sources, including combinatorial chemistry library, nature products, and 
commercial compound collections are arrayed onto chemical modified surfaces. (B) 
Screening and detection of samples by incubation and applications on the microarrays, 
followed by fluorescence scanning using microarray readers. (C) Potential hits are 
identified for lead development. In addition the overall binding fingerprint could also 
lead to valuable pharmacophores or comparative profiling of proteins. Probes may 
also be designed from the hits identified, to pull down and identify known and 
unknown protein targets. 
 
 
It was nearly 5 long years after the discovery and application of the DNA microarrays 
that immobilization strategies were developed to immobilize molecules other than 
DNA on glass surfaces. In general, these platforms adopted the same infrastructure 
and instruments that were already in use for DNA microarrays. Accordingly, these 
other microarray types have a shorter history and timeline of development. 
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(Nevertheless, over 7000 articles have been published using these newer classes of 
microarrays, as searched in ISI WOS in Aug 2010, Figure 1.2) 
 
Figure 1.2 Yearly publication numbers in the field of microarrays over the period 
from 1995 to Aug 2010. Articles are segregated by type: DNA microarrays in blue, 
emerging non-DNA based microarrays in red. 
 
 
 SMMs, as we know them today, thus trace their origins to 1999, when 
Schreiber et al. immobilized thiolated versions of biotin, digoxigenin steroid and an 
FKBP12 ligand on maleimide derivatized glass surfaces.14 The respective target 
proteins bound successfully to the respective compounds on the microarray, and were 
detected under fluorescence. It was only after this milestone was achieved that various 
methods of immobilizing peptides,15-17 chemical libraries,18,19 carbohydrates20-23 and 
other kinds of small molecules (like peptidomimetics24) began appearing, all after the 
turn of the century, covering the different sub-classes of SMMs. Schreiber’s group 
went on in 2002 to discover the first ligand for a protein target, uretupamine using an 
SMM comprising of 3780 compounds.25 Notably, Schultz et al. also developed an 
alternative style of SMMs using PNA tags, where the small molecule libraries 




 Peptide microarrays emerged as a broad and interesting class in themselves, 
with applications in serological testing and enzyme profiling.15 A variety of classes of 
enzymes, notably kinases, phosphatases and proteases have been profiled using 
peptide microarrays.29,30 This SMM sub-class will thus only be discussed briefly in 
this chapter, further interest will be referred elsewhere, to more comprehensive recent 
reviews.15,31 Other types of microarrays were also developed during the early years of 
the 21st century, namely protein,32 membrane protein,33 proteome,34 cell,35,36 and 
tissue microarrays,37 each possessing unique properties and filling different niche 
applications.  
 We will begin this chapter by describing key developments in library synthesis 
and microarray fabrication. We will then go on to showcase specific examples of 
SMM technology, which has been recently applied, followed by our conclusion and 
the challenges and prospects we think the next decade will bring. 
 
1.2.1 Library Design and Synthesis 
 In this section we will discuss early developments and conceptual changes in 
the ways microarrays have been applied. This includes the kinds of chemical 
strategies used to fabricate libraries of compounds, the tags that have been utilized as 
well as the corresponding surfaces developed for immobilization onto glass slides.  
 Even though there are examples of SMMs that have applied natural compound 
libraries, the majority of SMMs are fabricated using synthetic combinatorial libraries. 
This is perhaps because it has been more complex to develop a method to stably 
immobilize natural product libraries, though there having been examples of such 
methods becoming available, for example through the use of photo-cross linking or 
other highly reactive surfaces.38,39 
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1.2.1.1 Combinatorial Library Synthesis 
 The design of chemical libraries for microarrays screening is a challenging 
task. In principle, the molecules of library contain three parts: 1) tag, through which 
the molecules will be immobilized on the array, this part will be discussed in next 
section; 2) linker, give space between surface and small molecules, to make small 
molecules more flexible and stable; 3) diversity head, which is the interest compounds 
designed according to their targets. The most challenge part here is to create a high-
quality target oriented library or a completely diverse library from which to discover 
hits. 
 In 1991 Lam and Furka developed split-pool synthesis techniques and one-
bead, one-compound approaches, enabling chemists were develop large libraries of 
diverse compounds on polymeric beads.40,41 Even though techniques were available 
for on-bead screening,42 it was a lot more attractive to perform screening using 
microarrays, because of the number of arrays that could be printed and screened cost 
effectively from a single library. IRORITM technology,43 which is a radiofrequency 
tagging mediated combinatorial chemistry tool, was used in our lab. The system 
employs three technological innovations to achieve its high efficiency and reliability: 
(1) application of microreactors as the reaction units in solid-phase synthesis; (2) use 
of radiofrequency tagging as the non-chemical tracking method; and (3) development 
of the directed sorting technology for split & pool synthesis. (Figure 1.3) Before each 
split step of the synthesis the MicroKan reactors are sorted (split) into appropriate 
groups according to the assignments in the relational database generated in the 
enumeration. After reactions, the reactors can be combined (pooled) and processed in 
a single batch for common manipulations such as non-diversity reactions, washing 
and drying. A unique characteristic of the RF-tagged reactors is the ID code of every 
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reactor. The number of reactors equals the number of members in the library and one 
unique copy of each library member is produced.  
 Schreiber and colleagues then went on to develop an impressive way of 
generating combinatorial libraries with variable backbones, in order to capture greater 
diversity space through combinatorial libraries.44,45 This has led to several interesting 
SMM developments, with large and diverse libraries spanning in the tens of thousands 
of molecules arrayed.46,47 Our group developed an early method of synthesizing 1,3,5-
triazines using a tagged linker strategy.48  Among the things learnt from these initial 
developments, was that input quality of molecules is important, as it will determine 
the quality of results generated on the microarrays. While considering this, the 
efficiency of every step in the combinatorial synthesis is of great importance because 
such libraries, because of their size, are not usually purified and spotted crude.  
 Several synthetic strategies, including position scanning approach, alanine-
scanning approach, diversity-oriented synthesis, fragment-based approach, and click 
chemistry have been developed to create various types of molecular libraries for 
microarray application.49-51 Fragment-based approach is one of the most exciting 
developments in drug discovery. It facilitates the identification of fragments that bind 
to the adjacent binding pockets, for example in the targets active sites, providing 
potentially an ability to confer greater selectivity to a lead molecule. Recently, in our 
lab, we used this strategy and explored improved small molecule inhibitors to a confer 
inhibition selectivity with a closely related group of 14-3-3 proteins.51 
 
1.2.1.2 Microarray Fabrication 
 The microarray surface represents the next critical component of a successful 
SMM strategy. It is important to consider the need for linker, the 
8	  
	  
hydrophobicity/hydrophilicity of the surface being used, in regard to the types of 
molecules being screened. That said, there are a wide range of immobilization 
strategies and approaches, which have become available Table 1.1. These successes 
represent the efforts from many groups working in SMMs from around the world. In 
this section, we may only have the space to describe some of the more instructive 
approaches. 
 Several mild coupling reactions have been applied to immobilize compounds 
onto glass surfaces covalently, including Michael addition, Diels-Alder reaction, 
Staudinger ligation, thiol-ene reactions (Table 1.1). There are many coated slides 
available from commercial sources, like epoxy, aldehyde, NHS that could react 
directly with small molecules containing primary amines. The Schreiber group have 
developed isocynanate-mediated covalent capture approach based on isocyanate could 
react various functional groups including alcohols (primary and secondary), amines, 
carboxylic acids, thiols, phenol and so forth.39,52 Using this isocyanate surface-
attachment chemistry, Schreiber et al. have immobilized over 15,000 compounds  
1 4 2 5 3 6
1 4 2 5 63
1 2 3 4 5 6
1 2 3 4 5 6






	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 1.3 IRORITM technology. (A) Schematic representation of a MicroKan reactor. 


















from different sources to test their ability to bind large collections of proteins and then 
studied the relationship between structure features and binding specificity.19,52  
 Click chemistry type ligations, including the Staudinger ligation between a 
phosphane and azide moiety and the 1,3-dipolar cycloaddition reaction between 
alkynes and azides (click chemistry) have been applied in SMM construction.53,54 
Disney et al. used Huisgen reaction to immobilize RNA motifs on azide 
functinaolized agarose microarrays.54 Similarly, Waldmann et al. used Staudinger 
ligation for preparing phosphopeptide microarrays to map the substrates of protein 
tyrosine phosphatises (PTPs).55  
 Photo-activation chemistry has also been applied for printing small molecules. 
This provides greater spatial and temporal control over when the molecules are 
immobilized, on which components of the array surface. Ramstrom et al. developed a 
photo-cross linking strategy for fabricating carbohydrate microarrays.56 Yan et al. 
incorporated perfluorophenylazides which became converted into a highly reactive 
nitrene species.57  
 Various non-covalent interactions have also been adopted in microarray 
construction through the use of antibody/antibiotics interactions, biotin/avidin 
interactions, fluorous affinity interaction and hybridization. The biotin-avidin system 
is mostly used in our lab to immobilize peptides and other drug like small molecules, 
because of its stability and robustness, and its ability to generate a hydrophilic surface 







Table 1.1 Surfaces and tags developed for SMM fabrication. 
Attachment Method Surface Tag 





Silyl Chloride Alcohol25,61 
Hydrazides Glycan62 
Thiol Ene63 















Staudinger Ligation Phosphane Azide55 
Thiazolidine Ring 
Formation 
Glyoxylyl 1,2-Amino Thiol16 
Oxime Formation Glyoxylyl Aminoxyl16 
Photo-crosslink 
Diazirine Various70,71 
Aryl Azide Various56 
Photolithography Amine Various72 
Boronate Formation Boronic Acid Carbohydrate73 




Fluorous Capture C8F17 C8F1778-80 
Hydrogen Bond Avidin Biotin50,51,58,81 
 
 Alternatively, highly fluorinated compounds have also been applied for 
fabrication of SMMs. Fluorous-fluorous interactions are strong and selective. Pohl et 
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al. used this property to capture polyfluorocarbon-tagged carbohydrates on 
fluoroalkylsilane-coated slides.78 Schreiber et al. also used the same strategy to 
immobilize fluorous tagged compounds that targeted histone deacetylases. This 
method also confers excellent signal-to-noise ratios and low uniform background 
signals.79 Also recently, gel based capture of molecules (or 3D arrays) is also 
emerging as a useful method for SMM generation, because of potentially greater 
catchment of molecules on the surface.74,75,76-77  
 
1.2.2 Applications of SMMs 
 SMMs present valuable opportunities to screen for leads against known drug 
targets, as well as to assess molecular interactions en masse. As Figure 1.1 illustrates, 
screening on SMMs is not restricted to pure proteins and antibodies, but can also be 
performed with whole cells and crude lysates.  
1.2.2.1 SMMs to Screen for Enzyme Activities 
 A variety of substrate microarrays have been applied for assessing the activity 
of enzymes. For example, Ellman et al. developed coumarin-based peptide microarray 
to functional profiling protease specificity.82 A similar concept was demonstrated 
using via coating ﬂuorogenic small molecule coumarin derivatives on microarrays as 
sensors for the rapid characterization of different classes of hydrolases.18 Droplet-
based methods using microarrays to determine the substrate specificity of enzymes 
have also been developed.83,18 High-density peptide microarray profiling kinase 
substrates in cell lysates have also been reported by Katayama et al.84 Several groups 
have also generated phosphopeptide libraries and immobilized on microarrays to test 
the activities of phosphatases. 55,85 Various groups, namely Wong et al.,86 Shin et al.87 
and Mrksich et al.88 have also tested a variety of different transferases on microarrays. 
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1.2.2.2 SMMs to Screen for Binding Profiles and Inhibitors 
 Mihara and co-workers were among the earliest to develop protein 
fingerprinting approaches using immobilized peptides on microarrays.89,90 Similarly, a 
library of octameric peptoids which were applied in the large-scale protein 
ﬁngerprinting of three model proteins by Kodadek et al.24 In recent two years, these 
types of microarray were not only using to generate fingerprints, but also lead to a 
further understanding of biological functions of these identified compounds.  
 Creative application and library design strategies have introduced novel ways 
in which inhibitors or modulators of can be discovered. Recently, Woodbury and co-
workers used peptide microarrays to discover peptides that not only bind, but also 
modulate the enzyme activity.91 Our group developed phosphopeptide microarray 
which were capable of non-covalently “trapping” catalytically inactive mutants of 
protein tyrosine phosphatases (PTPs), for high-throughput determination of PTP 
substrate specificity.92 Disney et al. reported a chemoenzymatic route toward the 
synthesis of aminoglycosides using acetyltransferases and developed microarray-
based platforms to probe modification of bio-molecules by acetyltransferases.93 
1.2.2.3 Successful Hits Identified Using SMMs 
 Proteins from many different functional classes have been successfully 
targeted using SMMs (Figure. 1.4). For example, haptamide and uretupamine bind 
and modulate two yeast proteins, Hap3p and Ure2p, respectively, involved in 
transcriptional regulation and nutrient-sensing.25,46 Compound 21 and 22 were 
identified as competitive inhibitors of N-acyl-homoserine-lactone (AHL) mediated 
quorum sensing.76  
 Our group screened several metalloproteases with a synthetic hydroxamate 
peptide library on SMM. The lead compounds produced inhibition constants in the 
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low micromolar range, including hydroxamate tagged lF-F-L against the Anthrax 
lethal factor.81 Separately, screens have also been performed in cellular lysates, 
successfully converting the lead compound to aﬃnity-based probe (Biotin F5) that 
target γ-secretase.94  
 Schreiber and co-workers screened various HDACs against SMMs, 
uncovering several hits that were selective to respective HDACs.79 Recently, small 
molecule ligands have also been identified for tyrosinase95 and Alzheimer’s Aβ 
peptide.96 Another hit, 2-5, was identified to be selective against 14-3-3σ. 51 
	  
Figure 1.4 Representative small molecules discovered from chemical library 
screening using SMMs. Molecule name is listed in italics, above its corresponding 
protein target. 
 
1.2.2.4 Recent Applications of SMMs 
 Wong et al. have investigated a library of different glycans using carbohydrate 
microarray that mimic the HIV surface.97 This work suggested that heterogeneous-
ligand glycans might serve as a novel strategy for the development of carbohydrate-
based vaccine design. Wong et al. also arrayed a library of 27 sialosides, to screen for 













































































































against the whole viruses, producing binding patterns indicative of the HA subtypes 
(Figure 1.5A).  
 We also generated a novel peptide-aldehyde based SMM to specifically target 
cysteine proteases, thereby enabling large-scale functional assessment of this 
subgroup of proteases. We also performed screening on these arrays using cellular 
lysates, including those from malaria infected RBC.99 We were able to differentiate 
various stages of the parasitic infection using our arrays. Stages where no spots were 
observed were consistent with those where the parasite secretes falstatin, a cysteine 
protease inhibitor, enabling these stages to be differentiated on the microarrays. 
(Figure 1.5B) 
 Yousaf et al. developed a quantitative electroactive microarray strategy that 
can present a variety of ligands with precise control over ligand density to study 
human mesenchymal stem cell differentiation.100 Hecht and co-workers showed that 
the SMMs represent a promising tool for identifying compounds that bind the 
amyloid-β (Aβ) peptide, and exploring the Aβ aggregation pathway.96 The identified 
compounds may prove useful as probes for the biochemical pathways that result in 
Alzheimer’s disease. (Figure 1.5C) 
1.3 Summary and Outlook 
 In summary, we have highlighted successful accomplishments and challenges 
with the design, fabrication and application of SMMs. But what lies ahead? We, for 
one, think that SMMs are ripe for the picking. Already various SMM spin-off 
companies have appeared, notably JPT Peptide Technologies, Reaction Biology 
Corporation and Ligon Discovery. These companies are adopting a CRO model, 




Figure 1.5 Unique applications using SMMs. (A) Binding of various haemagluttinin 
proteins to carbohydrate microarrays, revealing unique signatures,98 (B) Ability to 
discern stages of malaria infections in RBC using a peptide aldehyde microarray,99 (C) 
Discovery of a compound that bind the Alzheimer’s Aβ peptide, and functionally 
rescues PC12 cells exposed to Aβ peptide.96 
 
 
performing microarray experiments. Alternatively they offer packaged slides or 
screening options for customers, depending on their research needs. We think this is 
an important development. Now that the SMM technology has matured, more public-
private partnerships are also being worked out with more university labs and 
pharmaceutical companies willing to share compound libraries for joint screening. 
Positive developments with service providers, research laboratories and 
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pharmaceutical industry indicate much more potential benefit from applying and 
deploying SMM strategies in the years to come. In addition, more laboratories are 
now equipped with combinatorial chemistry resources and instruments, automated 
microfluidics and microarray spotters and scanners. Taken together with the declining 
cost of library synthesis and microarray fabrication, the barriers to entry into SMM 
research have significantly dropped, and will continue to dissipate. Once the 
foundation provided by more successful start-up companies from this sector, we can 
envision even greater access to SMM technology. The traditional barriers to using 
SMM technology have been the access to instruments/technology, chemical libraries, 
and relevant expertise, which should be overcome now with increasing access and 
familiarity. 
 The first decade of SMMs has been an exciting one, with many improvements 
in the chemistry aspects of the platform now yielding actual biological impact. New 
applications using cells and fabrication techniques have made the platform much 
more amenable to a host of applications. Biologists with interesting targets and 
chemists and pharmaceutical companies with collections of libraries may now work 
together through common SMMs for mutual benefit. At the same time, SMM 
technology will also continue to evolve. The next generation may see further 
miniaturization with ‘nano’arrays, using nanolithography and other techniques, which 
are also being developed, aiming to reduce the feature sizes on arrays by several 
orders of magnitude. With all these exciting developments, the next decade promises 





1.4 Project Objectives 
 It is the aim of this thesis to develop novel technologies to functionally 
annotate and characterize enzymes inhibitors. The technologies developed should 
ideally be highly scalable and offer a high-throughput insight into enzyme biology. 
By understanding the functional differences of these inhibitors through these methods, 
it is hoped that one could identify small molecule compounds, which could desirably 
regulate or modulate enzyme function in vivo, offering rapid method for drug design 








A Peptide Aldehyde Microarray for High-





 Microarrays provide exciting opportunities in the field of large-scale 
proteomics. With the aim to elucidate enzymatic activity and profiles within native 
biological samples, we herein developed a microarray comprising a focused 
positional-scanning library of enzyme inhibitors. The library was diversified across 
P1 - P4 positions, creating 270 different inhibitor sub-libraries which were 
immobilized onto avidin slides. The peptide aldehyde-based small molecule 
microarray (SMM) specifically targeted cysteine proteases, thereby enabling large-
scale functional assessment of this sub-group of proteases, within fluorescently 










arrays were shown to elicit consistent binding fingerprints with model proteins, 
specifically caspases and purified cysteine proteases from parasites (rhodesein and 
cruzain). When tested against lysates from apoptotic Hela and red blood cells infected 
with Plasmodium falciparum, clear signatures were obtained that were readily 
attributable to the activity of constituent proteases within these samples. 
Characteristic binding profiles were further able to distinguish various stages of the 
parasite infection in erythrocyte lysates. By converting one of our brightest 
microarray hits into a probe, putative protein markers were identified and pulled down 
from within apoptotic Hela lysates, demonstrating the potential of target validation 
and discovery. Taken together, these results demonstrate the utility of targeted small 
molecule microarrays in dissecting cellular biology in complex proteomic samples. 
2.2 Introduction 
 “Omic” methodologies have in recent years enabled comprehensive 
differentiation of complex biological samples and cell states.101,102 DNA microarrays, 
for instance, measure quantitative changes in overall mRNA levels.103,104 Mass 
spectrometry provides sensitive ways in which to elucidate differences in protein and 
metabolite abundance.105,106 These platforms, however, are greatly challenged when 
measuring functional differences, for example, in detecting the changing activity 
levels of enzymes en masse.107,108 Activity-based protein profiling (ABPP), pioneered 
by Cravatt, has made an attempt to bridge this gap, by making use of activity-based 
small molecule probes to delineate enzymatic activities.109-111 This has however been 
restricted to mostly a single probe (in some cases several related probes), covering 
only a narrow pool of enzymes that can be screened at a time. Small molecule 
microarrays (SMMs) are, in contrast, a highly scalable screening platform. They have 
20	  
	  
predominantly been applied over the last decade for the purpose of screening pure 
proteins, in a one-to-many format, for ligand identification against known protein 
targets.15,19,112,113 We conceived that screening using SMM could be extended to 
comparative functional assessment of complex proteomes in high throughput, 
something not easily performed with competing techniques.103-111 Our goal was thus 
to apply the SMM platform much more broadly, in a many proteins-to-many ligands 
format. By taking advantage of the key characteristics of microarray-based 
technologies (miniaturization, high density and throughput) which enable 
simultaneous measurements of many interactions of component proteins across 
different cell states, we hoped to dissect complex proteomic samples (like cellular 
lysates) by rapidly examining their global activity profiles. 
 Enzymes are involved in every cellular process. Their functional state is 
tightly regulated across transcriptional and translational levels. SMMs of enzyme 
ligands (such as substrates or inhibitors) may therefore be used as a tool to accurately 
reflect the activity state. This was demonstrated in previous work with pure proteins, 
as well as pure enzymes.50,58,81,82,85,92,94,114,115 Several other groups have applied 
similar techniques in fingerprinting proteins based on their affinity profiles on the 
microarrays.24,67,116 In order to discern different cell states and to gain insight into the 
underlying molecular events, we designed our SMM to target cysteine proteases, 
which are an important class of enzymes that play vital roles in numerous 
physiological processes.117-119 Notably, the over-expression of human cysteine 
cathepsins and caspases have been implicated in a multitude of pathological 
conditions including Alzheimer’s disease and cancer.117,118 Many cysteine proteases 
are also essential in the life cycles of pathogenic protozoa.119 For example, brucipain 
21	  
	  
(also called rhodesain) is the major cysteine protease in Trypanosoma brucei, a 
parasite that causes African sleeping sickness. Cruzain is another parasitic cysteine 
 
Figure 2.1 Overall strategy of the SMM platform for comparative profiling of 
biological events. (A) Unique enzyme/inhibitor interaction profiles were generated 
upon screening pre-labeled cellular lysates with the SMM. (B) Design of the peptide 
aldehyde SMM. The PSL was designed using five individual P1 aldehyde warheads 
(in Red) targeting different sub-classes of cysteine proteases, and diversity elements 
from P2 to P4 positions (in Blue). P2, P3 and P4 were either individual amino acids for 
mapped positions, or isokinetic mixture of 18 amino acids (which excluded cysteine 
and methionine). 
 
protease in Trypanosoma cruzi which causes Chagas disease. Falcipains are cysteine 
proteases from Plasmodium falciparum, the parasite that causes malaria and infects 























































entire subset of functionally active cysteine proteases from different biological 
samples, by using SMMs of tight-binding enzyme inhibitors to detect the 
corresponding enzyme/inhibitor interactions (Figure 2.1). Signals on the microarrays 
would be diminished in the presence of inhibitory cues, down-regulation or inactivity 
of any of the enzymes in question. 
2.3 Results and Discussion 
2.3.1 Synthesis of Peptide Aldehydes and Construction of the Corresponding 
SMM 
 Peptide substrate and inhibitor libraries have become an established tool for 
dissecting the activity of proteases.83,121-129 As shown in Figure 2.1, our SMM 
comprises a positional-scanning library (PSL)130,131 of peptide aldehydes, which are 
reversible inhibitors of cysteine proteases.117,118 They were favoured over other 
known inhibitors, including those that contain reversible (i.e. azidomethylenes and 
azanitriles) and irreversible (i.e. epoxyl derivatives, peptidyl Michael acceptors, 
(acyloxy)methyl ketones, and halomethyl ketones) warheads, because they can be 
synthesized conveniently and are known to bind tightly to active cysteine proteases. 
The PSL design covers a diverse array of amino acids strategically positioned across 
P1, P2, P3 and P4 positions, thus facilitating comprehensive and specific interactions 
with most known cysteine proteases.117-120 First, five different amino aldehyde 
warheads (WH) were synthesized in solution phase from the corresponding Fmoc-
protected amino acids (Asp, Phe, Lys, Leu and Arg) for the P1 position (Figure 2.2, 
Scheme 6.1).132,133 These residues were chosen in order to provide sufficient coverage 
of P1 substrate specificity for most cysteine proteases documented in the MEROPS 
database.134 These aldehydes were then loaded onto a threonine-functionalized resin 
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by acid-catalyzed oxazolidine formation (Scheme 2.1). Solid-phase combinatorial 
library synthesis was then carried out, as previously described,135 by using standard 
solid-phase peptide synthesis with Fmoc chemistry. Eighteen different amino acids 
(excluding methionine and cysteine) were used to permute the P2 to P4 positions, 
generating 270 different sub-libraries. In addition, five positive control inhibitors were 
synthesized, namely DEVD, DEVF, DEVK, DEVL and DEVR, all of which also 
contained an aldehyde warhead. A hydrophilic linker and biotin were introduced to 
the N-terminus of each of the 275 peptide aldehydes, which were subsequently 
immobilized onto avidin-coated glass slides, to generate the corresponding peptide 
aldehyde SMM. 
 
Figure 2.2 The diverse peptide aldehyde PSL. The library was synthesized using five 
different amino aldehydes as P1. Mix means an equimolar mixture of 18 amino acids 
(omitting cysteine and methionine). The library consists of P2, P3, and P4 libraries, and 
each of them consists of 5 × 18=90 sub-libraries. Each sub-library is composed of 18 
× 18=324 species of tetra peptide-aldehyde inhibitors. The library totals 29,165 
compound diversities. 
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Mix = Isokinetic mixture of 18 amino acids omitting cysteine and methionine 
= Individual amino acid of the 18 amino acids omitting cysteine and methionine 
= 5 different individual amino aldehydes 
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The peptide aldehyde library was synthesized in two different sub-libraries (Positional 
Scanning Libraries (PSL) and DEVX library) by using IRORITM technology. The 





















































































Scheme 2.1 Synthesis of peptide aldehyde PSL. (a) i, Fmoc-Gly-OH, HBTU, HOBt, 
DIEA, DMF, 4 h; ii, 20% piperidine/DMF, 30 min; iii, Fmoc-Thr(OtBu)-OH, HBTU, 
HOBt, DIEA, DMF, 4 h;  iv, Ac2O, DIEA, DCM, 2 h. (b) i, 20% piperidine/DMF, 30 
min; ii, TFA/DCM (1:1) 1 h; iii, 10% DIEA/DCM. (c) 1% DIEA/MeOH , 2 h, 60°C. 
(d) Boc2O, 1% DIEA/DCM, 2 h. (e) i, TFA/TIS/EDT (95:5:0.1); ii, ACN:H2O:TFA 
(60:40:0.1), 30 min, 60 °C. Procedure described in Section 6.3.1. 
 
2.3.2 Inhibitor Fingerprinting with Pure Enzymes on SMMs 
 We first evaluated our SMM by screening the platform against four 
recombinant cysteine proteases (each was fluorescently labelled with an amino-
reactive Cy5 dye). Although these proteases were chemically modified, they still 
remain their activities in vitro (data not shown). These included two that belong to 
clan CA (cruzain from T. cruzi and rhodesain from T. brucei), and another two from 
clan CD (caspase-3 and caspase-7 involved in apoptosis). Clan CA proteases, 
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including the papain family (e.g. cathepsins and calpains), have a relatively broader 
tolerance of amino acid side chains at the P1 position. This is unlike the CD clan, 
which exhibits a much stronger specificity at this position. Unique binding 
fingerprints (or 2D barcodes) were observed for each enzyme on the microarrays 
(Figure 2.3A). As expected, Asp consistently appeared in the P1 position for both 
caspases (Figure 2.4), while various different amino acids (including Phe, Lys, Arg) 
were preferred by cruzain and rhodesain at this position. Across P2 to P4 positions, it 
was noted that different side chains contributed at varying levels to the overall 
binding potency of these inhibitors. Caspases 3 and 7 share extremely high homology 
in both protein sequence and substrate specificity. As a result, their SMM binding 
fingerprints were almost identical (see top two panels in Figure 2.3A). Overall 
binding profiles of the four enzymes were also displayed as position specific scoring 
matrixes (Figure 2.3C) and position-specific bar graphs (Figure 2.4). KD 
measurements were performed by dose-dependent application of proteins on the 
microarrays. These selectivity profiles for the various inhibitors were further validated 
using IC50 measurements with a solution-phase microplate enzyme assay (Figure 2.5). 
Results with our PSL were in general consistent across microarray and microplate 
assays, as well as with published reports on the substrate specificity of these enzymes 
(Table 2.1). The most potent inhibitor for Caspase 3 was DEVD-CHO, as expected, as 
this inhibitor has been well-reported. This inhibitor was the most potent across both 
microplate and microarray measurements, with an IC50 of 17 nM and an apparent 
microarray of KD of 172 nM. (Figure 2.5A, and Figure 2.6) When the enzymes were 
denatured by heat and rendered inactive, no binding was observed on the arrays (data 
not shown). Taken together, these results correlate very well with established findings 
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against these cysteine proteases.115,117,118,126,136 Our SMM platform hence provides a 
highly miniaturized, rapid tool to establish the specificity of cysteine proteases. 
 
Figure 2.3 Microarray profiles of the peptide aldehyde SMM with 4 different 
recombinant cysteine proteases. All compounds were spotted in duplicate. See Figure 
6.1 for spotting patterns/IDs. (A) Microarray binding profiles of Cy5-labeled cysteine 
proteases. (B) Combined heat map of the total PSIL against different Cy5-labeled 
proteins/cellular lysates. Data were organized in the order of P1 > P2 = P3 = P4. The 
heat map readily revealed both the potency and specificity of any member of the 
library against any of the proteins/lysates. (C) Position specific scoring matrix 
(PSSM) representing binding affinity across P1 to P4 positions for each amino acid, in 
single letter code. The height of each letter represents the weighted contribution of 
that residue to overall binding. The side chains are colored according to their 
properties: hydrophobic/aromatic (black), acidic (red), basic (blue), polar (cyan), 
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Figure 2.4 Microplate inhibitor specificity screening of cysteine proteases determined 
using the complete diverse inhibitor library. The results are presented in the order of 
amino acid sequence identity to each protease. All assays were performed in triplicate. 
The height of the bars denotes mean of Log10(IC50) value for caspase-3/-7 and 
Log10(Enzyme Activity) for Cruzain and Brucipain. The x axis in P2/P3/P4 indicates 18 
amino acids held constant at each position, designated by the single-letter code. The x 






































Figure 2.5 Representative example of the quantitative IC50 and KD results against 
pure Caspase-3. (A) Biotin-GG-DEVD-CHO was used. (B) Inhibitory binding curves 
of KD analysis for selected compounds. 
DEVD-CHO 
IC50 = 17.0 ± 2.0 nM 
DEVD-CHO 
KD = 172 ± 7 nM 
























































































































































































































































































































Figure 2.6 Microarray images of concentration-dependent experiments with Caspase-
7 (top), and Caspase-3 (bottom). Data were extracted and fitted, assuming a saturation 
binding model, to derive the corresponding KD. 
 
 




P4 P3 P2 P1 
Caspase-3 
D, E, S E, L, S V, T, L D Ref118,134 
D, E, T E, F, A V, I, L D Present Study 
D E, G, F V, P, Q D Present Study 
Caspase-7 
D, E, I E, A V, T, P D Ref118,134 
D, E, S E, D, A V, T, I D Present Study 
D E, H, F V, K, I D Present Study 
Cruzain 
Broad Broad F, W, L K, R, Q Ref126,134 
K, R, L K, L, R F, L, Y F, K, R Present Study 
Broad Broad N, A, E K, L, F Present Study 
Rhodesain 
Broad K, R, P F, W L K, R Ref126,134 
Broad L, R, I F, Y, L F, K, R Present Study 
Broad Broad K, I, F K, R, L Present Study 
*The most strongly contributing positions from the averaged profiles are shown for 
the present study in red and blue. These positions are displayed in bold if also shown 
to be preferred consistently with published substrate preferences.118,126,134 Blue color 





(µM)     0                 0.05                 0.25                0.50               1.00               2.00                 4.00 
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2.3.3 Profiling Mammalian Cell Lysates on SMMs 
 Having established that the platform provided reproducible fingerprints with 
pure enzymes, we went on to establish its utility in differentiating cell states. One 
model pathway we identified was apoptosis, which is an important physiological 
process in cells, and causes cancer when deregulated.118 The apoptosis cascade is 
mediated by cysteine proteases, namely caspases, and we hence sought to profile the 
changing functional state of these proteins using our SMM (Figure 2.7A). Hela cell 
lines were incubated with an apoptotic trigger, staurosporine (STS).137 The presence 
of active Caspase-3 in the resulting apoptotic cells was unambiguously confirmed by 
western blotting and a caspase enzymatic assay (Figure 2.7B). Cy5-labelled crude 
apoptotic and/or non-apoptotic cellular lysates were then applied on the microarrays, 
producing characteristic binding profiles (Figure 2.7A, and Figure 2.8). Apoptotic 
Hela (ApHela) lysates displayed distinct binding profiles with the peptide aldehyde 
SMM. Interestingly, it seemed that the binding patterns obtained were highly similar 
to that of Caspase-3/-7 shown in Figure 2. To ensure that these results were indeed 
attributable to Caspase-3/-7, tyramide signal amplification (TSA) was performed on 
the ApHela-treated arrays with anti-Caspase-3 antibodies (Figure 2.7A, right panel). 
The Venn diagram shown in Figure 2.7C clearly displayed that the majority (20 out of 
26) of strong binders detected by TSA assay overlapped with those from pure 
Caspase-3. Notably 12 out of 14 strong binders of the apoptotic Hela samples 
overlapped with Caspase-3, indicating that the profile observed on the SMMs was a 
result of triggered caspase activation. We further performed pull-down experiments 
against one of the strongest hits (Biotin-GG-DxxD-CHO) identified on the 
microarray, and results showed that Caspase-3 could indeed be enriched (Figure 2.9). 
In a separate experiment, it was found that our SMM could be used to generate 
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calcium-dependent binding profiles of Hela cells over-expressing activated calpains (a 
class of clan A calcium-dependent, non-lysosomal cysteine proteases; Figure 2.8B), 
which were readily distinguishable from those of STS-induced apoptotic cells. 
 
Figure 2.7 Microarray profiles of apoptotic events. (A) Top panels, microarray 
binding profiles of Cy5-labeled apoptotic Hela lysate, and TSA assay using anti-
Caspase-3 antibody; lower panels, corresponding 2D barcodes illustrating the binding 
profiles from the microarray images. The spots corresponding to DEVD-CHO, a 
known Caspase-3 binding sequence was boxed in Figure 3A (top panel). (B) Caspase-
3 activation of Hela lysate monitored by western blot and activity assay. Activated-
Caspase-3 appears as a 17 kD band, while pro-Caspase-3, is larger at 35 kD (Hela). A 
significant increase in Caspase-3 activity was shown after its activation by STS (curve 
shown in red, monitored by Ac-DEVD-AFC cleavage). (C) Venn diagram illustrating 
distribution of the top-binders (intensity greater than 500 RFUs). The overlapping 
regions shown in red indicate 11 common potent binders across the 3 microarrays 
(including those of pure Caspase-3, obtained from Figure 2.3A top panel). Regions in 
white were generally unpopulated, indicating the Hela-binding profiles arose 
predominantly from Caspase-3/-7 activity. The duplicated spots corresponding to 
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Figure 2.8 Cellular lysates screening on microarray including STS induced and 
Calcium dependent activity. (A) Hela cell was induced by STS for different lengths of 
time (as indicated), after which the cell lysates was collected and labeled. 
Subsequently, 0.16 µg/µL of the lysate was applied onto each grid; (B) Calcium-
dependent microarray images (0.16 µg/µL of lysate on each gride); B1, Cy5-labeled 
apoptotic Hela cells (ApHela) induced with 20 µM Ca2+; B2, Cy5-labeled apoptotic 
Hela cells only; B3, Cy5-labeled Hela cells (Non-apoptotic) induced with 20 µM Ca2+; 
B4, Cy5-labeled Hela cells (Non-apoptotic) only. (C) Western blots of non-
apoptosis/apoptosis Hela lysates, indicating the successful activation of the 
corresponding cysteine proteases (e.g. caspases and calpains). 
STS inducing time  
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Figure 2.9 Proteomic validation of protein targets by pull-down and western blotting 
experiments. Pull-down of Hela lysate with non-covalent compound D10 (structure 
shown on the right) as described in Chapter 6. Pull-down proteins positively identified 
by immunoblotting with the corresponding antibody. Asterisks show the expected 
locations of pro-Caspase-3 and active Caspase-3 bands. CBB: Coomassie Brilliant 
Blue; PD: Pull-Down assay; Ctrl: negative pull-down (with avidin beads only); 
CASP3: Caspase-3. 
 
2.3.4 Parasite Lysates and Infected Erythrocytes Screened on SMMs 
 To further explore more interesting cellular events, two parasites were selected 
for studies on the peptide aldehyde SMM (Figure 2.9). One was Trypanosoma brucei, 
the etiologic agent of human African sleeping sickness.119,120 The parasite 
(bloodstream form, BSF) was lysed and labelled with Cy5. Many positive spots 
appeared on the microarrays, the majority of which (41 out of 62) were attributable to 
rhodesain (Figure 2.9A left panel). The activity of enzymes in this parasite may thus 
be potentially tracked using our small molecule microarray. The other fluorescent 
spots identified may be a result other protein binding, the nature of which has yet to 
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x = an isokinetic mixture of 18 amino acids 	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be identified. The other parasite we investigated was Plasmodium falciparum. The 
ability to track malaria infection and develop new drugs targeting this deadly disease 
is still a major healthcare priority in many countries.120,138 By comparing the two 
parasites (Figure 2.9B), we were able to identify a total of 41 binders on the 
microarrays that uniquely bound either parasite (18 sequences for T. brucei and 23 
sequences for P. falciparum). This enabled reliable differentiation of each parasite on 
the array, indicating our SMM might be further developed into a platform for high-
throughput rapid parasite screening. We next assessed whether our SMM platform 
could be used to dissect enzymatic profiles of red blood cells (RBCs) infected at 
different parasitic stages by closely monitoring the up-/down-regulation of 
endogenous calpains expressed in RBCs. Most of the calpains present in RBCs (both 
normal and parasite-infected) were pro-calpains, and failed to produce any significant 
binding profile in our SMM (Figure 2.10). Ca2+-activated normal RBCs, on the other 
hand, produced a very distinctive microarray-binding profile, similar to that of Ca2+-
activated Hela cells (Figure 2.9D, top-left panel). It is well-established that falstatin, a 
potent cysteine protease inhibitor, is secreted into RBCs by the parasite at the ring and 
schizont stages but not at the trophozoite stage (Figure 2.9C),120 Upon Ca2+ activation 
of parasite-infected RBCs, we observed the corresponding calpain-binding profiles 
ONLY at the trophozoite stage, but NOT at the ring and schizont stages (Figure 
2.9D). We also observed the corresponding protease activity in the lysates (Figure 
2.11). We reasoned that this is due to characteristic biological differences across these 
different infection stages in controlling falstatin secretion, which consequently 
affected the binding of active calpains to our SMM. This demonstrates that our 





Figure 2.10 Profiling parasites and infected red blood cells lysates using the peptide 
aldehyde SMM. (A) Microarray profiles with T. brucei (BSF) and P. falciparum 
(trophozoite) lysates. (B) Venn diagram distribution of the top-binders (> 500 RFUs) 
in (A). (C) The typical life cycle of P. falciparum within the human blood stages. The 
black arc represents stages where falstatin was secreted. (D). Microarray profiles with 
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Figure 2.11 Ca2+ induced RBC lysates of different malaria parasite stages (Normal 
erythrocyte, without infection; Early-ring stage of P. Falciparum infected erythrocyte; 
Trophozoite staged erythrocyte; and Schizont staged erythrocyte). 
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Figure 2.12 Kinetic reading of Ca2+ activated protease assay using non-/infected RBC 
lysates monitored by microplate reader.	  Curves shown in red are lysates pre-activated 
by CaCl2 (20 µM). Curves shown in green are those without activation of Ca2+. 
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2.3.5 Protein Target Identification and Validation 
 Another advantage of our SMM platform is the ability to conveniently 
transform hits into chemical probes for target validation and identification of potential 
new biomarkers in different cellular events. To demonstrate this, we selected one 
ubiquitous hit sequence ARFK-CHO based on our microarray results against Hela 
cells, and converted it into an affinity-based photo cross-linking probe, (Biotin-GG-
ARFK(Bp)-CHO) (Figure 2.13A). Previously, others and we had used similar 
approaches to successfully convert non-covalent enzyme inhibitors into covalent 
activity-based probes (ABPs) suitable for large-scale activity-based protein profiling 
(ABPP) applications.139-142 The introduction of the photo-active moiety benzophenone 
(Bp) at the P1 position of the probe enables us to target clan CA proteases (which 
accept P1 changes with high tolerance117,118,143,144), and at the same time might reveal 
other potential binders. As shown in Figure 2.13B and Table 2.2, the probe 
successfully pulled-down several proteins. Cathepsin L and Calpain-1, both of which 
are clan CA proteases, were detected by immunoblotting (Figure 2.13B). Another two 
members of the same clan, Cathepsin B and Cathepsin Z, were also identified by mass 
spectrometry (Figure 2.13C). Proteins that appeared in the control pull-down 
experiment (beads only) were excluded from the mass spectrometry hit list. Most of 
other potential targets identified by MS were found to contain cysteine residues in 
their functional domains (Table 2.2).145-150 Several, like β-tubulin and GAPDH, are 
high-abundant proteins, so might not be true hits. Nevertheless, this demonstrates the 
potential of our SMM strategy in the development of novel probes and the 




Figure 2.13 Identification of protein targets by pull-down experiments with a selected 
probe modified with a photo-crosslinking moiety. (A) The chemical structure of the 
benzophenone (Bp)-containing probe used for pull-down experiments. Aldehyde 
warhead coupled with benzophenone is highlight in red, the peptide recognition 
element is indicated in blue and the biotin tag is shown in green. (B) Western blot 
analysis of protein targets pulled down from Hela cell lysates using the probe shown 
in (A). Proteins were identified by the respective antibodies. Asterisks show the 
expected locations of Cathepsin L and Calpain-1. (CBB - Coomassie Brilliant Blue; 
PD – Positive pull-down assay; Ctrl - Avidin beads without probe; CTSL - Cathepsin 
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Table 2.2 Proteins identified by pull-down and mass spectrometry.* 
No ID Description Mass Score emPAI Peptides Matched 
Related 
References 
1 IPI00295741 Cathepsin B 30781 119 0.36 11  
2 IPI00002745 Cathepsin Z 34530 87 0.20 3  
3 IPI00219018 GAPDH 36201 508 0.69 12 Ref
145 
4 IPI00645452 β-Tubulin 48135 493 1.21 21 Ref
146 
5 IPI00027493 SLC3A2 58023 119 0.12 6 Ref
147 
6 IPI00022774 VCP 89950 113 0.11 3 Ref
148 
7 IPI00013508 ACTN1 103563 105 0.06 2 Ref
149 
8 IPI00011062 CPS1 165975 95 0.04 2 Ref
150 
9 IPI00784154 HSPD1 61187 395 0.37 15  
10 IPI00021439 Actin 42052 350 0.83 25  
11 IPI00414676 HSP90AB1 83554 317 0.31 10  
12 IPI00302592 FLNA 282581 185 0.07 8  
13 IPI00550731 IGKC 26503 146 0.27 2  
14 IPI00643920 Transketolase 69382 141 0.15 4  
15 IPI00001639 KPNB1 98420 140 0.10 4  
16 IPI00793443 IPO5 125032 118 0.08 3  
17 IPI00169383 PGK1 44985 92 0.24 3  
18 IPI00339226 FN1 243861 90 0.03 3  
19 IPI00219217 LDHB 36900 83 0.29 6  
20 IPI00302925 CCT8 60011 78 0.05 2  
*Score is greater than 70. 
 
2.4 Conclusion 
 We have developed a peptide aldehyde small molecule microarray (SMM) for 
profiling the activity of cysteine proteases. Unlike other existing enzyme-detecting 
microarray platforms which are mostly substrate-based,24,50,58,67,81-83,85,92,94,114,115,128,129 
our study herein represents the first example of small molecule inhibitors being 
applied en masse, in a microarray format, for large-scale functional profiling of 
cysteine proteases present in native biological samples. We have demonstrated the 
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utility of the platform in dissecting functional cellular signatures at the proteome level 
to characterize cell states, as well as to develop probes with which to identify 
potential protein targets and biomarkers. The ability to screen within lysates provides 
a distinct advantage for SMM-based screening; solution-phase PSL screening, in 
general, only works with pure proteins.83,121-129 This approach will thus open up 
important ways in which small molecule microarrays can be applied to probe 
biological states, by providing a new-found means to differentiate complex proteomic 
samples based on differences in activity profiles. Comparative functional proteomics, 
with the use of SMMs will strongly supplement existing proteomic techniques and 
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 En route to new 14-3-3 binder: Small-molecule modulation of protein–protein 
interactions (PPIs) has gained much interest in the last years.152 The identification of 
potent low-molecular-weight PPI modulators such as the Nutlins, ABT-737 and 
SP4206 has led to a revision of the long-standing perception of PPIs as 
“undruggable”.153-155 Despite these advances, the development of suitable small-
molecule PPI modulators is still a challenge. A fragment-based combinatorial small 





protein. One small molecule that disrupts the 14-3-3/protein interactions has been 
identified. The compound is cell-permeable and possesses both in vitro and in-cell 
activities.	   Small-molecule modulation of protein–protein interactions (PPIs) has 
gained much interest in the last years. The small-molecule inhibitor of 14-3-3 protein–
protein interactions with potent cellular activity is a significant breakthrough in the 
long way towards rationalizing the development of suitable PPI modulators. 
3.2 Introduction 
 Protein-protein interaction (PPI) controls important regulatory pathways in 
virtually all cellular processes.152 For example, the phosphorylation-dependent PPI, 
tightly regulated by kinases, phosphatases and a large number of proteins containing 
phosphopeptide-binding domains, forms the basis of the highly complex, cellular 
signal transduction network. Inappropriate interactions between proteins are known to 
cause many human diseases.156 Inhibitors capable of disrupting protein-protein 
interactions, especially those made of small-size, cell-permeable chemicals, are 
therefore attractive leads for drug discovery.157,158 In contrast to mainstream drugs, 
which are usually active-site inhibitors of enzymes (i.e. Gleevec™ for Abl kinase), 
and have historically been the focus of pharmaceutical research, the development of 
PPI inhibitors is perceived to be highly challenging, but at the same time rewarding, 
especially for treating diseases of less common therapeutic targets such as 
transcription factors. Examples include inhibitors that bind to different Src Homology 
2 (SH2) domains, which have been extensively investigated.159,160 SH2 domains are 
phosphotyrosine (pTyr)-binding domains present in many important proteins (i.e. Src 
and Abl kinases). Phosphoserine/phosphothreonine (pS/pT)-binding domains 
constitute another major class of signalling domains with prominent roles in 
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regulation of mitosis, DNA damage and apoptosis.161 Among them, 14-3-3 proteins, 
made up of a family of acidic, dimeric, α-helical, cup-shaped molecules present in all 
eukaryotic cells, have been well characterized.162-164 Small molecule-based PPI 
inhibitors of 14-3-3 proteins, however, are not currently available. 
 In human, seven highly homologous 14-3-3 isoforms (β, ε, η, γ, σ, τ, and ζ) are 
present. Together, they regulate several hundred proteins, many of which are 
important pharmaceutical targets such as Raf, p53, Cdc25 and histone deacetylases 
(HDACs).162 So far, only 14-3-3σ, through its direct interaction with p53 (a major 
tumor suppressor protein), has been linked to cancer. Inactivation of 14-3-3σ has been 
shown to be crucial in tumorigenesis. Due to the highly conserved nature of residues 
in 14-3-3 isoforms that constitute the pS/pT-peptide binding pocket, most 14-3-3 
family members display significant functional redundancy both in vitro and in 
vivo.163,164 The elegant work of Yaffe et al. has unequivocally established that most 
proteins bind to 14-3-3 proteins through a consensus hexa- or hepta-phosphopeptide 
binding motif, RXX[pS/pT]XP or RXXX[pS/pT]XP, respectively (where X 
represents any amino acid but in most cases, aromatic/hydrophobic residues).163 
Recent studies have further identified sequences such as RFRpSYPP and 
RLSHpSLPG as optimal peptides recognized by all 14-3-3 proteins,163 as well as 
LFGpSLLR and LFGpSLVR that confer some preference toward the 14-3-3σ over 
other isoforms.50 
 The high redundancy of 14-3-3 proteins makes classical gene knockout 
approaches ill-suited for the study of their general functions in cells, since single gene 
knockout will be compensated for by other 14-3-3 isoforms, and simultaneous 
knockout of all seven genes would be technically impossible. Fu et al. used the so-
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called Difopein (two 18-amino acid peptides joined via a linker) as a general 14-3-3 
PPI inhibitor. Upon over-expression in mammalian cells from the corresponding 
DNA, the compound was shown to disrupt 14-3-3/ligand interaction, resulting in cell 
cycle arrest and apoptosis.165,166 The method, however, depends on transient 
transfection and is difficult to control (in terms of time, concentration, etc). Yaffe and 
Imperiali recently showed the use of caged phosphopeptides for both in vitro and in-
cell studies of 14-3-3 functions in a temporally controlled manner.167 The peptides 
were chemically synthesized and conjugated (to a cell-penetrating peptide, or CPP) 
prior to being delivered into cells, and subsequently “turned on“ by UV irradiation. 
While elegant, this approach lacks a “turn-off“ mechanism and requires the use of UV 
(which is harmful to cells). In addition, these peptides lack sufficient cellular 
permeability (thus the need for CPP conjugation) and hydrolytic stability (they are 
readily degraded by endogenous proteases in cells), making them unsuitable for 
general chemical biology applications. Our ongoing interests in 14-3-3 proteins and 
their protein-protein interacting partners as potential therapeutic targets have 
prompted us to ask whether it is possible to develop cell-permeable, small molecule 
chemicals capable of binding to all 14-3-3 proteins, or to a specific isoform, i.e. 14-3-
3σ. We envisioned such chemicals would be highly valuable not only as a research 
tool for studies of 14-3-3 biology (especially that of 14-3-3/ligand interaction), but 
also as potential anti-cancer agents. Herein, we report, for the first time, one such 
compound, 2-5 (shown in Figure 3.1). To the best of our knowledge, this compound is 
the first-ever small molecule PPI inhibitor of 14-3-3 proteins. We have carried out 
extensive biochemical assays to confirm that 2-5 directly competes for 14-3-3/ligand 
binding in a potent and specific manner in vitro. In mammalian cells, it induces 




Figure 3.1 Overall scheme of SMM-assisted, fragment-based method for HT 
identification of potential peptide-small molecule hybrid molecules (Steps I and II), 
which were subsequently reconstituted (Step III) to obtain the corresponding cell-
permeable, small molecule hits, followed by biological validation (Step IV). 
3.3 Results and Discussion 
3.3.1 Synthesis of Peptide-Small Molecule Hybrid Library 
 To identify 2-5 and related compounds in high throughput, we used the 
recently developed small molecule microarray (SMM) technology,2,19 and followed 
the work flow shown in Figure 3.1. In order to convert the original optimal 14-3-3-
binding peptide, RFRpSYPP, into a small molecule-based 14-3-3 binder, we first 
synthesized a peptide-small molecule hybrid library (Step I); it is made up of the 243-
member N-terminal and 50-member C-terminal sub-libraries (For synthesis, see 
Chapter 6). We retained the key pS residue in the library, and at the same time 
systematically replaced the two flanking peptide fragments (RFR and YPP) with 
commercially available acid and amine building blocks (R1 and R2, respectively, in 
Figure 3.1, corresponding to the P-1/-2 and P+1/+2 positions in the original peptide). A 
recently introduced library design concept termed “fragment-based combinatorial 
























































































































chemistry” was adopted to ensure that a sufficient chemical space was covered by a 
limited number of building blocks (243 R1 & 50 R2), and at the same time all library 
members retained some degrees of binding affinity toward 14-3-3 proteins.50 
Aliphatic/aromatic building blocks were chosen in the library construction, as they 
may improve the cell permeability of potential “hits”, and based on x-ray structures of 
14-3-3 proteins, the binding pockets immediately adjacent to the pS-binding site are 
mostly hydrophobic.163,164 Briefly, the N-terminal sub-library was made by coupling 
243 different acids (i.e. R1) to the rink amide resin pre-loaded with peptide NH2-
pSYPP (where R1 is an aliphatic building block) or NH2-GpSYPP (where R1 is an 
aromatic building block). Similarly, the C-terminal sub-library was synthesized by 
first immobilization of 50 different amines (i.e. R2) onto the PL-FMP resin via 
reductive amination (Chapter 6.3.3), following previously published procedures,168 
then coupling of the peptide sequence RFRpS. For both sub-libraries, biotin and a GG 
linker were introduced at either the N- or C-terminus of each member to facilitate 
subsequent immobilization onto avidin-functionalized glass slides. All compounds 
were characterized by LCMS and most were shown to be of the correct molecular 
weight and sufficient purity for direct microarray applications.81,85 
 
 
3.3.2 Identification of Hybrid Binder with 14-3-3 on SMMs 
 The entire library together with a positive control peptide, Biotin-GG-
RLSHpSLPG, was spotted (in duplicate) to generate the corresponding SMM. To 
ensure uniform immobilization, spotted slides were stained with Pro-Q diamond dye 
(Figure 3.2); minimal slide-to-slide and spot-to-spot variations (r > 0.95) were 
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observed. We next examined whether this fragment-based, peptide-small molecule 
hybrid SMM could be used to identify, in high throughput, ligands that bind strongly 
to 14-3-3 proteins (Step II in Figure 3.1). A fluorescently labeled, recombinant GST-
14-3-3σ was used in the SMM screening (Figure 3.4); upon data analysis, highly 
reproducible (as judged from duplicated spots/slides), concentration-dependent 
binding profiles were observed for five of the 293 compounds (boxed in red in Figure 
3.4A). The positive control peptide (boxed in yellow in Figure 3.4A) also showed a 
robust binding profile. Microarray-based KD determination was subsequently carried 
out (Figure 3.4B); besides the control peptide which showed an apparent KD of 0.25 
µM (compared to the reported value of ~200 nM50), the newly identified ligands 
(N111, N180 & N231 from the N-terminal sub-library, and C021 & C033 from the C-
terminal sub-library) all showed relatively good affinity toward 14-3-3σ (0.6 – 1.03 
µM in KD). Further validation was carried out with a competitive fluorescence 
polarization (FP) assay (Figure 3.3 and Figure 3.4C);169 the same set of compounds 
emerged as “hits” and with IC50 values within the same range as the microarray-
measured KD, indicating that all of them are likely true binders of 14-3-3σ, and the 
corresponding R1 and R2 building blocks (boxed in green and blue, respectively, in 
Figure 3.1) may be further reconstituted to obtain the corresponding small molecule-




Figure 3.2 Microarray-based HT screening and KD determination of selected peptide-
small molecule hybrids in their binding to 14-3-3σ. (A) Microarray printing pattern, 
decoding data please refer to Chapter 9. (B) Pro-Q image of entire library indicating 
mostly uniform spotting pattern. (C) Concentration-dependent screening of the 
microarrray against Cy3-labeled 14-3-3σ. 
 
 
Figure 3.3 Colored heatmap displaying the potency of the entire peptide-small 
molecule hybrid library (243 N-terminal and 50 C-terminal sub-libraries; 5 µM) 
against 14-3-3σ. Red squares indicate Hits; yellow and green ones indicate positive 
control peptide and negative control (in duplicate), respectively. Decoding IDs are 
shown by the sides. 
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Figure 3.4 SMM-assisted identification of potential peptide-small molecule hybrid 
binders of 14-3-3σ, and quantitative KD determination. (A) Microarray image 
displaying binding profiles of the 293-member library against fluorescently labeled 
GST-14-3-3σ. Spots corresponding to the control peptide RLSHpSLPG and positive 
“hits” were boxed in yellow and red, respectively. Other un-boxed spots were weak 
binders (see Chapter 9) which were rejected without further follow-ups. (B) 
Microarray-based KD determination of the control peptide and five “Hits”. The 
corresponding dose-dependent microarray images were shown below (A), obtained by 
screening the SMM with varied concentrations of the fluorescently labeled 14-3-3σ 
(0.1 to 10 µM). (C) Summary of the microarray-measured KD and the corresponding 
IC50 values obtained from competitive FP experiments. Detailed microarray data was 
































N111 0.92 ± 0.04 N111 1.96 ± 0.05 
N180 1.03 ± 0.10 N180 1.98 ± 0.06 
N231 0.97 ± 0.03 N231 2.27 ± 0.10 
C021 0.99 ± 0.02 C021 1.87 ± 0.20 
C033 0.60 ± 0.02 C033 1.92 ± 0.10 
Ctrl 0.25 ± 0.04 Ctrl < 0.5 
    
 




























3.3.3 Synthesis Hybrid Binders and Competitive Fluorescence Polarization Assay 
 From the above peptide-small molecule hybrid library, we have rapidly 
identified key building blocks (i.e. three R1 and two R2) capable of substituting 
peptidyl recognition fragments in a known 14-3-3-binding phosphopeptide without 
significant loss of its original binding property. We next reconstituted the 
corresponding phosphoserine-containing small molecules (2-1 to 2-6 in Figure 3.1; 
Step III). All six potential 14-3-3 small molecule binders (from three R1 & two R2) 
were synthesized by solution-phase chemistry and characterized by 1H 13C and 31P 
NMR, as well as MS. The non-phosphorylated controls, 1-1 to 1-6, were similarly 
prepared (Scheme 6.2).  
 Competitive FP experiments showed potent dose-dependent binding of 2-1 to 
2-6, but not the non-phosphorylated counterparts (1-1 to 1-6), toward 14-3-3σ, giving 
rise to the corresponding IC50 values of 2.6 - 3.6 µM, which are only 2-3 folds less 
potent than the parental peptide-small molecule hybrids (Figure 3.5 and 3.6A). It 
should be noted that, unlike most active site-targeted enzyme inhibitors (which are 
often nanomolar or even picomolar inhibitors), small molecule micromolar PPI 
inhibitors are considered reasonably potent inhibitors.157,158 In our case, the most 
potent inhibitor, 2-5 (Figure 3.5A, with a IC50 value of 2.6 ± 0.4 µM, is only ~10 fold 
lower in binding affinity than its peptide counterpart (and other well-known 14-3-3-
binding phosphopeptides),50,162-164 thus making it a good candidate as a potential cell-
permeable, small molecule 14-3-3 PPI inhibitor. This compound was therefore chosen 






































































































Compound 1-1 1-2 1-3 1-4 1-5 1-6 
IC50/ µM N.A. N.A. N.A. N.A. N.A. N.A. 
Compound 2-1 2-2 2-3 2-4 2-5 2-6 
IC50/ µM 3.2 ± 0.4 3.3 ± 1.0 3.6 ± 0.1 3.1 ± 0.2 2.6 ± 0.4 3.6 ± 0.7 
Compound N111 N180 N231 C021 C033  
IC50/ µM 1.9 ± 0.4 2.0 ± 0.3 2.2 ± 0.6 1.8 ± 0.2 1.9 ± 0.1  
Figure 3.5 Competitive fluorescence polarization results. (A) Chemical Structure of 
compound 2-5. (B) IC50 graphs of the non-phosphorylated negative controls (1-1 to 1-
6; in green) and the phosphorylated hits (2-1 to 2-6; in red). Results were obtained 
from three independent assays then averaged. (C) The corresponding IC50 values 
obtained from (B). For 1-1 to 1-6, no significant inhibition (< 20%) was observed 
even at the highest tested concentration. Therefore no IC50 values were obtained 
(N.A.). IC50 values of the 5 original peptide-small molecule “hits” were similarly 







Figure 3.6 Biological activities of 2-5 (and related compounds) in vitro and in cells. 
(A) Summary of IC50 obtained from competitive FP experiments for 2-1 to 2-6 and 
their non-phosphorylated controls. (N.A. = IC50 too high to be determined within 
experimental settings). (B) In vitro competitive binding of 2-5 with cellular proteins 
for 14-3-3σ binding. 100 µM of compounds 1-5 and 2-5 were incubated with A549 
cell lysates, and then bead-immobilized GST-14-3-3σ was added to the mixture and 
14-3-3σ. Bound proteins were detected by SDS-PAGE and immunoblotting with 
antibodies against various 14-3-3-binding partners. Controls show proteins bound by 
GST-14-3-3σ beads in the absence of compounds, or by beads alone. TCL denotes 
total cell lysate; GST denotes beads alone. (C) Time-dependent (1-24 hr) inhibition of 
A549 cell proliferation by 2-5 (1-5 as control) using XTT assay. Data represent the 
average s.d. for two independent trials. (D) Fluorescence microscopic images of A549 
cells treated with compound 2-5 or 1-5 (100 µM), respectively. Caspase activity was 
monitored by addition of Ac-DEVD-SG1 as previously reported.170 All images were 
acquired in the same way, scale bar = 10 µm. DIC images were shown as insets. (E) 
Immunoblotting results of the cells from (d), detected with anti pro-caspase 3 and anti 
caspase-3 (P17) antibodies. Lane 1: un-induced A549 lysate; Lanes 2-4: 2-5 treated 
A549 for 2, 8 and 12 hours, respectively; Lane 5: STS-treated cells (12 hr). (F) Flow 
cytometry results of A549 cells treated with 100 µM of 2-5 for 4, 8 and 12 hours 









1-1 N.A. 2-1 3.2 ± 0.4 
1-2 N.A. 2-2 3.3 ± 1.0 
1-3 N.A. 2-3 3.6 ± 0.1 
1-4 N.A. 2-4 3.1 ± 0.2 
1-5 N.A. 2-5 2.6 ± 0.4 
1-6 N.A. 2-6 3.6 ± 0.7 
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3.3.4 in vitro and in vivo Activities of Compound 2-5 
 To investigate whether compound 2-5 competes with cellular proteins for 14-
3-3 binding in a biological complex, pull-down experiments were performed with 
A549 cell lysates.167 Bead-immobilized GST-14-3-3σ was pre-incubated with 2-5 (1-5 
and DMSO were used as negative controls) and then added to cell lysates. 14-3-3-
bound proteins were separated by SDS-PAGE followed by immunoblotting with a 
group of different antibodies that recognize either the 14-3-3 phosphopeptide-binding 
motif, p53 or Raf-1 substrate proteins. As shown in Figure 3b, the phosphoserine-
containing small molecule, 2-5, was able to completely disrupt PPI between 14-3-3σ 
and its substrate proteins. On the other hand, a same amount of the non-
phosphorylated control, 1-5, was unable to disrupt the binding between 14-3-3σ and 
its endogenous substrates. This indicates 2-5 is a good small molecule PPI inhibitor of 
14-3-3 proteins in vitro. 
Subsequently, the cell permeability and in-cell biological activities of 2-5 were 
assessed. A standard cell permeability assay using MDCK cells indicated 2-5 indeed 
possesses reasonable cell permeability with a Papp value of 554 nm.s-1 (Table 3.1). 
Previously, it was shown that expression of 14-3-3/ligand interaction inhibitors (i.e. 
Difopein) in mammalian cells leads to induction of apoptosis and cell death. We 
therefore tested the cytotoxicity of 2-5 in A549 cells using the XTT cell proliferation 
assay (Figure 3.6C); results indicate that, at 100 µM concentration, 2-5 caused a large 
amount of cell death starting from 4 hours to up to 12 hours of drug treatment. The 
negative control 1-5, on the other hand, had a significantly lower but noticeable 
degree of cell toxicity, indicating that though both compounds might have some 
intrinsic cytotoxicity (cause of this is still under investigation), phosphorylation of 1-5 
(i.e. giving 2-5) had drastically improved its cell-killing activity, presumably through 
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the increase in its binding affinity toward 14-3-3 proteins. Subsequently, we 
investigated whether 2-5-induced cell death was a direct result of caspase activation 
and apoptosis, as previously observed for other 14-3-3/ligand interaction 
inhibitors.165,166 2-5 treated A549 cells were monitored in a live-cell bioimaging 
experiment, as previously reported,169 using the Ac-DEVD-SG1 fluorogenic caspase 
3/7 substrate. As shown in Figure 3.6D and Figure 3.7, A549 cells treated with 2-5 
and staurosporine (STS - a positive control) developed a strong green fluorescence, 
indicating apoptosis had occurred. In contrast, no significant increase in fluorescence 
was observed for nonapoptotic cells (i.e. cells treated with 1-5 or DMSO) even after 
extended incubation. Addition of a caspase 3/7 inhibitor, Ac-DEVD-CHO, to the STS 
and 2-5-treated cells rendered the fluorescence undetectable (Figure 3.7). Further 
analysis of the corresponding cell lysates by SDS-PAGE and immunoblotting 
experiments unambiguously confirmed the time-dependent activation of caspase 3 
activity in both the STS and 2-5 treated cells (Figure 3.6E). These results agree well 
with previous studies that disruption of 14-3-3/ligand interactions leads to caspase-
mediated apoptosis,165,166 and further supports the hypothesis that 14-3-3/ligand 
interactions are required for critical cellular processes including regulating pro-
survival cell signalling.162-164 Finally, 14-3-3/ligand interaction inhibitors are known 
to regulate cell cycle by causing premature cell cycle entry, release of G1 cells from 
interphase arrest and loss of the S-phase checkpoint after DNA damage.167 We asked 
if 2-5 behaves similarly in a flow cytometry-based cell-cycle experiment (Figure 
3.6F); by measuring the population of cells containing cleaved DNA upon treatment 
with 2-5, we observed a dramatic increase in the fraction of sub-G1 cells, indicating 
internucleosomal DNA cleavage (which is a commonly used marker of apoptosis). 1-
5-treated cells, on the other hand, behaved similarly like normal cells. This again 
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validates the critical roles that 14-3-3 proteins play in cell cycle regulation, as 
previous reports.165-167 
A     
STS + - - - 
2-5 - + - - 
1-5 - - + - 
Ac-DEVD-SG1 + + + + 
Ac-DEVD-CHO - - - - 
DIC/GFP 
    
B   
STS + - 
2-5 - + 
1-5 - - 
Ac-DEVD-SG1 + + 
Ac-DEVD-CHO + + 
DIC/GFP 
  
Figure 3.7 Bioimaging results. (A) A549 cells after treated with staurosporine (STS), 
compound 2-5 and compound 1-5, respectively. Caspase activity was monitored by 
Ac-DEVD-SG1 as previously reported.170 Cells showed significant fluorescence 
increase after 3 hr. (B) A549 cells after apoptosis induction with staurosporine and 
compound 2-5, respectively. Inhibitor Ac-DEVD-CHO was added. No significant 
fluorescence increase in the GFP channel was sustained for at 3 hr when cells were 
visibly apoptotic, scale bar = 10 µm. 
 
Table 3.1 Results of the permeability of compound 2-5. 
 Positive control Negative control 2-5 
Caffeine / 50µM + - - 
Lucifer Yellow / 60µM + + + 
Compound / 100µM - - + 
DMSO 1% 1% 1% 





3.3.5 Hydrolytic Stability of 2-5 in Cellular Lysates 
 2-5 showed very good stability toward cellular proteases (i.e. no peptide 
hydrolysis was detected for 2-5 in cell lysates over 12 hours, Figure 3.8), but showed 
a dephosphorylation t1/2 of ~ 6 hours in mammalian cell lysates. Its intracellular 
dephosphorylation life time, however, will likely be significantly longer, due to the 
highly regulated, localized endogenous phosphatase activities in living cells. 















































Figure 3.8 Hydrolytic analysis of compound 2-5 in A549 cell lysates. (* indicates 
compound 2-5, # indicates the dephosphorylated product), indicating 
dephosphorylation t1/2 = 6 hr for 2-5 in mammalian cell lysates. Its intracellular 
dephosphorylation life time, however, will likely be significantly longer, due to the 
highly regulated, localized endogenous phosphatase activities in living cells. 2-5, 
however, showed very good stability toward cellular proteases, as shown above. 
 
3.3.6 Docked Positions of 2-5 with 14-3-3σ 
 Lastly, to explore the binding mode of 2-5 with 14-3-3σ (PDB ID 1YWT171), 
molecular docking studies were carried out using Autodock Vina software.172 Results 
showed that, as one might have expected, 2-5 binds well to 14-3-3σ in the 
phosphopeptide-binding site of the protein (Figure 3.9).171 The negatively charged 
phosphate group in 2-5 was observed to be involved in extensive interactions with the 














core of the phosphopeptide binding pocket (Figure 3.9). The two hydrophobic R 
groups (R1 and R2), are now also engaged in contact with the nearby hydrophobic 




Figure 3.9 Molecular docking of 2-5 in the phosphopeptide binding pocket of 14-3-
3σ. Protein is shown in green. The x-ray structure of 14-3-3σ binding to the 
phosphopeptide SHpSYPA was used.173 (A) Overlapped structures of 2-5 (in white) 
and the phosphopeptide SHpSYPA (in red) binding to the phosphopeptide-binding 
pocket of 14-3-3σ (K49, R56, R129 and Y130 from the protein are shown). Possible 
hydrogen bonds are shown as dotted lines. (B) Superimposition of 2-5 bound to 14-3-
3σ (surface representation, active site indicated in colors). (C) More angles of illusion. 
3.4 Conclusion 
 In conclusion, we have successfully demonstrated that SMM technology, 
when coupled with the recently introduced “fragment-based combinatorial chemistry” 
concept, offers a highly miniaturized yet powerful approach for rapid identification of 









permeable small molecule PPI inhibitor targeting 14-3-3 proteins, we have 
successfully developed a versatile chemical biology approach for studies of 14-3-3 
biology. Compared to other existing methods,165-167 our strategy makes use of the 
newly discovered compound, 2-5, which can be administered to cells by conveniently 
adding it to the cell medium. It therefore does not require ectopic delivery of genetic 
materials or asynchronously delivered peptides/proteins. If needed, the compound, 
once inside cells, could be reversibly washed away (due to its good cell permeability), 
thus giving our strategy a “turn-off” mechanism. It also possesses other reasonable 
“drug-like” properties such as small size and hydrolytic stability (Figure 3.8). All of 
these attributes should make 2-5 a valuable chemical for inquiring 14-3-3 biology. We 
note that in a recent work, Waldmann and Ottmann have identified small molecules 
that selectively stabilize, rather than disrupt, 14-3-3/ligand interactions.173 We believe 
these two types of reagents might offer a powerful synergistic combination for future 
studies of 14-3-3/ligand interactions and associated signalling pathways. Our strategy 
should be directly applicable to other signalling modules that are functionally 
redundant, in which the protein of interest is part of a large conserved protein family, 
including other modular protein domains that recognize phosphoamino acids (e.g. 
FHA domains, WW domains, SH2 domains, and others159-161). Throughout the course 
of our study, we have also reaffirmed various critical roles 14-3-3 proteins play in cell 









High-Throughput Discovery of Mycobacterium 
Tuberculosis Protein Tyrosine Phosphatase B 






 A ~3500-member library of bidentate inhibitors against protein tyrosine 
phosphatases (PTPs) was rapidly assembled using click chemistry. Subsequent high-
throughput screening had led to the discovery of highly potent (Ki as low as 150 nM) 
and selective MptpB inhibitors, some of which represent the most potent MptpB 








 Protein tyrosine phosphatases (PTPs) are important signalling enzymes in the 
cell. Dysregulation of these enzymes has been linked to various human diseases.175-179 
For example, PTP1B is one of the best-known PTPs and has been identified as a key 
player against diabetes, obesity, and cancer. MptpB, another well-known protein 
tyrosine phosphatase encoded by Mycobacterium tuberculosis, is a promising target 
for new tuberculosis (TB) drugs.180 Progress in the development of potent and 
selective PTP inhibitors, however, has been slow because of the highly conserved 
active site shared by most members of the PTP family. A significant advance came 
from the seminal discovery that there exists a unique secondary site near the active 
site of PTP1B (and possibly in many other PTPs).181 As a result, major drug discovery 
efforts have focused on the use of fragment-based approaches for the identification of 
the so-called bidentate PTP1B inhibitors capable of binding to both the active site and 
the secondary site of the enzyme simultaneously.182,183 We recently demonstrated the 
first example of using click chemistry followed by direct in situ screening for the 
rapid assembly and identification of potent bidentate inhibitors against PTP1B.184 
This approach takes advantage of the highly efficient and modular Cu(I)-catalyzed 
1,3-dipolar cycloaddition reaction between an azide and an alkyne185,186 and has thus 
far been successfully applied to the discovery of small molecule inhibitors against 
other classes of enzymes.187,188 In our previous study, we were able to identify a 
“click-based” inhibitor that possesses inhibitory properties against PTP1B similar to 
those identiﬁed from conventional fragment-based approaches.184 
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 Herein, we report a ∼3500-member PTP bidentate inhibitor library 
synthesized using our collection of alkynes and our previously synthesized azide 
library168 and, from the in situ screening of this library, the discovery of the ﬁrst click-
based small molecule inhibitor against MptpB (Ki) 150 nM), which not only 
possesses a high speciﬁcity (11-to 43-fold) over other PTPs but also represents the 
most potent inhibitor of MptpB known in the literature. 
4.3 Results and Discussion 
4.3.1 Design and Synthesis of the Bidentate Inhibitors 
 Our bidentate inhibitors have three components: (i) the warheads, alkyne-
containing N-phenyloxamic acids that are cell-permeable, potent bioisosteric 
phosphotyrosine mimics;182-184 4,5 (ii) a variety of different types of building blocks 
that act as the secondary-site binders; and (iii) azidecontaining linkers of different 
lengths joining the warhead and the building blocks (Figure 4.1). We anticipated that 
combining these components would result in a sizable bidentate inhibitor library that 
might be used to target different PTPs with little structural knowledge of the nature of 
their active and secondary sites. We were particularly interested in finding inhibitors 
for MptpB as it is a relatively new target. Recent X-ray structural studies have also 
revealed the presence of a unique secondary binding site near the enzyme active site, 







Figure 4.1 Overall strategy of the “click-based” high-throughput discovery of MptpB 
inhibitors. A total of 11 alkyne warheads and 325 azides were assembled to generate 
the ~3500-member bidentate library which, upon in situ screening, gave rise to two 
highly potent MptpB inhibitors (boxed). 
 
 Of the 11 warheads used in this library, W2, W3, W5, W6, W7, and W9 were 
synthesized as previously reported.168,184 W1, W4, W8, and W10 were newly 
designed N-phenyloximic acid analogues guided by our previous results and 
computational modeling.184 The final warhead, W11, was inspired by the recently 
discovered MptpB inhibitor from Ellman and co-workers.189 The synthesis of the 325-
member secondary-site binders, which consist of diverse aromatic and aliphatic 
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building blocks linked to various azide-containing linkers, was previously reported.168 
With both the alkyne and the azide libraries in hand, we carried out high-throughput 
click assembly of the 11 × 325 compound combinations in 384-well microtiter plates 
with the aid of an automatic liquid handling system as previously reported.190 Upon 
optimizations, we found click chemistry conditions carried out with CuSO4 and 
sodium ascorbate as catalysts and H2O/t-BuOH as co-solvents gave the best results. 
Subsequently, approximately 10% of the ∼3500 compounds obtained were further 
characterized by LC-MS and confirmed to be of sufficient purity (>90% in most 
cases). They were subsequently used for direct in situ screening against recombinant 
MptpB enzyme. It should be highlighted that the key attribute of our strategy lies in 
the ability to rapidly assemble high-quality bidentate inhibitors in a matter of weeks 
or even days, thereby alleviating one of the major challenges in the traditional drug 
discovery process. The ~3500-member library shown herein represents the largest 
click-based library assembled to date. 
 
4.3.2 High-Throughput Screening of Entire Library against MptpB 
 Upon screening against MptpB, the relative potency of each inhibitor was 
obtained and presented as a colored heat map (Figure 4.3). The inhibition fingerprints 
from the largest sub-libraries consisting of Type I and II azides are also presented in 
4-D cube plots in Figure 4.2A. A quick survey of the heat map and the cube plots 
revealed that almost all of the inhibitors derived from W11 were more potent than 
those from other warheads, implying that W11 plays a dominant role in contributing 
to inhibitor potency against MptpB. Interestingly, most inhibitors, especially those 
assembled fromW1, showed varying degrees of inhibition potencies across different 
azides, highlighting the cooperative binding effect from both the warhead and the 
azide component in the bidentate inhibitor. Next, quantitative data analysis was 
64	  
	  
carried out by averaging the inhibition potency across sub-libraries derived from each 
warhead, and the results are graphically presented in Figure 4.2B. Inhibitors derived 
from W11 were found to be 24-fold more potent than those from W6, which lacks the 
cyclohexyl group. This is presumably due to the considerable plasticity of the active 
site in MptpB;189 the additional cyclohexyl group may be accommodated to gain 
favorable hydrophobic interactions. W7, which has a pyrazole ring in place of the 
isoxazole, was the least potent among the eleven warheads, indicating that the oxygen 
atom in the isoxazole ring is crucial as a hydrogen bond acceptor with the enzyme, 
since replacement with a hydrogen bond donor abolished most of the inhibitory 
activity. For further sub-library analysis, an arbitrary threshold of “8%” (equivalent to 
10% of the highest averaged inhibition potency (~80%) exhibited by inhibitors 
derived from W11) was set to select for the seven most potent warheads, W11, W1, 
W10, W5, W8, W2, and W3 (Figure 4.2B). Next, the contribution of the linker units 
and the building blocks were further analyzed (Figure 4.4); the Type I and Type II 
azide-containing sub-libraries were chosen as they gave the most comprehensive 
representation of different inhibitor components. Two interesting observations were 
made from this analysis. First, for the Type I azides, there was a marked preference 
for the 4-carbon alkyl linker, indicating an optimal length for fitting the bidentate 
inhibitor into the active and secondary sites of MptpB (Figure 4.4, Type I and Figure 
4.5). In contrast, inhibitors assembled using the Type II azides did not displayed a 
distinct preference for any of the alkyl linkers (Figure 4.4, Type II and Figure 4.5). 
Second, there were recurring building blocks that consistently showed high potency 
regardless of the linker length among the Type I and II azides (Figure 4.4, in red). The 
top-50 inhibitors from each of the seven sub-libraries were next identified, listed in 
Table 4.2, and analyzed using Venn diagram (Figure 4.6) to obtain inhibitors that 
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were potent across all the warheads. A total of 10 individual azides were found to be 
particularly strong secondary-site binders. Most of these azides contain hydrophobic 
building blocks (Table 4.1), with the highest-ranked azide being the recurring one as 
shown in Figure 4.4. Taken together, these observations indicate the potential of our 
small molecule library for evaluating individual components in a bidentate PTP 
inhibitor. 
	  
Figure 4.2 Inhibition profiles of the click library against MptpB. (A) 4-D plots of the 
inhibition fingerprints from the 2 largest sub-libraries that are assembled using the 11 
warheads and the Type I and II azides. Each inhibitor is represented by spheres 
positioned spatially across the warheads, linkers, and azides. Relative potency is given 
by both color spectrum (blue = least potent, red = most potent) and by size of the 
sphere (big = more potent, small = less potent) (B) Bar graph representation of 
averaged inhibitor potencies across sub-libraries derived from each of the 11 
warheads (red bar) sub-library derived from W11). An arbitrary threshold of “8%” 
(dashed line) was set to distinguish the seven most potent warheads. 
 
A 


























Figure 4.3 Colored heatmaps displaying the potency of the ~3500 member PTP 
inhibitor library against MptpB. The most potent inhibitor is highlighted in red while 











































Figure 4.4 Bar graph representing the averaged inhibition potencies from inhibitors 
assembled using the seven warheads and the Type I and Type II azides. The two 
recurring building blocks (structures shown below the bar graph) from each set of 
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Figure 4.5 Linker-specific scoring bar graphs representing the averaged inhibition 




Figure 4.6 Distribution of the top 50 inhibitors from the seven sub-libraries. (A) The 
top 50 inhibitors from W1, W5, W8 and W10 assembled libraries were first analyzed 
using the Venn diagram to generate 12 overlapping azides (Boxed in red). (B) The 
overlapping 12 azides were analyzed together with the top 50 inhibitors from W2, W3 
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Table 4.1 Structures of the 10 overlapping azides obtained from the Venn diagram 
analysis. The averaged ranking score was determined by averaging the ranking score 
of each corresponding inhibitor (Table 4.2) across the seven sub-libraries. 











































































Table 4.2 Comparison between the top 50 inhibitors obtained from the seven sub-
libraries. Overlapping azides from each group of inhibitors were shaded with the same 
color. 
Score W1 W2 W3 W5 W8 W10 W11 
1 F11-4C G8-4C G11-4C G1-4C G8-4C F11-2C H1-4C 
2 C2S-2C F11-4C G8-4C G11-4C G11-4C G8-4C F10-4C 
3 H2-4C E9-4C G1-4C G8-4C G1-4C F11-4C F12-4C 
4 H4-4C G5-4C F11-4C G6-4C E2S-6C G11-4C E9-4C 
5 G11-4C F3-4C F3-4C H2-4C H4S-3C F3-4C E6-4C 
6 E8-4C G6-4C G5-4C F11-4C A2S-5C E9-4C F3-4C 
7 G2-4C G11-4C G4-4C F9-4C H3-4C F9-4C E4-4C 
8 B6S-2C E6-4C G2-4C H3-4C G2S-3C G6-4C F6-4C 
9 H4S-3C F7-4C C11-2C D1-2C H1-4C F7-4C F9-4C 
10 E9-4C E4-4C G6-4C G4-4C G12-4C G5-4C F4-4C 
11 G12-4C F9-4C F8-4C G2-4C H4-4C F10-2C H2-4C 
12 E10-4C F8-4C F9-4C H4-4C G9-4C G1-4C E10-4C 
13 G6-4C G2-4C H2-4C F6-4C F11-4C E6-4C E5-4C 
14 E4-4C G4-4C H1-4C G5-4C A4S-2C G4-4C F2-4C 
15 F12-4C G1-4C H3-4C F10-4C H2-4C G11-6C H4-4C 
16 A2S-2C E8-4C D1-5C F8-4C C11-2C G2-4C F8-4C 
17 H10S-3C E7-4C E8-4C E9-4C G10-4C F6-4C G4-4C 
18 G5-4C E10-4C F7-4C G9-4C B2S-5C F8-4C E7-4C 
19 F7-4C H3-4C H4-4C F3-4C F3-4C E8-4C G5-4C 
20 H3-4C F10-4C E9-4C F9-2C A3S-5C F5-4C E12-4C 
21 G8-4C F5-4C F12-4C H1-4C E2S-4C C11-5C E3-4C 
22 E11-4C H2-4C G12-4C G4-2C F9-4C H1-4C F7S-4C 
23 E1-4C F2-4C E11-4C E8-4C H6S-3C G10-4C F1-4C 
24 G4S-3C G10-4C F6-4C F7-4C H2S-3C E4-4C G9-4C 
25 E7-4C F4-4C G9-4C C11-2C D1-5C F10-4C G10-4C 
26 G1-4C E3-4C F10-4C E7-4C F7S-6C G12-4C F9S-4C 
27 C1C-2C H4-4C D1-2C G11-6C H9S-3C H2-4C E11-4C 
28 C3S-2C G11-6C A9S-2C E11-4C F6S-6C F2-4C C2S-2C 
29 A2S-5C G9-4C E1-4C E10-4C F8S-6C G9-4C F5-4C 
30 F4-4C G12-4C H7-4C F11-6CS G6-4C E7-4C H3-4C 
31 A1S-2C F6-4C F5-4C H5-4C A4S-5C H3-4C F7-4C 
32 F6S-6C E11-4C E10-4C E6-4C F9S-6C G8-6C G1-4C 
33 F4S-6C H1-4C E7-4C D1-5C F2S-6C H4-4C G6-4C 
34 B4S-2C G8-6C G10-4C C11-5C A2S-2C D3-5C E8-4C 
35 E2S-4C C11-5C E3-4C E4-4C A3S-2C E11-4C E1-4C 
36 G3S-3C E5-4C E12-4C H7-4C B6S-5C G1-6C G12-4C 
37 H1-4C A2S-5C F11-6CS F8S-4C B4S-5C E2S-6C H2S-3C 
38 B7S-2C C8-5C H11S-3C G12-4C C2S-2C C11-2C G2-4C 
39 B4S-5C C2S-2C E6-4C E3-4C B6S-2C F4-4C F5S-4C 
40 C11-2C E2S-6C E4-4C E2-2C C1C-5C H1-6C G8-4C 
41 H5S-3C F11-6CS H3-6C G10-4C H3S-3C F12-4C B2S-2C 
42 B2S-2C D3-5C G7-2C C2-2C G1C-6C E2S-4C F8S-4C 
43 A11-2C E2S-4C D4-5C G3-2C B11-2C A2S-5C B9S-2C 
44 G7S-3C F11-2C C1-5C E1-4C F8-4C H3-6C B5S-2C 
45 F7S-6C H3-6C C8-5C A2S-2C C11-5C D1-5C F6S-4C 
46 A12S-2C F8S-6C E5-4C C8-2C D3-5C E10-4C E4S-4C 
47 E12-4C C11-2C C11-5C F6S-4C H5S-3C D3-2C E12S-4C 
48 G6S-3C F5S-6C B9S-2C B9S-2C C3S-2C D1-2C G11-4C 
49 E6-4C F2S-6C F11S-4C D3-2C F7-4C C8-5C H9S-3C 







4.3.3 Final Hits Selection and Biochemical Evaluations 
 Finally, to obtain a better quantitative representation of the inhibitor potency, 
IC50 determination was carried out with ~350 selected compounds (Figure 4.7), of 
which 16 of the most potent inhibitors (structures shown in Figure 4.8) were scaled up, 
purified, and fully characterized (by LCMS and NMR) before full biochemical 
evaluations were carried out against MptpB and other PTPs. The IC50, Ki values, and 
cell permeability of selected potent inhibitors are shown in Table 4.3 (see Tables 4.4, 
4.5 and 4.6 for full data). All compounds tested were in general cell permeable. The 
most potent and selective inhibitors, H1-6C-W11 and F1S-6C-W11 (see structures in 
Figure 4.1), showed Ki values of 170 and 150 nM, respectively, against MptpB, which 
are even more potent than the best MptpB inhibitor known in the literature (Ki) 220 
nM; reported by Ellman et al.189). More significantly, it showed 11- to 52- fold 
increases in selectivity over other PTPs tested. The azide and warhead components of 
the purified inhibitors were also screened individually against MptpB. Though W11 
alone was 10-fold less potent than H1-6C-W11 and F1S-6C-W11, none of the azide 
components showed any significant inhibition against MptpB. Finally, the two most 
potent inhibitors were computationally docked against the active site of MptpB using 
the Sybyl software, on the FlexX suite (Figure 4.8); results indicate that in both cases 
the N-phenyloxamic acid containing warhead binds in the active site pocket of MptpB, 
with its azide-containing secondary binder projecting into the secondary pocket, thus 







Table 4.3 IC50 (in µM) and Ki (in µM) of selected purified inhibitors against MptpB 
and other PTPs. 





H1-6C-W11 0.55 ± 0.03 (0.17 ± 0.03) 23-52 ND 
F1S-6C-W11 0.64 ± 0.09 (0.15 ± 0.01) 11-43 ND 
G4-6C-W11 0.84  ± 0.09 (0.77 ± 0.12) 9-43 545 
F7S-6C-W11 0.95 ± 0.08 (0.45 ± 0.01) 7-26 ND 
E4S-4C-W11 1.3 ± 0.18 (1.1 ± 0.11) 6-24 ND 
F5S-4C-W11 1.4 ± 0.12 (1.3 ± 0.04) 2-19 ND 
F7S-4C-W11 1.5 ± 0.28 (1.3 ± 0.15) 6-21 ND 
E2S-4C-W11 1.6 ± 0.10 (ND) 2-15 ND 
F6S-4C-W11 1.8 ± 0.03 (ND) 5-18 ND 
W11 3.56 ± 0.04 (1.62 ± 0.04) ND ND 
* Ratio of IC50 for other PTPs to that for MptpB. ND not determined. 
 
Figure 4.7 Colored heatmap displaying the IC50 of the ~350 selected MptpB 
inhibitors. 9 of the most potent inhibitors (Table 4.3) selected are boxed in green. 
IC50 < 0.5 µM 
IC50 > 17.0 µM 
IC50 = 2.0 µM 































Table 4.4 IC50 plots of selected purified inhibitors against different PTPs. 
Inhibitor MptpB PTP1B TCPTP YopH LMWPTP 


















IC50 = 0.55 µM 


















IC50 = 14.57 µM 



















IC50 = 12.86 µM 



















IC50 = 13.21 µM 



















IC50 = 28.72 µM 


















IC50 = 0.64 µM 





















IC50 = 7.12 µM 


















IC50 = 8.15 µM 



















IC50 = 7.23 µM 



















IC50 = 27.39 µM 
G4-6C-W11 



















IC50 = 0.84 µM 



















IC50 = 8.14 µM 



















IC50 = 7.82 µM 



















IC50 = 9.34 µM 























Table 4.4 (continued) 
Inhibitor MptpB PTP1B TCPTP YopH LMWPTP 
F
7S-6C-W11 




















C50 = 0.95 µM 




















50 = 6.70 µM 




















C50 = 6.79 µM 




















C50 = 8.94 µM 




















C50 = 24.90 µM 
E
4S-4C-W11 



















IC50 = 1.31 µM 




















C50 = 12.69 µM 



















IC50 = 12.20 µM 



















IC50 = 7.77 µM 




















C50 = 30.84 µM 
F
5S-4C-W11 



















IC50 = 1.44 µM 




















C50 = 5.03 µM 



















IC50 = 3.11 µM 



















IC50 = 27.03 µM 

























Table 4.5 Ki plots of selected purified inhibitors against MptpB. 
Inhibitor Ki Inhibitor Ki 
 
H1-6C-W11 













Ki =0.17 µM 
 
F1S-6C-W11 












Ki =0.15 µM 
 
G4-6C-W11 












Ki = 0.77 µM 
 
F7S-6C-W11 















Ki = 0.45 µM 
 
E4S-4C-W11 











Ki = 1.10 µM 
 
F5S-4C-W11 










Ki =0.17 µM 
 
F7S-4C-W11 























Table 4.6 Complete IC50, in µM, (and Ki in µM) of all purified inhibitors against MptpB, other PTPs and their cell permeability. Selected results 
were also shown in Table 4.3. 













H1-6C-W11 0.55 ± 0.03 (0.17 ± 0.03) 14.6 ± 0.02 12.9 ± 3.62 13.2 ± 3.33 28.7 ± 0.80 23-52 ND 
F1S-6C-W11 0.64 ± 0.09 (0.15 ± 0.01) 7.1 ± 0.41 8.1 ± 0.91 7.2 ± 0.60 27.4 ± 1.93 11-43 ND 
G4-6C-W11 0.84 ± 0.09 (0.77 ± 0.12) 8.1 ± 0.87 7.8 ± 0.77 9.3 ± 1.39 36.3 ± 1.84 9-43 545 
F7S-6C-W11 0.95 ± 0.08 (0.45 ± 0.01) 6.7 ± 0.63 6.8 ± 1.25 8.9 ± 0.31 24.9 ± 0.99 7-26 ND 
E4S-4C-W11 1.3 ± 0.18 (1.1 ± 0.11) 12.7 ± 2.02 12.2 ± 2.52 7.8 ± 0.97 30.8 ± 0.51 6-24 ND 
F5S-4C-W11 1.4 ± 0.12 (1.3 ± 0.04) 5.0 ± 0.58 3.1 ± 0.34 27.0 ± 0.94 11.0 ± 0.96 2-19 ND 
F7S-4C-W11 1.5 ± 0.28 (1.3 ± 0.15) 9.5 ± 0.82 15.7 ± 3.37 20.9 ± 2.53 32.0 ± 2.67 6-21 ND 
E2S-4C-W11 1.6 ± 0.10 (ND) 4.1 ± 0.80 2.4 ± 0.31 23.2 ± 5.0 11.7 ± 1.08 2-15 ND 
F6S-4C-W11 1.8 ± 0.03 (ND) 17.6 ± 2.17 8.4 ± 0.49 17.4 ± 3.47 32.9 ± 1.32 5-18 ND 
W11 3.56 ± 0.04 ND ND ND ND ND ND 
E9-4C-W11 6.0 ± 0.09 7.4 ± 1.41 5.4 ± 0.11 16.9 ± 0.05 20.2 ± 1.76 0.9-3 ND 
F8-4C-W11 14.6 ± 0.23 15.5 ± 1.04 28.8 ± 1.41 19.3 ± 2.96 317.7 ± 37.64 1-22 ND 
G4-4C-W11 6.4 ± 0.01 8.8 ± 0.93 7.4 ± 0.51 24.2 ± 4.90 22.8.3 ± 0.32 1-4 ND 
G6-4C-W11 8.6 ± 1.14 17.3 ± 3.14 21.1 ± 4.23 15.2 ± 0.26 254.8 ± 0.32 2-30 ND 
F8S-6C-W11 4.8 ± 0.49 8.1 ± 0.67 8.5 ± 0.34 9.0 ± 0.62 31.2 ± 0.69 2-7 653 
F3S-6C-W11 5.8 ± 0.82 7.1 ± 1.01 7.8 ± 1.09 10.0 ± 1.66 28.0 ± 1.22 1-5 558 




























Figure 4.8 Molecular docking of (A) F1S-6C-W11, (B) H1-6C-W11, (C) W11, and 
(D) Ellman-19 into the active site of MptpB. Inhibitor F1S-6C-W11 and H1-6C-





 In conclusion, a ~3500-member library of bidentate inhibitors against protein 
tyrosine phosphatases (PTPs) has been synthesized, in high throughput, using click 
chemistry. This, to the best of our knowledge, constitutes the largest click chemistry 
library ever assembled. Subsequent direct in situ screening led to the identification of 
highly potent and selective MptpB inhibitors. The systematic analysis of the structure-
activity relationship made possible by our inhibitor library against PTPs may shed 








High-Throughput Amenable Solid-Phase Synthesis 






 A highly efficient strategy for the solid-phase synthesis of azidomethylene 
inhibitors targeting cysteine proteases is described. The method is highlighted by its 
compatibility with readily available building blocks, as well as its ability to 
accommodate different functional groups. A 249-member library has thus far been 














































 Recent advances in genomics and proteomics necessitates the development of 
highly efficient chemical reactions capable of rapid synthesis of potential drug 
candidates.29 Such reactions are exempliﬁed by their high efficiency (e.g. quantitative 
product formation), good tolerance toward a variety of functional groups, and 
compatibility with screening (e.g., reaction is carried out in water; no product 
purification is necessary before biological assay). Thus far, the Cu(I)-catalyzed 1,3-
dipolar cycloaddition reaction, or better known as “click chemistry”, between an azide 
and an alkyne, has been extensively studied,185 and proven to be highly successful, 
especially for high-throughput synthesis and discovery of enzyme-inhibitors.191 The 
amide-forming reaction between an amine and an acid is one of the most efficient 
reactions known, and has recently been applied successfully in the rapid discovery of 
inhibitors against a number of enzymes, such as HIV proteases,192,193 β-aryl 
sulfotransferase,194 α-fucosidases,195,196 and SARS-3CL protease.197 This chemistry 
has some key characteristics of a high-throughput amenable reaction, in that 
quantitative product formation can be achieved using powerful acylating/coupling 
reagents. As such, in situ biological screening may be carried out directly without 
product purification. The method, however, is severely limited by the presence of 
coupling reagents and, more often than not, byproduct and excessive starting 
materials in the reaction, and subsequently during in situ screening, which may lead to 
false results (Figure 5.1a; pathway A).198 In fact, in a recent study by Wong et al., the 
authors unexpectedly discovered that it was the intermediate active ester formed 
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between a carboxylic acid (a starting material) and HBTU (a coupling reagent) which 






























































































Figure 5.1 Overall strategy of inhibitor design. (A) Two strategies using amide-
forming reactions. (B) Structures of different known caspase inhibitors. 
Herein, we report a traceless solid-phase method for rapid synthesis of novel small 
molecule inhibitors using amide bond-forming reactions (Figure 5.1A; pathway B); 
the strategy takes advantage of the 4-formyl-3-methoxyphenoxy (FMP) resin for (1) 
amine capturing using an aldehyde handle; (2) subsequent solid-phase amide-forming 
reaction with a linker and an incoming acid using suitable coupling reagents; and (3) 
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cleavage/release of desired products which are of sufficient purity for direct in situ 
screening. The method is “traceless”, allowing the use of the exact same sets of 
starting materials as in pathway A (e.g., same amine/acid building blocks) in solid 
phase without any modification. We have successfully implemented this strategy for 
the facile synthesis of 249-member azidomethylene inhibitors targeting cysteine 
proteases. 
5.3 Results and Discussion 
5.3.1 Design and Synthesis of Inhibitors 
 Among the numerous classes of cysteine proteases involved in human diseases, 
caspases are well-known to play key roles in the regulation of apoptosis and 
inflammatory responses.118 With more than 15 different members identified so far, the 
hallmark of this family of enzymes is their absolute requirement for an aspartic acid 
residue at the P1 site of their substrates. Over the past few years, a variety of caspase 
inhibitors, both reversible and irreversible, have been developed.199 Most inhibitors 
contain an electrophilic “warhead” such as an aldehyde, ketone, halomethyl ketone, 
epoxide, or vinyl sulfone (Figure 5.1B, I), which reacts with the cysteine residue 
located in the active site of a caspase. To improve “druglike” properties, the P2 and P3 
positions in a peptide-based caspase inhibitor may be replaced with suitable 
nonpeptide linkers (see II200,201 in Figure 5.1b) with minimal effect on the inhibitor 
potency. The P4 position in a caspase inhibitor is known to be the major determinant 
of both its binding and specificity toward different caspases.118 For example, it has 
been shown that caspases 3 and 7 prefer charged/hydrophilic groups at this position, 
while caspase 1 prefers predominantly hydrophobic groups. Consequently, potent and 
(in some cases) specific inhibitors, such as II and III, were successfully developed.200-
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203 We were particularly intrigued by inhibitors such as III, which were recently 
reported by Fairlie and co-workers,202 as they contain a relatively unreactive 
azidomethylene group as the electrophilic warhead. We thought since an 
azidomethylene group is chemically and metabolically inert, molecules possessing 
this “warhead” might offer special advantages as potential cysteine protease 
inhibitors.29 We therefore decided to develop an efficient route capable of making 
azidomethylene inhibitors targeting different classes of cysteine proteases including 
caspases (Scheme 5.1). It is noted that, while our manuscript was in preparation, 
Fairlie et al. reported that peptidic azidomethylene inhibitors were unexpectedly 




























































































Scheme 5.1 Traceless solid-phase synthesis of azidomethylene inhibitors. 
 A 249-member small molecule library was constructed following Scheme 5.1, 
using the IRORI directed sorting technology.43 As shown in Figure 5.1B (boxed), 
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most members consist of an aspartic acid-derived azidomethylene warhead, a suitable 
linker located at the P2 and P3 positions to render the inhibitors more druglike, and a 
diverse P4 group introduced from commercially available building blocks (acids, 
sulfonyl chlorides, chloroformates, and isocyanates). To make the central amino azide 
scaffold, 4, an Fmocprotected amino acid 1 was converted into the corresponding 
alcohol 2, then subsequently into the corresponding azide 3 by the Mitsunobu reaction 
with hydrogen azide.204 Following removal of Fmoc group with 20% piperidine in 
DMF, the desired amino azides, 4a-d, were obtained in good yields. Next, 4 was 
attached to the FMP resin by reductive amination (6 equiv of NaBH(OAc)3 in DCE 
with 1% AcOH) via its amino group, which was concurrently converted to the resin-
bound, secondary amine 5. Subsequently, acylation of the amines was efficiently 
carried out with the corresponding Fmoc-protected carboxylic acid chloride linker 
(6a-c, 5 equiv) with DIEA (10 equiv) in anhydrous CH2Cl2, giving 7. Upon Fmoc 
removal (20% piperidine in DMF), the resulting resin was treated with a variety of 
commercially available building blocks (see Supporting Information). In general, 
acylation with acids (aromatic/aliphatic) was found to proceed cleanly with 
HBTU/HOBt, but for less reactive carboxylic acids, PyBOP/HOAt was shown to 
work better. Sulfonylation was found to proceed cleanly in DCM/DIEA with a 
catalytic amount of DMAP. Reactions with isocyanates proceeded smoothly in the 
presence of DIEA in DMF. Lastly, the cleavage was accomplished with a 
TFA/DCM/H2O (5:4:1) mixture, affording the desired products as the corresponding 
amides, carbamates, sulfonamides, and ureas in good yields (based on a theoretical 
loading of 0.9 mmol/g). A variety of functional groups such as esters, nitriles, 


































































































































































Figure 5.2 Representative structures of the 249-member azidomethylene library. 
5.3.2 High-Throughput Screening of Entire Library against Caspases 
 To ensure crude products generated from our synthetic route were sufficiently 
pure for direct in situ screening, we characterized them by LCMS and NMR; in most 
cases the desired produts were obtained with >90% purity and shown to be 
spectroscopically homogeneous (by NMR). It is also worth noting that, unlike what 
Fairlie et al. reported,203 we have NOT noticed any product degradation from selected 
compounds in our library even after 10-month storage. We next screened the 
compounds for inhibition against Caspase-1, -3, and -7 (Figure 5.3); at 10 µM 
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inhibitor concentration, while most compounds showed little or no inhibition against 
Caspase-3 and -7, a few of them inhibited Caspase-1 fairly well (i.e., W2-E1, W2-E2, 
W2-F6, W3-A2). Therefore these compounds were further screened against Caspase-
1 to obtain their IC50 and Ki values. We were pleased to find that the most potent 
inhibitor, W2-E1, was able to inhibit Caspase-1 with IC50 and Ki values of 1.78 and 
1.16 µM, respectively (Figure 5.4, 5.5). The same compound showed much weaker 
inhibition against Caspase-3 and -7 (IC50 > 200 µM and Ki values could not be 
accurately determined due to compound precipitation at higher concentrations). These 
values are moderate when compared to other potent Caspase-1 inhibitors.199,205 It 
nevertheless indicates that methylene azides are indeed useful pharmacophores for 









Figure 5.3 Inhibition profiles of the 249-member library against three caspases. 




Figure 5.4 Inhibition of identified “Hit”. (A) Structure of W2-E1; (b and c) IC50 and 
Ki of W2-E1 against Caspase-1, respectively. 
 
Figure 5.5 IC50 graphs for other inhibitors against Caspase-1. 
 
 











































































 In summary, we have developed an efficient and traceless solid-phase 
synthesis of azidomethylene derivatives as potential cysteine protease inhibitors. The 
strategy allows facile assembly of azidomethylene warheads with suitable nonpeptide 
linkers as well as a variety of readily available building blocks, all without the need of 
introducing extra functionalities in each of the components. Products generated were 
of uniformly high quality, enabling future direct in situ screening with a suitable 
biological target. Preliminary results indicate selected compounds are indeed 
moderate caspase inhibitors. This method should serve as a useful model for future 











6.1 General Information 
 All chemicals were purchased from commercial vendors and used without 
further purification. Rink Amide resin, all Fmoc amino acids, O-benzotriazole-
N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU), N-hydroxy-
benzotriazole (HOBt), triisopropylsilane (TIS) and Bromo-tris-pyrrolidino 
phosphonium hexafluorophosphate (PyBrOP) used in peptide synthesis were 
purchased from GL Biochem (China). 4-Formyl-3-methoxyphenoxy Resin (PL-FMP 
Resin, 0.9 mmol/g, 75~150 µm, Part no: 1465-799) was purchased from Polymer 
Laboratories (USA). All reactions requiring anhydrous conditions were carried out 
under an argon or nitrogen atmosphere using oven-dried glassware. HPLC grade 
solvents were used for all other solvents. Unless otherwise stated, all reactions were 
carried out at room temperature. Reaction progress was monitored by TLC on pre-
coated silica plates (Merck 60 F254, 0.25 µm) and spots were visualized by UV, iodine 
or Cerium Ammonium Molybdate (CAM) stain. Peptide synthesis progress was 
monitored by ninhydrin and/or chloranil test. Flash column chromatography was 
carried out using Merck 60 F254 0.040-0.063 µm silica gel. 
 1H, 13C and 31P NMR spectra were recorded on Bruker Avance 300 MHz, or 
Bruker Avance 500 MHz spectrometer. Chemical shifts were reported in parts per 
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million relative to internal standard Tetramethylsilane (Si(CH3)4 = 0.00 ppm) or 
residual solvent peaks (CHCl3 = 7.26 ppm, DMSO-d6 = 2.50 ppm). Chemical shift for 
31P spectra were reported relative to 85% phosphoric acid (H3PO4 = 0.00 ppm). 1H 
NMR data are reported as follows: chemical shift in ppm from the respective internal 
standard, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet, dd= doublet 
of doublets, ddd= doublet of doublets of doublets, dt = doublet of triplets or overlap of 
nonequivalent resonances), integration, coupling constant. 
 Mass spectra were recorded on a Finnigan LCQ mass spectrometer, a 
Shimadzu LC-IT-TOF spectrometer or a Shimadzu LC-ESI spectrometer. Analytical 
HPLC was carried out on Shimadzu LC-IT-TOF or Shimadzu LC-ESI system 
equipped with an autosampler, using reverse-phase Phenomenex Luna 5 µm C18 100 
Å 50 × 3.0 mm columns. Preparative HPLC was carried out on Gilson preparative 
HPLC system using Trilution software and reverse-phase Phenomenex Luna 5 µm 
C18(2) 100 Å 50 × 30.00 mm column. 0.1% TFA/H2O and 0.1% TFA/acetonitrile were 
used as eluents for all HPLC experiments. To purify selected compounds, semi-
preparative HPLC was carried out on a Phenomenex Luna C18 column (250 × 21.2 
mm). The flow rate was 0.6 mL/min for analytical HPLC and 8 mL/min for 
preparative HPLC. 
 Recombinant Caspases were expressed, purified and fluorescently labeled as 
previously described.81,133 Cruzain and Rhodesain were kindly provided by the 
McKerrow lab (UCSF). The parasites (P. Falciparum and T Brucei (BSF)) were 
generously donated by the groups of Kevin Tan and Cynthia He (NUS), respectively. 
 Recombinant 14-3-3σ protein was expressed, purified and fluorescently 
labeled as previously described.50 
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6.2 Solution Phase Synthesis 
























































a. Asp(t -Bu) b. Phe c. Lys(Boc) d. Leu e. Arg(Pbf)
NHBoc PbfHN NH
	  
Scheme 6.1 Synthesis of amino aldehyde. 
 All amino aldehyde Synthesis were based on previously published procedures 
(Scheme 6.1).132,133 Three methods were used for synthesis of amino aldehydes. The 
Fmoc-protected amino acid I was initially activated using isobutylchloroformate, 
followed by reduction of the mixed anhydride to the amino alcohol II. Swern 
oxidation/ Dess-Martin oxidation gave the amino aldehyde III (Method 1&2). 
 Method 3: To a dried flask flushed with N2 was added Fmoc-AA-OH (3 
mmol), N-hydroxy-benzotriazole (0.51 g, 3.3 mmol), dicyclohexylcarbodiimide (0.68 
g, 3.3 mmol) and 6mL DMF. After stirring for 30 min at room temperature, a solid 
formed and was removed by filtration. N,O-dimethylhydroxylamine (0.35 g, 3.6 
mmol), N,N’-diisopropylethylamine (0.46 g, 3.6 mmol) and another 4 mL DMF were 
added. After 3 hr, the mixture was concentrated. The crude oil was dissolved in ethyl 
acetate and washed with saturated sodium bicarbonate, 0.1M hydrochloric acid and 
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brine. The organic layer was dried (MgSO4), concentrated and further purified yield 
dimethylhydroxyl amide II intermediate. After then, LiAlH4 (137 mg, 3.6 mmol) was 
added to Fmoc-AA-dimethylhydroxyl amide II (2.55 mmol) in THF (10 mL) at 0 °C. 
The reaction was stirred for 20 min and quenched by addition of 10 mL 5% KHSO4. 
After aqueous work-up, the pure product was obtained by purification with flash 
chromatography to give amino aldehyde III. 
Fmoc-Asp(tBu)-H (IIIa): yield 86%. 1H NMR (300 MHz, CDCl3) 9.64 (s, 1H), 7.20-
7.90 (m, 8H), 4.10-4.50 (m, 4H), 2.86 (m, 2H), 1.31 (s, 9H). 13C NMR (60 MHz, 
CDCl3) 198.7, 170.1, 156.1, 143.6, 141.2, 127.7, 127.0, 125.0, 120.0, 82.1, 67.2, 56.5, 
47.0, 35.6, 27.9. (Method 1) 
Fmoc-Phe-H (IIIb): yield 90%. 1H NMR (300 MHz, CDCl3) 9.64 (s, 1H), 7.10-7.90 
(m, 12H), 4.10-4.60 (m, 4H), 3.15 (d, J = 6.4 Hz, 2H). 13C NMR (60 MHz, CDCl3) 
198.6, 155.8, 143.6, 141.3, 135.4, 129.2, 128.7, 127.7, 127.1, 127.0, 124.9, 119.9, 
66.9, 61.0, 47.1, 35.3. (Method 3) 
Fmoc-Lys(Boc)-H (IIIc): yield 87%. 1H NMR (300 MHz, CDCl3) 9.57 (s, 1H) 7.20-
7.90 (m, 8H), 4.10-4.60 (m, 4H), 3.11 (b, 2H), 1.2-1.7 (m, 15H). 13C NMR (60 MHz, 
CDCl3) 199.2, 156.1, 143.6, 141.2, 127.6, 127.0, 124.9, 119.9, 79.2, 66.9, 60.0, 47.1, 
39.7, 33.8, 29.7, 28.4, 22.0. (Method 2) 
Fmoc-Leu-H (IIId): yield: 81.0%. 1H NMR (300 MHz, CDCl3) 9.58 (s, 1H), 7.20-
7.90 (m, 8H), 4.10-4.60 (m, 4H), 1.71 (b, 2H), 1.30 (b, 1H), 0.97 (d, J = 4.4 Hz, 6H). 
13C NMR (60 MHz, CDCl3) 199.6, 156.1, 143.7, 141.2, 127.6, 127.0, 124.9, 119.9, 
66.8, 58.7, 47.1, 38.0, 24.5, 23.0, 21.8. (Method 3) 
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Fmoc-Arg(Pbf)-H (IIIe): yield: 85%. 1H NMR (300 MHz, CDCl3): δ 9.57 (s, 1H), 
7.73 (d, J = 4.2 Hz, 2H), 7.56 (d, J = 4.2 Hz, 2H), 7.36 (t, J = 4.6 Hz, 2H), 7.28 (t, J = 
3.4 Hz, 2H), 6.59 (s, 1H), 5.66 (s, 1H), 5.27 (d, J = 5.6 Hz, 1H), 4.76 (br s, 1H), 4.35 
(d, J = 4.2 Hz, 2H), 4.17 (t, J = 4.2 Hz, 1H), 2.92 (s, 2H), 2.07-2.00 (m, 6H), 3.61, (m, 
1H), 3.15 (t, J = 6.8 Hz, 1H), 1.77-1.52 (m, 4H), 1.44 (s, 6H). (Method 2) 
6.2.2 Procedure for Synthesis of Immobilization Linker 
Synthesis of Biotin-NHS. To a solution of D-biotin (2.4 g, 10 mmol) in DMF was 
added Nhydroxysuccinimide (1.4 g, 12 mmol) and EDC (2.3 g, 12 mmol). The 
reaction was allowed to proceed overnight. The resulting mixture was concentrated in 
vacuo, giving a gel-like residue, which was recrystallized from EtOH/acetic acid/H2O 
(95:1:4) to afford biotin- NHS as a white solid (2.9 g, 85% yield). 1H NMR (300 MHz, 
CD3OD) d 6.40 (br s, 1H), 6.35 (br s, 1H), 4.33 – 4.29 (m, 1H), 4.17 – 4.13 (m, 1H), 
3.12 – 3.08 (m, 1H), 2.86 – 2.81 (m, 5H) including 2.81 (s, 4H), 2.67 (t, J = 7.2, 2H), 
2.61 – 2.59 (m, 1H), 1.70 – 1.24 (m, 6H). ESI-MS: m/z [M+Na]+ = 367.1. 
Synthesis of Fmoc-Lys-(Biotin)-OH. To a solution of Fmoc-Lys(Boc)-OH (3.98 g, 
8.5 mmol) in DCM (4 ml) was added TFA (4 ml). The reaction was stirred at room 
temperature for 1 hr and concentrated in vacuo. The oil residue was dissolved in an 28 
ml of dioxane/water mixture (1:1), and the pH of the solution was adjusted to 8 – 8.5 
(using 4M NaOH) at 0ºC. Biotin-NHS (2.9 g, 8.5 mmol) was subsequently added, and 
the reaction mixture was stirred at room temperature overnight. To the resulting 
gelatinous solid was added ether and stirred for 5 min, then the supernatant ether was 
decanted off. Acetone was subsequently added. The pH of the solution was adjusted 
to 3 (using 2M HCl) at 0 ºC. Finally, the solid was filtered, washed several times with 
MeOH to afford the pure Fmoc-Lys-(Biotin)-OH as a white solid (4.15 g, 82%). 1H 
NMR (300 MHz, CD3OD) d 7.89 (d, J = 7.6, 2H), 7.72 (d, J = 7.7, 2H), 7.42 (t, J = 
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7.3, 2H), 7.33 (t, J = 7.3, 2H), 6.41 (br s, 1H), 6.35 (br s, 1H), 4.31 – 4.22 (m, 4H), 
4.13 – 4.09 (m, 1H), 3.91 – 3.84 (m, 1H), 3.10 – 3.00 (m, 3H), 2.80 (dd, J = 4.9, J = 
12.2, 1H), 2.56 (d, J = 12.5, 1H), 2.03 (t, J = 7.3, 2H), 1.61 – 1.29 (m, 12H). ESI-MS: 
m/z [M+Na]+ = 618.2. 
6.2.3 Synthesis of Small Molecule “Hit” Compounds and Corresponding 










































































































































































































































































6.2.3.1 General procedure for the synthesis of compound I  
 To a stirring DMF solution of the Fmoc-protection amino acid (Fmoc-
Ser(tBu)-OH or Fmoc-Ser[PO(OBzl)-OH]-OH, 1.0 eq.), coupling reagent HOBt (1.2 
eq.), HBTU (1.2 eq.) and DIPEA (2.4 eq.) were added. After pre-active for 10 min, 
corresponding amine (R2, 1.1 eq.) was added into the solution. Reaction was 
monitored by TLC. The finished reaction mixture was concentrated. The crude oil 
was re-dissolved in ethyl acetate and washed with 5% citric acid, 5% sodium 
bicarbonate, and brine. After aqueous work-up, the pure product was obtained by 
purification with flash chromatography to give the first coupling product I (85-95% 
yield). 
 
6.2.3.2 General procedure for the synthesis of compound II  
 To deprotect the Fomc group, compound I was re-dissolved in DMF. 
Subsequently, piperidine (5 eq.) was added. Reaction was monitored by TLC until 
completion. The reaction mixture was concentrated in vacuo and directly used for the 
next step without purification. Fmoc-Gly-OH (1.1 eq.) was active by stirring with 
coupling reagent HOBt (1.2 eq.), HBTU (1.2 eq.) and DIPEA (2.4 eq.). After pre-
activation for 10 min, the deprotected I (1.0 eq.) in DMF was added into the mixture. 
The reaction was monitored by TLC until completion. The resulting mixture was then 
concentrated, redissolved in ethyl acetate and washed with 5% citric acid, 5% sodium 
bicarbonate, and brine. After aqueous work-up, the pure product was obtained by 




6.2.3.3 General procedure for the synthesis of compound(1-1 to 2-6)  
 The Fmoc group was deprotected as described above. The corresponding acid 
(R1, 1.1 eq.) was activated by stirring with coupling reagent HOBt (1.2 eq.), HBTU 
(1.2 eq.) and DIPEA (2.4 eq.) for 10 min. Subsequently, the deprotected compound I 
or II (1.0 eq.) was added into the mixture. The reaction was monitored by TLC until 
completion. The resulting mixture was concentrated, redissolved in ethyl acetate and 
washed with 5% citric acid, 5% sodium bicarbonate, and brine. After aqueous work-
up, the pure product was obtained by purification with flash chromatography to give 
the final coupling product (85-95% yield). The coupling product was finally stirred in 
TFA to remove the protecting group tBu and Bzl, yielding the final products 1-1 to 2-6, 
which upon precipitation with diethyl ether, were further purified by semi-preparative 
HPLC to homogeneity. 
 
(S)-4-(chloromethyl)-N-(2-((3-hydroxy-1-((4-hydroxyphenethyl)amino)-1-oxopropan-
2-yl)amino)-2-oxoethyl)benzamide (1-1). 1H-NMR (500 MHz, DMSO-d6) δ 9.14 
(s, 1H), 8.81 (t, J = 5.77 Hz, 1H), 7.97 (d, J = 7.98 Hz, 1H), 7.88 (m, 3H), 7.54 (d, J = 
8.25 Hz, 2H), 6.98 (dd, J1 = 8.65 Hz, J2 = 2.37 Hz, 2H), 6.67 (d, J = 8.38 Hz, 2H), 
4.81 (s, 1H), 4.23-4.26 (m, 1H), 3.87-4.03 (m, 2H), 3.52-3.64 (m, 2H), 3.18-3.25 (m, 
2H), 2.57-2.60 (m, 2H). 13C-NMR (125 MHz, DMSO-d6) δ 169.6, 168.8, 166.2, 155.6, 
140.8, 133.7, 129.4 (2C), 128.7, 127.6, 115.1, 61.6, 55.2, 45.4, 42.8, 40.8, 34.3. IT-
















amino)-2-oxoethyl)-4-(chloromethyl)benzamide (1-2). 1H-NMR (500 MHz, 
DMSO-d6) δ 8.82 (t, J = 5.75 Hz, 1H), 8.28 (t, J = 6.00 Hz, 1H), 8.04 (d, J = 7.86 Hz, 
1H), 7.84 (d, J = 8.29 Hz, 2H), 7.53 (d, J = 8.24 Hz, 2H), 6.80 – 6.84 (m, 3H), 6.73 
(dd, J1 = 7.92 Hz, J2 =1.29 Hz, 1H), 5.95 (dd, J1 = 5.00 Hz, J2 = 0.89 Hz, 2H), 4.93 (t, 
J = 5.44 Hz, 1H), 4.81 (s, 2H), 4.31 (dt, J1 = 7.88 Hz, J2 = 5.32 Hz, 1H), 4.22 (d, J = 
6.02 Hz, 2H), 3.92-4.00 (m, 2H), 3.58-3.69 (m, 2H). 13C-NMR (125 MHz, DMSO-d6) 
δ 169.8, 169.0, 166.2, 147.2, 145.9, 140.8, 133.7, 133.1, 128.6, 127.6, 120.1, 107.8, 











enamide (1-3).  1H-NMR (500 MHz, DMSO-d6) δ 9.16 (s, 1H), 7.79 (t, J = 5.63 
Hz, 1H), 7.68 (d, J = 8.09 Hz, 1H), 6.97 (d, J = 8.44 Hz, 2H), 6.65 (d, J = 8.45 Hz, 
2H), 5.78 (s, 1H), 4.81 (t, J = 5.60 Hz, 1H), 4.26 (dt, J1 = 8.03 Hz, J2 = 5.73 Hz, 1H), 
3.52 (dd, J1 = 8.61 Hz, J2 = 3.33 Hz, 2H), 3.13-3.25 (m, 2H), 2.57 (t, J = 7.04 Hz, 2H), 
2.08 (d, J = 0.95 Hz, 3H), 1.79 (d, J = 0.92 Hz, 3H). 13C-NMR (125 MHz, DMSO-d6) 
δ 170.0, 165.8, 155.6, 148.9, 129.4, 119.0, 115.0, 61.7, 54.8, 40.5, 34.3, 26.8, 19.3. 












methylbut-2-enamide (1-4).  1H-NMR (500 MHz, DMSO-d6) δ 8.26 (t, J = 
5.99 Hz, 1H), 7.74 (d, J = 8.01 Hz, 1H), 6.80-6.82 (m, 2H), 6.72 (dd, J1 = 7.95 Hz, J2 
= 1.28 Hz, 1H), 5.96 (s, 2H), 5.79 (d, J = 1.11 Hz, 1H), 4.87 (t, J = 5.51 Hz, 1H), 4.32 
(dt, J1 = 7.96, J2 = 5.63 Hz, 1H), 4.19 (d, J = 6.01 Hz, 2H), 3.58 (t, J = 5.93 Hz, 2H), 
2.08 (d, J = 0.72 Hz, 3H), 1.78 (d, J = 0.68 Hz, 3H). 13C-NMR (125 MHz, DMSO-d6) 
δ 170.3, 165.8, 149.0, 147.2, 145.9, 133.3, 120.1, 119.0, 107.8, 107.7, 100.7, 61.7, 













yl)amino)-2-oxoethyl)benzamide (1-5).   1H-NMR (500 MHz, DMSO-d6) 
δ 9.15 (s, 1H), 8.80 (t, J = 5.69 Hz, 1H), 7.91-7.97 (m, 3H), 7.87 (t, J = 5.55 Hz, 1H), 
7.22 (d, J = 8.60 Hz, 2H), 6.98 (d, J = 8.37 Hz, 2H), 6.67 (d, J = 8.45 Hz, 2H), 4.86 (s, 
1H), 4.23-4.26 (m, 1H), 3.94 (qd, J1 = 16.25 Hz, J2 = 5.75 Hz, 2H), 3.57 (s, 2H), 3.19-
3.23 (m, 2H), 2.57-2.61 (m, 2H). 13C-NMR (125 MHz, DMSO-d6) δ 169.6, 168.9, 
165.7, 155.6, 142.5, 130.5, 129.4, 129.2, 118.9, 115.1, 61.6, 55.2, 42.8, 40.8, 34.3. IT-
















oxopropan-2-yl)amino)-2-oxoethyl)benzamide (1-6).  1H-NMR (500 
MHz, DMSO-d6) δ 8.81 (t, J = 5.71 Hz, 1H), 8.28 (t, J = 5.99 Hz, 1H), 8.04 (d, J = 
7.93 Hz, 1H), 7.89 (d, J = 8.61 Hz, 2H), 7.20 (d, J = 8.64 Hz, 2H), 6.80 - 6.83 (m, 2H), 
6.73 (d, J = 8.04 Hz, 1H), 5.95 (d, J = 3.60 Hz, 2H), 4.31 (dt, J1 = 7.82 Hz,  J2 = 5.32 
Hz, 1H), 4.21 (d, J = 6.00, 2H), 3.94 (ddd, J1 = 36.84, J2 = 16.23, J3 = 5.73 Hz, 2H), 
3.64 (ddd, J1 = 28.64 Hz, J2 = 10.68 Hz, J3 = 5.32 Hz, 2H). 13C-NMR (125 MHz, 
DMSO-d6) δ 169.8, 169.1, 165.7, 147.2, 145.9, 142.4, 133.1, 130.4, 129.2, 120.1, 


















oxopropyl dihydrogen phosphate (2-1). 1H-NMR (500 MHz, DMSO-d6) δ 9.15 
(s, 1H), 8.85 (t, J = 5.72 Hz, 1H), 8.28 (d, J = 8.00 Hz, 1H), 8.02 (t, J = 5.60 Hz, 1H), 
7.88 (d, J = 8.20 Hz, 2H), 7.54 (d, J = 8.22 Hz, 2H), 6.99 (d, J = 8.35 Hz, 2H), 6.67 (d, 
J = 8.39 Hz, 2H), 4.81 (s, 2H), 4.44-4.48 (m, 1H), 3.89-4.04 (m, 4H), 3.19-3.23 (m, 
2H), 2.58-2.60 (m, 2H).13C-NMR (125 MHz, DMSO-d6) δ 169.0, 168.3, 166.3, 155.6, 
140.8, 133.7, 129.4, 129.3, 128.7, 127.7, 115.1, 64.9, 53.2, 45.4, 42.8, 40.9, 34.2. 31P-






















acetamido)-3-oxopropyl dihydrogen phosphate (2-2). 1H-NMR (500 MHz, 
DMSO-d6) δ 8.85 (t, J = 5.78 Hz, 1H), 8.40 (t, J = 6.12 Hz, 1H), 8.36 (d, J = 8.05 Hz, 
1H), 7.84 (d, J = 8.20 Hz, 2H), 7.52 (d, J = 8.15 Hz, 2H), 6.80-6.82 (m, 2H), 6.74 (d, 
J = 7.60 Hz, 1H), 5.95 (d, J = 4.35 Hz, 2H), 4.81 (s, 2H), 4.51-4.55 (m, 1H), 4.18-
4.26 (m, 2H), 3.88-4.07(m, 4H).13C-NMR (75 MHz, DMSO-d6) δ 169.2, 168.5, 166.4, 
147.2, 146.0, 140.8, 133.7, 132.8, 128.6, 127.7, 120.3, 107.9, 107.8, 100.7, 64.9, 62.3, 
45.37, 42.9. 42.0. 31P-NMR (121 MHz, DMSO-d6) δ -0.53. IT-TOF: m/z [M+H]+ 













dihydrogen phosphate (2-3). 1H-NMR (500 MHz, DMSO-d6) δ 9.21 (s, 1H), 8.02 (t, 
J = 5.60 Hz, 1H), 7.88 (d, J = 8.15 Hz, 1H), 6.96 (dd, J1 = 8.45 Hz, J2 = 3.30 Hz, 2H), 
6.66 (dd, J1 = 8.42 Hz,  J2 = 3.21 Hz, 2H), 5.77 (d, J = 6.80 Hz, 2H), 4.44-4.53 (m, 
1H), 3.37-4.04 (m, 2H), 2.56-2.58 (m, 2H), 2.11 (s, 3H), 1.82 (m, 3H).13C-NMR (125 
MHz, DMSO-d6) δ 168.7, 165.6, 155.6, 149.7, 129.5, 118.7, 115.1, 65.1, 52.8, 40.8, 
34.3, 26.8, 19.4. 31P-NMR (121 MHz, DMSO-d6) δ -0.63. IT-TOF: m/z [M+H] + calcd: 
















oxopropyl dihydrogen phosphate (2-4).  1H-NMR (500 MHz, DMSO-d6) 
δ 8.41 (t, J = 5.92 Hz, 1H), 7.98 (d, J = 8.05 Hz, 1H), 6.80-6.82 (m, 2H), 6.72 (dd, J1 
= 7.82 Hz, J2 = 1.59 Hz, 1H), 5.96 (s, 2H), 5.77 (s, 1H), 4.53 (dd, J1 =13.56 Hz, J2 = 
5.95 Hz, 1H), 4.19 (ddd, J1 = 25.78 Hz, J2 = 14.98 Hz, J3 = 5.94 Hz, 2H), 3.94-4.00 
(m, 2H), 2.08 (d, J = 0.83 Hz, 3H), 1.79 (m, 3H). 13C-NMR (75 MHz, DMSO-d6) δ 
169.0, 165.9, 149.7, 147.2, 146.0, 133.0, 120.3, 118.8, 108.0, 107.8, 100.8, 65.0, 52.9, 
42.0, 26.9, 19.4. 31P-NMR (121 MHz, DMSO-d6) δ -0.57. IT-TOF: m/z [M+H]+ calcd: 
















dihydrogen phosphate (2-5).  1H-NMR (500 MHz, DMSO-d6) δ 9.23 (s, 1H), 
8.89 (t, J = 5.69 Hz, 1H), 8.17 (d, J = 8.17 Hz, 1H), 8.11 (t, J = 5.47 Hz, 1H), 7.92 (d, 
J = 8.63 Hz, 2H), 7.22 (d, J = 8.63 Hz, 2H), 6.98 (d, J = 8.45 Hz, 2H), 6.68 (d, J = 
8.40 Hz, 2H), 5.75 (s, 1H), 4.49 (dd, J1 = 14.8 Hz, J2 = 7.28 Hz, 1H), 3.81-4.07 (m, 
4H), 3.12-3.16 (m, 2H), 2.59 (t, J = 7.59 Hz, 2H). 13C-NMR (75 MHz, DMSO-d6) δ 
169.6, 169.5, 166.3, 156.1, 143.0, 130.6, 129.7, 129.5, 129.4, 119.3, 115.5, 63.4, 55.2, 
43.1, 41.3, 34.7. 31P-NMR (121 MHz, DMSO-d6) δ -0.56. IT-TOF: m/z [M+H]+ calcd: 



















3-oxopropyl dihydrogen phosphate (2-6). 1H-NMR (500 MHz, DMSO-d6) δ 8.84 (t, 
J = 5.67 Hz, 1H), 8.40 (t, J = 5.98 Hz, 1H), 8.36 (d, J = 8.00 Hz, 1H), 7.89 (d, J = 
8.62 Hz, 2H), 7.20 (d, J = 8.62 Hz, 2H), 6.79-6.81 (m, 2H), 6.74 (dd, J1 = 8.01 Hz, J2 
= 1.29 Hz, 1H), 5.96 (d, J = 2.80 Hz, 2H), 4.53 (dd, J1 = 13.34 Hz, J2 = 5.71 Hz, 1H), 
4.18-4.26 (m, 2H), 4.00-4.08 (m, 2H), 3.93 (ddd, J1 = 40.24 Hz, J2 = 16.26 Hz, J3 = 
5.71 Hz, 2H). 13C-NMR (125 MHz, DMSO-d6) δ 169.2, 168.5, 165.9, 147.2, 146.0, 
142.4, 132.8, 130.4, 129.2, 120.2, 118.8, 107.9, 107.7, 100.7, 64.9, 53.4, 42.9, 42.0. 
31P-NMR (121 MHz, DMSO-d6) δ -0.53. IT-TOF: m/z [M+H]+ calcd: 521.11, found: 
521.11. 
6.3 Solid Phase Synthesis 
6.3.1 Procedure for Peptide Aldehyde Library Synthesis 
6.3.1.1 Synthesis of Threonyl-Glycyl Resin (TG-resin) 
 Fmoc-Gly-OH was loaded onto aminomethyl polystyrene resin (10 g, loading 
0.3 - 0.8 mmol/g) previously swollen in DMF as described in the general procedure 
for coupling amino acids onto solid support. After the coupling reaction, the resin was 
filtered and washed with DMF (3 ×), DCM (3 ×) and DMF (3 ×). Fmoc deprotection 
was carried out in 20% piperidine/DMF for 30 min. The resin was extensively washed 
with DMF (3 ×), DCM (3 ×) and DMF (3 ×). The procedure was repeated with Fmoc-
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Thr(tBu)-OH to give the O-protected TG-resin. Any unreacted resin was capped with 
a solution of Ac2O (10 eq.), DIEA (20 eq.) in DCM for 2 hr at RT, followed by 
extensively wash with DCM and DMF. Deprotection of tert-butyl group was carried 
out with TFA/DCM (1:1) for 1 hr. The resin was subsequently washed with DCM (5 
×), then 10% DIEA/DCM for 2 × 10 min, then with DCM (3 ×), DMF (3 ×) and 
MeOH (3 ×) and dried in vacuo to give the final TG-resin. 
6.3.1.2 Loading Fmoc-Amino-CHO onto TG-resin  
 Fmoc-Amino-CHO (3 eq.) was dissolved in 1%DIEA/MeOH and added to the 
TG-resin and shaken for 2 hr at 60°C. The resin was washed with MeOH (3 ×), then 
with DCM (3 ×), DMF (3 ×). 
6.3.1.3 Boc-protection of Secondary Amine in Oxazolidine Moiety 
 Boc2O (10 eq.) was dissolved in DMF and added to the loaded resin and DIEA 
(20 eq.) was added. The resin was shaken for 2 hr, filtered and washed with DMF (3 
×), DCM (3 ×), DMF (3 ×). The resin was then dried and swollen in DMF for 30 min 
before prior to coupling the first Fmoc amino acid. 
6.3.1.4 Peptide Synthesis 
 Fmoc amino acids were coupled sequentially onto the resin-bound aldehyde 
using the standard procedures for coupling and Fmoc deprotection for the synthesis of 
the peptide. Biotin was coupled to the N-terminus of each peptide using the same 





6.3.1.5 Side-chain Deprotection and Cleavage of Peptide Aldehyde from Resin 
 The side chains and Boc-protected oxazolidines were deprotected by shaking 
the resin in deprotection cocktail of TFA/TIS/EDT (95:5:0.1) for 30 min. The peptide-
aldehyde were released from the solid support by adding a cleavage cocktail of 
ACN/H2O/TFA (60:40:0.1) to the resin and shaking for 30 min at 60°C. This release 
procedure was repeated for another 2 times. Subsequently the compounds were 
concentrated in vacuo (Genevac, USA) to remove most of the cleavage cocktail (> 
80%), followed by addition of cold ether (chilled to -20°C) and kept in -20°C freezer 
overnight. The precipitated peptides were collected, and washed with more cold ether, 
then dried thoroughly in vacuo. The resulting peptide solids were dissolved in 1 mL 

































































































Scheme 6.3 Reagents and conditions for synthesis of the peptide aldehyde probe. (a) i: 
Fmoc-Gly-OH, HBTU, HOBt, DIEA, DMF, 4 hr; ii: 20% piperidine/DMF, 30 min; iii 
Fmoc-Thr(OtBu)-OH, HBTU, HOBt, DIEA, DMF, 4 hr;  iv: Ac2O, DIEA, DCM, 2 hr. 
(b) i: 20% piperidine/DMF, 30 min; ii: TFA/DCM (1:1) 1 hr; iii: 10% DIEA/DCM. (c) 
i:1%DIEA/MeOH , 2hr, 60°C. (d) Boc2O, 1%DIEA/DCM, 2hr. (e) i: 1% TFA/DCM, 
30 min; ii: BP, HBTU, HOBt, DIEA, DMF, 4hr. (f) i. TFA/TIS/EDT (95:5:0.1); ii. 




 The synthesis was followed by section 6.3.1, except the peptide sequence was 
changed to Biotin-Gly-Gly-Ala-Arg-Phe-Lys(BP)-CHO, where BP stand for 
benzophenone (Scheme 6.3). 
6.3.3 Synthesis of Peptide-Small Molecule Hybrid Libraries 




















































































Scheme 6.5 Synthesis of the C-terminal sub-library. 
 The synthesis was performed by using standard Fmoc Strategy combined with 
IRORITM directed sorting technology, following previously published procedures.135 
For the N-terminal sub-library (Scheme 6.4), Rink amide resin was used as the solid 
support. Standard HOBt/HBTU/DIPEA coupling method was used throughput the 
whole process. The HOBt/HBTU/DIPEA coupling method was proved to be the most 
ideal way to incorporate Fmoc-Ser[PO(OBzl)-OH]-OH. Each microreactor contains 
around 40 mg of rink amide resin and a unique RF tag for sorting application. The 
resin was swelled in HPLC-grade DMF for 1 hr at room temperature. Subsequently 
the Fmoc group was deprotected by treatment of 20% piperidine for 1 hr at room 
temperature. Following removal of the piperidine, the resin was washed extensively 
with DMF and DCM. The microreactors were dried thoroughly in vacuo. After the 
first coupling of Fmoc-Lys(Biotin)-OH, any unreacted resin residue was capped with 
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a solution of Ac2O (10 eq.), DIPEA (20 eq.) in DCM, and the reaction mixture was 
allowed to react for 2 hr at room temperature, followed by extensive wash with DCM 
and DMF.	  Subsequently the resin was deprotected with 20% piperidine again and 
ready for next coupling cycle. Repeat the above cycle until the last amino acid, Fmoc-
Ser[PO(OBzl)-OH]-OH or Fmoc-Gly-OH, was coupled. Next, the microreactors were 
sorted and distributed into several reaction vessels, and each containing a unique acid 
building block (5.0 eq.), pre-activated with HATU/HOAt/DIPEA (1/1/2 ratio relative 
to the acid). The resins were swelled in DMF for half an hour before coupling. The 
coupling reactions were carried out for overnight at room temperature with shaking. 
At the end of coupling, the microreactors were collected and washed thoroughly with 
DMF and DCM. Final capping was done with a solution of Ac2O (10 eq.), DIPEA (20 
eq.) in DCM , and the reaction mixture was allowed to react for 2 hr at room 
temperature, followed by extensive wash with DCM and DMF.  
 For the C-terminal sub-library (Scheme 6.5), reductive amination was done in 
first step, following previously published procedures.168 PL-FMP resin was swelled in 
DCE for 2 hr. Then DCE was removed, followed by the addition of the amine 
building block (4 eq.) solution in DCE and the reaction mixture was shaken for 2 hr. 
Then HOAc (1%) and Na(OAc)3BH (6 eq.) were added and the reaction mixture was 
shaken for further 16 hr. The reaction was then decanted and the resulting resin was 
extensive washed with THF, MeOH, DCM, and dried in vacuo. The completeness of 
the reaction was monitored by chloranil test. To the resulting resin was added a pre-
activated solution containing Fmoc-Ser[PO(OBzl)-OH]-OH (4.0 eq.), PyBrOP (4.0 
eq.), and DIPEA (8.0 eq.) in DMF. The reaction mixture was shaken overnight at 
room temperature and the resin was washed with DMF and DCM extensively, and 
dried in vacuo. The completeness of the reaction was also monitored by chloranil test. 
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Subsequently the resin was deprotected with 20% piperidine again and ready for next 
coupling cycle. Repeat the cycle using HOBt/HBTU/DIPEA coupling method until 
the last amino acid was coupled. Biotin-GG was attached at the N-terminus of 
peptides for future microarray immobilization. Final capping was done with a solution 
of Ac2O (10 eq.), DIPEA (20 eq.) in DCM , and the reaction mixture was allowed to 
react for 2 hr at room temperature, followed by extensive wash with DCM and DMF.  
 The compound cleavage, microreactors containing of both N- & C-terminal 
sub-libraries were decoded first, then cleaved with a TFA cocktail (95% TFA, 2.5% 
TIS, 2.5% H2O) for 6 hr at room temperature. Following prolonged concentration in 
vacuo until > 90% of cleavage cocktail was removed. Cold ether (chilled to -20 °C) 
was added to the liquid residue to precipitate the peptides. The peptides were allowed 
to precipitate at -20 °C for overnight. The ether layer was discarded and the 
precipitates were dried thoroughly in vacuo. This ether precipitation process was 
repeated for a couple more times. The resulting peptide solids were dissolved in 1 mL 
of DMSO and stored at -20 °C for future use. LCMS was performed to ensure the 
peptides were of correct mass and sufficient purity. Subsequent microarray work was 
carried out directly with these peptides without further purifications. 
6.4 Microarray Work 
6.4.1 Preparation of Avidin Slides 
 25 × 75 mm glass slides (Sigma-Aldrich) were cleaned in piranha solution 
(sulfuric acid/ hydrogen peroxide, 7:3). An amine functionality was incorporated onto 
the slides by silanization using a solution of 3% (aminopropyl)triethoxysilane in 2% 
water and 95% ethanol. After 1-2 hr incubation, the slides were washed with ethanol 
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and cured at 150 °C for at least 2 hr. The resulting amine slides were incubated in a 
solution of 180 mM succinic anhydride in DMF for 30 min before being transferred to 
a boiling water bath for 2 min. The slides were rinsed with ethanol and dried under a 
stream of nitrogen. The carboxylic acid-derivatized slide surface was activated with a 
solution of 100 mM HBTU, 200 mM DIPEA, and 100 mM N-hydroxysuccinimide in 
DMF, thus generating the NHS-derivatized slides. These surfaces were reacted with a 
solution of 1 mg/mL avidin in 10 mM NaHCO3 (pH 9.0) for 40 min, washed with 
water and air dried. The unreacted NHS group was quenched with a solution of 2 mM 
aspartic acid in a 0.5 M NaHCO3 buffer (pH 9.0). These slides were washed with 
water, dried and stored at 4 °C. 
6.4.2 Microarray Preparation for Peptide Aldehyde Library 
 Stock solutions of the peptide aldehydes were prepared to ~1.0 mM in 50% 
DMSO with 50% PBS, and were distributed in 384-well plates. All peptide aldehydes 
were shown to be completely soluble in this spotting solution. Slides were spotted on 
an ESI SMA arrayer (Ontario, Canada) with the printhead installed with four Stealth 
SMP8B Micro-spotting pins (Telechem, U.S.A.). Spots generated were of 
approximately 350 µm diameter and were printed with a spot-spot spacing of 375 µm. 
The pins were rinsed in between samples using two cycles of wash (for 10s) and 
sonication (for 10s) in reservoirs containing 70% ethanol followed by drying under 
reduced pressure (for 10s). The slides were allowed to stand for 2 hr on the printer 
platform and stored at 4ºC until use. Before incubation with the labeled protein, the 
slides were rinsed with PBS (pH 7.4) for 20 min and blocked with PBS containing 




Figure 6.1 The spotting format of the aldehyde microarrays used in Chapter 2. 
Compounds were printed duplicate in horizontal direction. Decoding table see 
Chapter 9. 
 
6.4.3 Protein/Proteome Labeling and Screening on Peptide Aldehyde Microarray 
 Protein/proteome samples were minimally labeled with either Cy5/FITC-NHS 
ester (Cy5: Amersham, G.E. Healthcare; FITC: Pierce, Thermo Scientific) for 1 hr on 
ice, following the manufacturer’s protocols and our previously published 
procedures.50 The non-reacted dye was quenched with a 10-fold molar excess of 
hydroxylamine for a further 1 hr. The excess dye was further removed by buffer 
exchange with a Microcon® centrifugal filter units (Millipore, USA). The labeled 
protein was reconstituted in a final buffer volume of 80 µL PBS (pH 7.4) containing 
1% bovine serum albumin (BSA). In a standard microarray experiment, the labeled 
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protein (vary concentration; 50 µL, 1 mM DTT) was applied under cover slip to the 
array. In a dose dependent experiment for KD measurements, various concentrations 
of the protein (4000 nM to 100 nM) were applied to different sub-arrays on the same 
slide, as previously described.5 The samples were incubated with the array in a 
humidified chamber for 2 hr at room temperature, before repeated rinses with PBST 
(PBS containing 0.05% Tween® 20), typically 3 × 10 min washes with gentle shaking. 
Slides were scanned using an ArrayWoRx microarray scanner installed with the 
relevant filters (Cy3: λex/em = 548/595 nm; Cy5: λex/em = 633/685 nm; FITC: λex/em = 
490/528 nm). 
 For mammalian lysates, cell pellets were thawed on wet ice with 100 µL lysis 
buffer (0.1% NP-40 in PBS) added. Pellet was resuspended, incubated on ice for 15 
minutes then spin at 13,000 rpm at 4°C for 20 minutes. Cleared supernatant was 
decanted to Eppendorf tube, and keep in 4°C. Protein concentration was assessed by 
Bradford assay (Bio-Rad). 
 For P. Falciparum and RBC lysate, the lysate preparation was as below. 
Briefly, P. Falciparum 3C7 strain was used in this study. Parasites were cultured in 
RPMI medium 1640 (Invitrogen, USA) supplemented with 0.29 g of L-glutamine, and 
0.05 g of hypoxanthine dissolved in 1 ml of 1 M NaOH. Parasites were synchronized 
twice 16 hr apart at ring stage using 2.5% sorbitol. Cultures were stored at 37 °C after 
gassing with a 5% CO2, 3% O2 and 92% N2 gas mixture and their hematocrit 
maintained at 2.5%. Parasitized red blood cells were collected by centrifugation and 
treated with 0.1% Saponin in PBS for 15 min at room temperature with shaking. The 
parasites were centrifuged and the pellet was resuspended (in 50 mM sodium acetate 
(pH 5.5), 1 mM DTT, and 0.1% NP-40) and homogenized. The supernatant (infected 
RBC lysates, without parasites) was kept for further microarray study. Protein 
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concentration was assessed by Bradford assay (Bio-Rad). For Trypanosoma Brucei 
(Bloodstream Form, BSF), it was a kind gift from Prof Cynthia He, Deparment of 
Biological Sciences, NUS. The parasites were direct lysed by lysis buffer (50 mM 
sodium acetate pH 5.5, 1 mM DTT, and 0.1% NP-40). Protein concentration was 
assessed by Bradford assay (Bio-Rad). 
 To detect the RBC infection on microarray, four different stages of RBC 
lysates were used. The Cy5 labeled lysate was pre-actived with CaCl2 (20 µM) at 
room temperature for 30 min before apply onto the array. Control experiments were 
done without CaCl2. Lysate concentration was fixed in 0.16 µg/µL during the array 
incubation. 
6.4.4 Microarray Preparation for Peptide-Small Molecule Hybrid Library 
 The peptide-small molecular hybrid library (both N- and C- terminal) stock 
solutions were prepared to ~1.0 mM in 50% DMSO with 50% PBS, and were 
distributed in 384-well plates. Slides were spotted on an OmniGrid® Accent (DigiLab, 
USA) microarray spotter with the printhead installed with four Stealth SMP8B Micro-
spotting pins (TeleChem, USA.). Spots generated were of approximately 350 µm 
diameter and were printed with a spot-spot spacing of 350 µm. The pins were rinsed 
in between samples using two cycles of wash (for 10 s) and sonication (for 10 s) in 
reservoirs containing 70% ethanol followed by drying under reduced pressure (for 10 
s). The slides were allowed to stand for 2 hr on the printer platform and stored at 4ºC 
until use. Before incubation with the labeled protein, the slides were rinsed with TBS 




6.4.5 14-3-3 Protein Labeling and Screening on Peptide-Small Molecule Hybrid 
Library Microarray 
 14-3-3 protein samples were minimally labeled with either Cy3-NHS for 1 hr 
on ice, following the manufactor’s and our previously published procedures. The 
unreacted dye was quenched with a 10-fold molar excess of hydroxylamine for a 
further 1 hr. The excess dye was further removed with a Sephadex G-25 spin column. 
After analysis by DED-PAGE gel to ensure successful labeling and purity, the labeled 
protein was reconstituted in a final buffer volume of 80 µl TBS (pH 7.4) containing 
1% bovine serum albumin (BSA). In a standard microarray experiment, the labeled 
protein (1 µM; 50 µL) was applied under cover slip to the array. In a dose-dependent 
experiment for KD measurements, various concentrations of the protein were applied 
to different sub-arrays on the same slide, as previously described. The samples were 
incubated with the array in a humidified chamber for 2 hr at room temperature, before 
repeated rinses with TBS with 0.05 % Tween® 20, typically 2 × 10 min washes with 
gentle shaking. Slides were scanned using a Tecan LS Reloaded canner installed with 
the relevant filters (Cy3: λex/em = 548/595 nm). 
 
6.4.6 Data extraction and Analysis 
 Microarray data was extracted using the ArrayWoRx or Array-Pro software. 
Values from duplicated points were background subtracted and averaged (Duplicated 
spots with a standard deviation > 0.2 were rejected). The dataset was presented as 




6.4.7 KD analysis of Selected High Binders 
 All peptide aldehydes were spotted onto slide where up to 4 identical sub-
arrays were generated on the same microarray, so as to allow consistent/uniform 
screening and comparison of different protein samples, e.g. Caspases, Rhodesain, and 
cell lysates, to be carried out concurrently on the same platform. Using dose-
dependent experiments, we extracted binding data of Caspase-3/-7 against 26 
potential peptide aldehyde binders. 
 The peptide-small molecular hybrid library was spotted onto the same slide 
where up to 8 identical sub-arrays were generated on the same platform, allowing 
consistent/uniform screening and binding of 14-3-3σ protein. By using dose-
dependent experiments, as previously described50, we extracted the binding data of 
14-3-3σ against five potential binders made of peptide-small molecule hybrids. 
The corresponding KD was generated by fitting the data to the following 
equation, under the assumption that equilibrium is achieved during the incubation 
period: 
 
Saturation dynamics observed when plotting Observed Fluorescence against the 
applied Protein Concentration were then fitted to the above equation using the Graph 
pad Prism software ver 4.03 (GraphPad, San Diego, USA) revealing the binding 




6.4.8 Tyramide Signal Amplification (TSA) Assay 
	   Diluted apoptotic Hela cellular lysates were applied onto microarray slides. 
After incubation, slides were quickly rinsed with deionized water. Primary antibody 
blocking solution was applied onto slides and incubated at RT for 1 h, followed by 
washing step and incubation with the HRP-conjugated secondary antibody. Slides 
were washed 3 × 2 min with PBST (PBS containing 0.1% Tween® 20). TSA kit 
(Invitrogen, USA) was used by following the manufacturer’s recommended protocols. 
6.5 Microplate Screening 
6.5.1 Microplate Screening of Aldehyde Sub-library against Caspase-3/-
7/Cruzain/Rhodesain 
 We performed screening on microplates to evaluate the relative potencies of 
Caspase-3/-7Cruzain/Rhodesain against the library. Assays were performed under 
optimized conditions as previous reported.133,206 The relative potencies of each 
inhibitor were calculated from the normalized data through the following relationship: 
 







6.5.2 Competitive Fluorescence Polarization Assay 
 The 14-3-3σ FP assay was carried out in black 384-well microplates in a total 
volume of 50 µL in each well. For each assay, three basic solutions were prepared. 
The reaction buffer used in the FP assay throughout this study contains HEPES (10 
mM, pH 7.4), NaCl (150 mM), Tween-20 (0.05%), and DTT (0.5 mM). Solution A 
contained a fluorescently labeled, known 14-3-3 binding peptide, TMR-GG-
RLSHpSSLPG-NH2, in the reaction buffer (1.25 × solution with 500 nM of the 
peptide probe or as specified). Solution B contained the 14-3-3σ protein in the 
reaction buffer (1.25 × solution with 5 µM of 14-3-3σ or its serial dilutions, or 
without 14-3-3σ as control). Solution C contained either a peptide-small molecule 
hybrid compound or a small molecular binder (e.g. 2-1 to 2-6) in 5% DMSO/H2O 
(with varied concentrations). Briefly, 10 µL of solution C and 20 µL of solution B 
were mixed and pre-incubated for 30 min at room temperature, then 20 µL of solution 
A was added. After 60 min of incubation at RT, the polarization values were 
measured using an Infinite F200 microplate reader (Tecan, Austria) installed with 2 
pairs of polarizers (λEx: 540 nm; λEm: 590 nm). The competitive effect was expressed 
as the percentage of control. IC50 values were determined from the model with 
nonlinear regression analysis. 
6.5.3 Inhibition Assays against PTPs 
 Phosphatase activity was assayed in black polypropylene flat-bottom 384-well 
microtiter plates (Greiner, Germany) by monitoring the hydrolysis of the fluorogenic 
phosphatase substrate, 6,8-difluoro-methylumbelliferyl phosphate (DiFMUP, 
Invitrogen, USA). For MptpB, an optimized screening concentration of 10 µM was 
used across the entire inhibitor library together with 20 µg of enzyme in 25 µl assays 
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buffered in appropriate MptpB buffer - 25 mM HEPES (pH 7.5) buffer supplemented 
with 0.05 M NaCl, 2.5 mM EDTA, 2 mM DTT 
 
and 0.02 % Triton X-100. The 
enzyme was incubated with each inhibitor at room temperature for 30 min before the 
addition of DiFMUP. The plate were immediately monitored with a BioTek Synergy 
4 fluorescence plate reader (BioTek, USA), at λex = 355 nm and λem = 460 nm for 30 
min.  
 A more comprehensive measurement of inhibitor potencies was carried out 
using the selected inhibitors (~350 members), which gave at least 70% potency at a 
single concentration of 10µM. The IC50 measurements were performed using varying 
concentrations of the inhibitor and keeping the concentration of enzyme and substrate 
constant. In the case of MptpB, a 2-fold dilution series from approximately 25 µM to 
31.25 nM (final concentration) was prepared for representative inhibitors in black 
384-well plates. Substrate, enzyme concentration and all subsequent steps were 
applied as previously described in the above phosphatase assay. The IC50 was 
calculated by fitting the fluorescent outputs obtained by using the Graphpad Prism 
software. Similar method as described above was used to determine the IC50 values 
for the selected purified inhibitors against MptpB as well as a panel of other PTPs 
including PTP1B, TCPTP, YopH and LMWPTP. 
 The Ki measurements were performed by varying both the concentration of the 
substrate and inhibitor while keeping the concentration of the enzyme constant. A 
two-fold dilution series from approximately 4 µM to 0.5 µM (final concentration) was 
set up for each selected inhibitor. Five different concentration of the substrate at 8 
µM, 4 µM, 2 µM, 1 µM and 0.5µM were applied to initiate the reaction after 30 min 
incubation. The reaction was monitored immediately under the kinetic mode at a 60 s 
interval for a period of 5 min using the BioTek Synergy 4 fluorescence plate reader 
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(BioTek, USA), at λex = 355 nm and λem = 460 nm. The best 3 sets of kinetic data 
obtained were used to construct a Dixon plot (1/initial velocity plotted against 
concentration of inhibitor), affording three different linear graphs, each corresponding 
to the different concentration of substrate used. Each of the three linear graphs 
converged onto a point on the horizontal axis to give a direct readout of the Ki value. 
6.5.4 Ca2+-activated Protease Assay 
 Protease activity in normal/infected RBC lysates was assayed in black 
polypropylene flat-bottom 384-well microtiter plates (Greiner, Germany) by 
monitoring the hydrolysis of the fluorogenic substrate, BODIPY FL casein 
(EnzChek® Protease Assay Kits, Invitrogen, USA). The screening concentration of 
0.16 µg/µL was used consistently for all lysate samples in 25 µL assays buffered in 
PBS (pH 7.4, containing 1 mM of DTT with or without 20 µM of CaCl2). The lysate 
was incubated with CaCl2 at RT for 30 min before addition of the substrate. 
Subsequently, the plate was immediately monitored with a BioTek Synergy 4 
fluorescence plate reader (BioTek, USA) at λex = 480 nm and λem = 530 nm. For RBC 
lysates, the lysate preparation was done as below. Normal red blood cells were 
collected by centrifugation and treated with 0.1% Saponin in PBS for 15 min at RT 
with shaking. Parasitized red blood cells were similarly collected. The parasites were 
removed by centrifuge. The supernatant (infected RBC lysates, without parasites) was 
kept for further studies. Protein concentration was assessed by Bradford assay (Bio-
Rad). 
6.5.5 Screening for Inhibition Activity against Caspases 
 The protein caspases activity was determined by measuring the rate of 
hydrolysis of the commercial available fluorogenic substrates (AnaSpec, USA). The 
inhibition of caspases were screened using black polypropylene flat-bottom 384-well 
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microtiter plates (Greiner, Germany) in a total reaction volume of 25µl/well, 
monitored with a Synergy 4 microplate reader (BioTek, USA). Different 
concentrations of inhibitors were used in the assay (200µM - 250nM), where 
necessary. Negative controls were performed in the absence of enzyme and positive 
controls were carried out in the presence of enzyme but without inhibitor. The 
Caspase-1 enzyme was purchased from Merck (Cat# 218783). The Caspase-3 and 
Caspase-7 enzymes were expressed and purified as previously reported133. The assay 
conditions were given below:  
 
Caspase-1:  
Caspase-1 (100U/ml in 1.25× Assay Buffer) = 10 µL 
Substrate Ac-WEHD-AFC (12.5µM in 1.25× Assay Buffer) = 10 µL  
Inhibitor (Varied in 40% DMSO/H2O) = 5 µL  
[Assay buffer (1×) = 100mM NaCl, 50mM HEPES, 10mM DTT, 1mM EDTA, 10% 
Glycerol, 0.1% CHAPS, pH=7.4].  
Caspase-3:  
Caspase-3 (10nM in1.25× Assay Buffer) = 10 µL  
Substrate Ac-DEVD-AFC (12.5µM in 1.25× Assay Buffer) = 10 µL  
Inhibitor (Varied in 40% DMSO/H2O) = 5 µL  
[Assay buffer (1×) = 25 mM PIPES, 250 mM NaCl, 2.5 mM EDTA, 25% Sucrose, 






Caspase-7 (10nM in1.25× Assay Buffer) = 10 µL 
Substrate Ac-DEVD-AFC (12.5µM in 1.25× Assay Buffer) = 10 µL 
Inhibitor (Varied in 40% DMSO/H2O) = 5 µL 
[Assay buffer (1×) = 25 mM PIPES, 250 mM NaCl, 2.5 mM EDTA, 25% Sucrose, 
0.25% CHAPS, 10 mM DTT, pH=7.2].  
 The enzymatic reactions were allowed to incubate at room temperature for 30 
min before being initiated by the addition of substrate, and the reaction was monitored 
at λex = 400 nm and λem = 505 nm, period of 1hr.  
 
6.5.6 IC50 Measurements of Selected Inhibitors against Caspase-1/-3/-7 
 Compounds W2-E1, W2-E2, W2-F6, W3-A2 were identified to be the 
relatively potent ones against Caspase-1. However not they were not potent ones 
against Caspase-3 and Caspase-7, respectively. These four compounds were further 
investigated by the measurement of their IC50 values. The IC50 values were obtained 
using dose-dependent reactions by varying the concentrations of the inhibitor, under 
the same enzyme concentration. Briefly, a two-fold dilution series of an inhibitor, 
from approximately 200µM to 250nM (final concentrations) was prepared. The 
reaction conditions for each enzyme were as listed above. The enzymatic reactions 
were allowed to incubate at room temperature for 30 min before being interrogated 
for end-point fluorescence at λex = 400 nm and λem = 505 nm. The IC50 value was 
calculated by fitting the fluorescence outputs obtained using the Graphpad Prism 




6.5.7 Ki Measurements of Selected Inhibitors against Caspase-1 
 A kinetic evaluation was performed for strongest inhibitors identified – W2-
E1 against Caspase-1. Dose-dependent reactions were carried out by varying both the 
concentration of substrate and inhibitor while keeping the enzyme concentration 
constant. Briefly, a dilution series from approximately 1250 nM to 100nM (final 
concentration) was prepared for W2-E1. The enzymatic mix was incubated for 30 
min before initiating the reaction with varying amount of substrate (312.5 nM~5 µM). 
The enzymatic reactions were immediately monitored at λex = 400 nm and λem = 505 
nm for a period of 10 min. The kinetic data obtained were analyzed using the Dixon 
Plot (1/initial velocity plotted against inhibitor concentration); affording four different 
linear graphs (corresponding to the different substrate concentration) that converged 
on the left of Y-axis to give a value that corresponds to – Ki. 
 
6.6 Cell Culture 
 The human carcinoma epithelial carcinoma cell line Hela was cultured in 
growth media (DMEM supplemented with 10% fetal bovine serum, 100.0 mg/L 
streptomycin, and 100 IU/mL penicillin). Cells were maintained in a humidified 
atmosphere of 5% CO2 at 37 °C. 
 The human lung adenocarcinoma epithelial cell line A549 was cultured in 
growth media (RPMI 1640 supplemented with 10% fetal bovine serum, 100.0 mg/L 
streptomycin, and 100 IU/mL penicillin). Cells were maintained in a humidified 
atmosphere of 5% CO2 at 37 °C. 
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 MDCK (Madin-Darby canine kidney) cells were maintained in DMEM 
containing 10% FBS and 2 mM fresh L-glutamine. Cells were cultured at 37 °C in an 
atmosphere of 5% CO2 and 95% relative humidity. 
6.7 Western Blot 
 To induce apoptosis, Hela cells were incubated with 200 nM of staurosporine 
(STS), for overnight. Cells were detached by cell scraper, washed by cold PBS for 
three times, centrifuged, and keep in -80°C for further usage. Caspase-3, Calpain-1 
and Cathepsin L antibodies were purchased from Abcam®. Briefly, equal amount of 
proteins were loaded and separated by SDS-PAGE and transferred onto PVDF 
membrane, blocked at room temperature for 1 hr using primary antibody blocking 
buffer (containing 0.1% Tween® 20) and incubated with HRP-conjugated secondary 
antibody for 1 hr at room temperature. At the end of this period, blots were washed 
thrice for 10 min each time in TBST (TBS containing 0.1% Tween® 20) and detected 
by chemiluminescence using ECL Plus Western Kit (Amersham, GE Healthcare, 
USA). 
6.8 Small Molecule Competition Studies 
 A549 cells were lysed in 50 mM Tris (pH 7.6) containing 150 mM NaCl, 5 
mM EDTA, 1% (vol/vol) NP-40, 2 mM DTT and 1 × Complete protease inhibitors 
cocktail (Roche, Germany) with the 1 × PhosSTOP phosphatase inhibitors cocktail 
(Roche, Germany). Lysates were incubated with GSH beads containing equal 
amounts of immobilized GST-14-3-3σ or GSH beads alone overnight at 4°C with 
rocking. The beads were washed three times with TBS + 0.5% NP-40, resuspended in 
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sample buffer, and analyzed by SDS-PAGE and immunoblotting. Complexes were 
resolved by SDS-PAGE, transferred to polyvinylidene fluoride (PVDF) membranes, 
and immunoblotted using a monoclonal antibody against p53 (ab26, Abcam), Raf-1 
(ab78330, Abcam), and the phosphoserine 14-3-3 binding motif (#9606, 4E2, Cell 
Signaling Technology). HRP-conjugated secondary antibodies were purchased from 
Pierce and detected by chemiluminescence using ECL Plus Western Kit (Amersham, 
GE Healthcare, USA). 
6.9 Cell Proliferation Assay 
 Cell viability was determined using the XTT colorimetric cell proliferation kit 
(Roche) following manufacturer’s guidelines. Briefly, A549 cells were grown to 20-
30% confluence (since they will reach ~90% confluence within 24 hr in the absence 
of compounds) in 96-well plates under the conditions described above. The medium 
was aspirated, washed with PBS, and then treated, in duplicate, with 0.1 mL of the 
medium containing different concentrations of the hit compound (100 µM) or 
Staurosporine (STS, 200 nM, as a positive control). Compound analogues were 
applied from DMSO stocks whereby the DMSO amount never exceeded 1% in the 
final solution. The same volume of DMSO was used as a negative control. After 
various treatment times, proliferation was assayed using the XTT colorimetric cell 
proliferation kit (Roche) following manufacturer’s guidelines (read at A460nm-A650nm). 





6.10 Flow Cytometry Cell Cycle Analysis 
 A549 cells were plated in 24-well plates at ~50% to 70% confluence and 
starved with basal media for 36 hours in order to induce a G1/S synchronized. Cells 
were incubated with 100 µM of compound 2-5, 1-5 (negative control) or 200 nM STS 
(positive control) for 12 hr. Cells were harvested using trypsin, washed with PBS 
twice, fixed in 70% (v/v) ethanol and stored at -20 °C (for flow cytometry analysis). 
Cell-cycle analysis was carried out by direct cell counting using a GUAVA 
EASYCYTE flow cytometer (Millipore, USA). The cells were washed with PBS 
twice, incubated with propidium iodide (20 µg/mL) and RNase A (100 µg/mL) in 
PBS at 37°C for 30 min, then counted, which allowed high-throughput, absolute cell 
counting. Results were analyzed using the system-installed software. 
6.11 Cell Permeability Assay 
 MDCK cells were passaged at 80-90% confluence (every 3-4 days) using 
Trypsin-EDTA solution (Gibco® #25200). Culture inserts were pre-incubated with 
culture medium (1 hr, 37 °C) and then seeded with 600,000~700,000 cells per cm2 
(0.11 cm2 per well insert, Millipore® #PSHT004R1). MDCK monolayers were 
cultured for 3 days before use. Two hours after feeding, monolayer was washed with 
transport medium (Hanks’ Balanced Salt Solution (HBSS, Gibco® #14025). 
Monolayer was equilibrated in transport medium for 30 min at 37 °C, in 95% 
humidity. Transport assay donor solutions consisted of 50 µM of the test compound in 
transport medium containing 60 µM of Lucifer Yellow (LY) and 1% DMSO. 
Transport assays were conducted using 75 µL of apical (AP) donor solution and 235 
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µL of basolateral (BL) acceptor solution (transport medium, pH 7.4, following 
manufacture descriptions). Monolayer was incubated with donor and acceptor 
solutions for 60 min at 37 °C, 95% humidity. BL and AL compartments were sampled 
at 60 min. The quality control compound set (caffeine and Lucifer Yellow) was 
assayed as a pool under the same conditions as the test compound, using a donor 
solution containing 100 µM of caffeine in transport medium (pH 7.4). All compounds, 
including the quality control compound set, were quantified by HPLC. Lucifer 
Yellow (LY) was quantified using a fluorescence 96-well plate reader (BioTek® 
Synergy 4 fluorescence plate reader at λex = 485 nm and λem = 539 nm). 
 Papp (apparent permeability) values were calculated according to the following 
equation: 
 
where dQ/dt is the permeability rate, C0 is the initial concentration in the donor 
compartment, and A is the surface area of the filter. Permeability rates were calculated 
by plotting the percent of initial AP drug mass (peak area) found in the BL 
compartment versus time and determining the slope of the line. Lucifer yellow (LY) 
results were used as an internal control for each monolayer to verify tight junction 
integrity during the entire assay period. Accordingly, LY Papp values were quantified 
from 60 min basolateral samples after background subtraction. As a quality control, 





6.12 Live Cell Imaging 
A549 cancer cells were cultured in growth media to a confluency of around 
80% and treated with the compounds as above described. Then the cells were 
permeabilized by treatment of 1% digitonin (10% DMSO) for 1 min and washed with 
1 × PBS for three times. Ac-DEVD-SG14 (or mixed with inhibitor, Ac-DEVD-CHO) 
was diluted with Hank's Balanced Salt Solution (HBSS) to 33 µM final concentration 
and added into the cells. The cells were incubated for another 1 hr and washed with 
HBSS for three times. Images were taken by Olympus IX71 inverted microscope, 
equipped with a 60× oil objective (NA 1.4, WD 0.13 mm) and CoolSNAP HQ CCD 
camera (Roper Scientific, Tucson, AZ, USA), as previously descirved.170 The filter 
sets used for Ac-DEVD-SG1 was as follows: SG1: Ex 460–480HQ, dichroic DM485, 
Em 495–540HQ; All images were processed with MetaMorph software (version 
7.1.2.; Molecular Devices, PA, USA). 
6.13 Pull-Down and Mass Spectrometry Identification. 
6.13.1 Pull-Down Assay 
The pull-down assays was carried out with two different ways: (1) with non-
covalent compound, Biotin-GG-DXXD-CHO (coding D10 on microarray) and (2) 
with photo-crosslinking, Biotin-GG-ARFK(Bp)-CHO. 
For non-covalent pull-down, compound D10 (5 µM) was incubated with 
NeutrAvidin™ agarose beads (Pierce, Thermo Scientific) for 2 hr at RT. 
Subsequently, the beads were washed with PBST for 3 times to remove excess 
compound. Then cellar lysates (apoptotic Hela, 5 mg) was incubated with the beads 
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for 1 hr at room temperature in acetic buffer (50 mM sodium acetate pH 5.5), 1mM 
DTT, and 0.1% NP-40). After incubation, beads were washed with PBST (PBS 
containing 0.1% Tween® 20) for 3 times. After washing, the beads were eluted with 
0.1 M NaOH, and boiled in loading buffer (50 mM Tris pH 6.8, 100 mM DTT, 1% 
SDS). This pull-down sample was then separated on SDS-PAGE gel together with 
negative control (pull-down without the probe). 
For photo-crosslinking pull down, cellar lysates (Hela, 5 mg) was incubated 
with probe (5 µM) for 1 hr at room temperature in acetic buffer (50 mM sodium 
acetate pH 5.5), 1mM DTT, and 0.1% NP-40). After incubation, sample was 
irradiated on ice for 30 min using a B100Alamp (UVP) at a distance of 5 cm. After 
irradiation, the mixture was then incubated with NeutrAvidin™ agarose beads (Pierce, 
Thermo Scientific) for 2 hr at RT. Then, the supernatant were removed by centrifuge 
and the beads were washed with 1% SDS in PBS for 4times. After washing, the beads 
were boiled in elution buffer (200 mM Tris pH6.8, 400 mM DTT, 4% SDS). This 
pull-down sample was then separated on SDS-PAGE gel together with negative 
control (pull-down without the probe). 
6.13.2 Mass Spectrometric Analysis 
The LTQ-FT ultra (Thermo Electron, Bremen, Germany) was coupled with an 
online Shimadzu UFLC systems utilizing nanospray ionization. Peptides were first 
enriched with a Zorbax 300SB C18 column (5 mm × 0.3 mm, Agilent Technologies, 
Santa Clara, CA) followed by elution into an integrated nanopore column (75 µm × 
100 mm, New Objective, Woburn, MA) packed with C18 material (5 µm particle size, 
300 Å pore size, Michrom BioResources, Inc.). Mobile phase A (0.1% formic acid, 
H2O) and mobile phase B (0.1% formic acid, acetonitrile) were used to establish the 
90-min gradient comprised of 3 min of 0 - 5 % B, then 52 min of 5 - 30% B, followed 
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by 12 min of 30 - 60% B; maintained at 80% B for 8 min, before re-equilibrating at 
5% B for 15 min. Sample was injected into the MS with an electrospray potential of 
1.8 kV without sheath and auxiliary gas flow, ion transfer tube temperature of 180 °C, 
and collision gas pressure of 0.85 mTorr. A full survey MS scan (350-2000 m/z range) 
was acquired in the 7-T FT-ICR cell at a resolution of 100 000 and a maximum ion 
accumulation time of 1000 ms. Precursor ion charge state screening was activated. 
The linear ion trap was used to collect peptides where 10 most intense ions were 
selected for collisioninduced dissociation (CID) in MS2, which were performed 
concurrently with a maximum ion accumulation time of 200 ms Dynamic exclusion 
was activated for this process, with a repeat count of 1 and exclusion duration of 30 s. 
For CID, the activation Q was set at 0.25, isolation width (m/z) 2.0, activation time 30 
ms, and normalized collision energy of 35%.  
6.13.3 Mass Data Analysis 
The Extract_Msn (version 4.0) program found in Bioworks Browser 3.3 
(Thermo Electron, Bremen, Germany) was used to extract tandem MS spectra in the 
dta format from the raw data of LTQ-FT ultra. These dta files were then converted 
into MASCOT generic file format using an in-house program. Intensity values and 
fragment ion m/z ratios were not manipulated. This data was used to obtain protein 
identities by searching against the corresponding database by means of an in-house 
MASCOT server (version 2.2.03) (Matrix Science, Boston, MA). The search was 
limited to maximum 2 missed trypsin cleavages; #13C of 2; mass tolerances of 10 
ppm forpeptide precursors; and 0.8 Da mass tolerance for fragment ions. Fixed 
modification was carbamidomethyl at Cys residue, whereas variable modifications 
were oxidation at Met residue, and phosphorylation at Ser, Thr or Tyr residues. Only 
131	  
	  
proteins with a MOWSE score higher than 70, corresponding to p < 0.05 were 













 The aim of my doctoral dissertation has been to set up a platform for 
microarray/microplate assistant inhibitor discovery. This platform can be used to (1) 
high throughput identify inhibitors targeting enzymes and profile cellular events, (2) 
study the behavior of inhibitory binders on non-enzymatic protein and (3) profile 
enzyme activity and regulation. A significant part of my work primarily focused on 
the application of microarray for high-throughput identification of inhibitors targeting 
proteases, an often-neglected class of enzymes even though they constitute 1.7% of 
the human genome. In recent years, there has been a major thrust towards regulation 
protease activities in vivo in addition to earlier interests’ in vitro studies. Their 
substrates and interaction network have also been used to identify and validate targets 
for therapeutic intervention including the profiling of inner cellular events. This is due 
to an increasing understanding that proteases play fundamental roles in shaping the 
proteome. Current solution-phase organic synthesis allows identification of inhibitors 
but in a low-throughput manner cannot be readily extended to leads discovery and 
optimization. To overcome this drawback, we adopted solid-phase synthesis of 
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inhibitor library that allows large-scale profiling of proteases and displays their 
fingerprints in different cellular events. 
 In chapter 2, a peptidyl aldehyde library has been developed that enables high-
throughput identification of potent and specific binders of cysteine proteases in 
cellular lysates. From this work, we successfully used microarray platform to detect 
cellular event (apoptosis, Ca2+ dependent protease activity), diagnose pathogen 
infection (P. falciparum), differentiate the sources of pathogen (T. brucei vs. P. 
falciparum), and even distinguish the infection stages of malaria disease. We 
demonstrated the use and applicability of microarray technology for detecting and 
distinguishing complex proteome. The high sensitivity and miniaturized format of 
microarray technology makes it suitable for studies such as large clinical trials where 
thousands of samples may need to be prepared for the expression level of a defined 
set of biomarkers. Microarray can be used for detecting the unusual feature of specific 
proteins present in these samples by generating enzymatic fingerprints, which were 
prepared using corresponding samples arrayed on the microarray. The onerous duty of 
profiling biomarkers for cellular events has been improved with the emergence of 
microarrays. However, there have been limited examples explored by this platform 
for the annotation of biologically relevant interactions. Future work in this area should 
probably use a much more focused library to display unique, reproducible, and 
richness of information for each enzyme/cellular events tested. The platform also 
facilitated the encoding bio-events in a high-throughput manner. Discovering 
functional differences through selective proteome barcode using microarrays will not 
only intensify the understanding of certain proteases in biological systems but also 
further accelerate the detection and determination of related diseases. 
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 Although inhibitor microarray has been developed to profile protease 
fingerprints and cellular events, it is more challenging for the profiling and 
identification of inhibitory binders for those non-enzymatic proteins. In chapter 3, a 
fragment based small molecular microarray has been used to identify inhibitory 
binders targeting 14-3-3 protein family. This work demonstrated that SMM 
constructed with a recognition sequence that targets an entire family of 
phosphoserine/phosphothreonine-binding proteins can be used to effectively identify 
small molecular inhibitory binders that disrupt protin/ligand binding and study 
signaling pathways in cells in a manner that allows temporal control. Through the 
development of inhibitors targeting 14-3-3/ligand interactions, it has been shown that 
14-3-3 proteins are important mediators of survival signals. This suggests that the 14-
3-3 proteins are essential in mammalian cells. This work may have practical 
applications in treatment of diseases involving dis-regulated apoptosis and could also 
aid in the dissection of the function of 14-3-3 in other cellular processes. Although the 
small molecular compounds identified and synthesized in this work have greatly 
improved the non-peptide based inhibitor discovery, they are relatively labile in inner 
cellular level because of the incorporation of phosphoserine. An improved version 
using non-hydrolysable mimic can be studied in the future. Furthermore, this 
chemical biology approach can be directly applied to any modular protein domain that 
recognizes phosphoserine, phosphothreonine or phosphotyrosine residues including 
FHA domains, WW domains, and SH2 domains in addition to 14-3-3 proteins. Thus, 
the SMM coupled with fragment-based screening described here constitutes a class of 
reagents with significant general utility for the molecular dissection of signaling 
pathways within cells.  
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 In chapter 4, a ∼3500-member PTP bidentate inhibitor library was reported to 
screen against Mycobacterium tuberculosis protein tyrosine phosphatase B. From the 
in situ screening of this library, the discovery of the ﬁrst click-based small molecule 
inhibitor against MptpB (Ki) 150 nM), which not only possesses a high speciﬁcity 
(11-to 43-fold) over other PTPs but also represents the most potent inhibitor of 
MptpB known in the literature. The systematic and static analysis of the structure-
activity relationship made possible by our inhibitor library against PTPs may shed 
light on the future development of other bidentate inhibitors against different PTPs. 
 In chapter 5, a 249-member library has been successfully synthesized, 
characterized and screened against caspase family. An efficient and traceless solid-
phase synthesis of azidomethylene derivatives has also been developed. The strategy 
allows facile assembly of azidomethylene warheads with suitable nonpeptide linkers 
as well as a variety of readily available building blocks, all without the need of 
introducing extra functionalities in each of the components. Preliminary results 
indicate selected compounds are indeed moderate caspase inhibitors. This method 
should serve as a useful model for future development of other high-throughput 
amenable chemistry in the emerging field of cysteine protease study. 
 Overall the high-throughput strategies in this thesis demonstrate the global 
evaluation of proteins at various levels and dimensions, contributing insight and 
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Table 9.3 Absolute fluorescent intensity [Fluorescent Intensity – Background 
Intensity] of each member of aldehyde library with pure protein and Hela lysates is 
shown the table below. 
ID 
Pure Protein Hela Cell Lysate 
Casp-3 Casp-7 Rhodesian Cruzain Ca
2+ 
Activition TSA Apoptosis 
A01 34.02 22.61 323.99 49.31 429.56 12.13 24.28 
A02 143.50 140.88 27.60 30.65 74.54 56.65 43.76 
A03 83.83 36.67 33.84 31.60 367.64 32.47 94.09 
A04 129.34 125.25 89.40 47.42 65.17 23.75 29.60 
A05 71.04 38.41 27.00 43.24 428.58 51.70 81.30 
A06 163.62 123.00 36.03 7.43 66.56 44.77 63.88 
A07 45.66 22.03 33.89 53.24 476.17 14.28 55.92 
A08 171.59 126.79 49.95 21.42 74.52 57.88 71.85 
A09 46.30 30.10 34.49 66.31 41.66 14.87 56.56 
A10 134.61 163.94 32.63 37.76 53.96 12.19 34.87 
A11 47.20 33.90 41.46 51.49 468.60 47.88 57.46 
A12 121.14 124.38 28.90 32.02 61.00 43.54 21.40 
A13 40.37 49.61 56.72 643.00 13.69 49.71 90.63 
A14 167.37 156.61 47.51 20.70 68.58 56.54 67.63 
A15 51.83 45.12 356.16 518.28 21.66 47.68 62.09 
A16 130.33 126.04 51.54 38.54 59.72 47.78 30.59 
A17 40.13 40.57 24.98 737.26 17.54 52.87 50.39 
A18 142.13 152.75 28.25 37.12 43.12 11.40 42.39 
A19 36.35 47.01 32.38 30.73 23.17 45.71 46.61 
A20 42.86 53.78 15.58 61.53 53.66 57.08 53.12 
A21 57.36 50.45 45.48 66.79 18.27 56.97 67.62 
A22 143.65 136.00 48.14 32.80 67.95 12.33 43.91 
A23 21.27 46.31 61.46 48.65 36.55 47.81 31.53 
A24 153.79 132.58 34.85 46.19 60.07 46.92 54.05 
B01 26.63 24.36 40.19 46.03 27.23 21.27 36.89 
B02 59.87 49.74 30.89 40.17 408.35 34.34 70.13 
B03 26.26 39.28 61.56 14.77 397.71 21.24 36.52 
B04 59.87 35.70 52.43 56.77 428.90 66.98 70.13 
B05 59.14 31.44 31.18 22.31 417.98 44.28 69.40 
B06 50.22 31.22 30.47 47.57 434.57 32.74 60.48 
B07 56.49 30.28 27.44 13.55 26.53 43.02 66.75 
B08 33.76 49.99 53.77 587.22 57.28 48.77 44.02 




Pure Protein Hela Cell Lysate 
Casp-3 Casp-7 Rhodesian Cruzain Ca
2+ 
Activition TSA Apoptosis 
B10 54.70 33.23 20.32 41.77 439.89 34.16 64.96 
B11 39.56 39.63 13.25 59.35 431.65 60.04 49.82 
B12 62.25 34.66 62.05 552.30 433.93 23.37 72.51 
B13 41.49 36.59 343.63 563.21 23.62 49.38 51.75 
B14 58.32 18.74 28.06 393.99 446.52 53.22 68.58 
B15 44.69 21.38 22.86 42.52 403.47 55.51 54.95 
B16 56.41 46.29 12.24 38.47 39.86 31.61 66.67 
B17 43.91 34.14 351.52 415.45 392.29 58.22 54.17 
B18 65.18 37.73 32.70 219.45 427.19 55.61 75.44 
B19 24.63 25.97 337.99 627.07 414.76 16.87 34.89 
B20 43.12 28.42 438.07 476.68 424.12 44.47 53.38 
B21 48.39 52.01 46.99 42.87 418.87 47.24 98.65 
B22 52.87 50.89 54.12 35.12 418.98 41.01 63.13 
B23 48.21 40.98 28.02 598.19 395.25 53.25 58.47 
B24 53.89 39.58 21.83 227.20 61.86 24.20 64.15 
C01 41.39 24.81 58.10 48.25 13.78 19.52 51.65 
C02 58.76 49.98 48.59 55.92 56.56 19.11 69.02 
C03 46.37 28.31 32.36 656.46 10.89 26.61 56.63 
C04 33.60 53.93 53.04 92.76 53.38 60.04 43.86 
C05 38.17 31.31 49.49 10.11 33.01 15.84 48.43 
C06 376.85 552.94 40.69 90.75 55.57 34.54 211.46 
C07 55.64 47.11 54.95 14.49 22.81 43.06 65.90 
C08 30.33 34.83 44.95 57.35 424.75 45.08 55.20 
C09 58.72 29.18 40.15 39.26 24.86 13.74 68.98 
C10 502.30 641.06 37.38 90.92 50.24 406.97 266.92 
C11 24.97 28.35 13.26 50.63 27.76 10.84 35.23 
C12 33.10 51.32 16.79 50.01 60.70 48.31 57.97 
C13 54.53 33.58 43.52 99.34 49.82 24.51 64.79 
C14 213.68 30.99 26.87 457.41 463.31 36.71 328.30 
C15 51.44 40.41 46.26 43.17 48.06 40.32 61.70 
C16 32.06 21.61 25.07 417.03 78.47 59.36 42.32 
C17 39.72 37.74 27.21 56.91 10.55 19.10 49.98 
C18 31.83 56.94 34.82 440.19 61.17 36.11 42.09 
C19 64.61 51.98 34.53 478.43 22.63 55.05 74.87 
C20 512.74 372.36 42.13 683.12 79.12 345.44 333.00 




Pure Protein Hela Cell Lysate 
Casp-3 Casp-7 Rhodesian Cruzain Ca
2+ 
Activition TSA Apoptosis 
C22 553.46 346.62 46.68 623.19 402.45 485.18 398.07 
C23 51.98 82.72 39.45 34.28 28.29 38.16 62.24 
C24 504.46 350.08 44.47 591.05 450.41 413.15 465.07 
D01 93.26 18.97 428.77 43.51 52.82 15.31 103.52 
D02 326.43 425.25 50.60 38.54 54.23 407.53 86.69 
D03 56.38 32.53 557.89 501.81 30.67 42.93 66.64 
D04 360.75 535.57 43.70 26.60 46.96 34.54 91.01 
D05 30.32 34.83 25.81 21.75 19.33 19.03 40.58 
D06 311.92 520.73 47.03 25.06 54.68 31.35 22.18 
D07 420.65 544.47 34.77 36.49 21.28 212.19 102.91 
D08 651.23 318.38 18.59 425.05 45.91 349.35 255.85 
D09 307.31 444.32 267.82 409.62 13.09 217.88 80.57 
D10 986.65 802.43 52.96 33.33 44.46 303.01 251.27 
D11 401.38 300.59 44.91 33.35 20.42 218.30 254.99 
D12 448.10 307.66 42.61 33.33 423.43 309.16 252.71 
D13 308.43 374.47 237.92 457.54 18.88 292.66 98.69 
D14 38.57 29.73 52.30 683.49 49.41 22.20 48.83 
D15 57.76 50.77 52.63 53.61 19.35 59.62 68.02 
D16 30.11 43.32 59.20 62.76 59.94 14.51 40.37 
D17 316.37 690.88 44.17 439.66 33.84 211.44 186.63 
D18 54.85 49.47 343.23 776.92 44.53 41.95 65.11 
D19 388.98 561.13 477.33 492.26 37.32 237.49 99.24 
D20 785.59 519.02 490.41 234.08 455.34 314.20 463.20 
D21 34.54 14.57 29.39 23.06 18.19 60.18 44.80 
D22 23.03 14.67 57.55 68.98 54.31 57.55 47.90 
D23 607.27 568.32 36.35 311.67 26.17 229.69 271.88 
D24 39.31 45.23 60.41 598.57 51.00 26.45 44.19 
E01 165.22 155.61 33.75 30.95 390.86 35.47 65.48 
E02 160.55 130.51 38.57 42.78 424.71 43.22 60.81 
E03 145.64 114.51 19.68 46.43 476.96 50.26 45.90 
E04 136.52 134.21 17.91 35.57 470.80 58.13 36.78 
E05 149.12 134.61 41.33 13.34 374.00 36.11 49.38 
E06 157.12 162.55 34.06 44.53 413.18 57.85 57.38 
E07 148.91 135.89 15.98 16.72 442.68 57.65 49.17 
E08 134.24 139.53 42.47 33.02 445.08 49.19 34.50 




Pure Protein Hela Cell Lysate 
Casp-3 Casp-7 Rhodesian Cruzain Ca
2+ 
Activition TSA Apoptosis 
E10 145.99 136.32 18.12 21.72 408.76 11.97 46.25 
E11 11.96 49.50 17.56 20.40 408.53 40.73 22.22 
E12 127.59 175.59 21.98 35.90 455.51 41.36 27.85 
E13 177.23 153.86 52.47 33.09 509.62 48.69 77.49 
E14 54.16 44.30 477.00 99.43 39.93 53.66 84.42 
E15 174.97 149.70 23.29 35.24 545.41 15.15 75.23 
E16 58.14 40.15 41.93 87.95 54.96 57.72 88.40 
E17 37.34 31.65 20.83 31.29 395.01 11.84 47.60 
E18 31.14 37.12 52.46 92.48 41.72 47.80 41.40 
E19 423.17 444.54 47.86 30.20 436.36 31.20 93.43 
E20 52.30 41.06 35.38 90.92 50.44 61.97 92.56 
E21 566.11 593.55 49.69 34.24 394.13 402.68 480.72 
E22 42.03 21.13 46.69 83.22 59.39 33.26 92.29 
E23 497.60 614.35 53.92 33.36 434.98 332.04 97.86 
E24 61.91 68.86 52.09 81.43 43.28 31.64 92.17 
F01 53.25 29.11 32.73 35.40 12.72 40.95 63.51 
F02 27.56 62.04 60.18 34.57 50.83 30.77 37.82 
F03 19.78 47.83 29.04 41.43 19.50 46.50 30.04 
F04 39.02 23.19 35.51 20.54 445.45 38.66 49.28 
F05 29.64 52.90 27.57 59.62 55.52 26.71 39.90 
F06 40.04 30.38 49.52 45.77 446.36 21.68 50.30 
F07 58.12 21.42 39.34 33.04 20.37 60.27 68.38 
F08 74.97 39.34 29.97 51.12 447.64 12.44 85.23 
F09 58.42 23.12 49.59 33.09 46.74 23.05 68.68 
F10 46.75 35.37 12.06 43.74 447.51 22.05 27.01 
F11 16.13 54.03 37.87 28.13 18.76 23.53 26.39 
F12 55.87 32.43 47.10 62.17 448.54 20.06 66.13 
F13 55.64 16.36 453.91 486.49 48.88 15.83 65.90 
F14 29.72 44.38 22.37 471.17 448.49 54.90 39.98 
F15 35.85 22.33 33.37 13.19 17.93 50.56 46.11 
F16 58.91 51.58 54.31 30.05 449.33 32.62 69.17 
F17 39.65 25.24 243.18 431.65 48.20 16.60 49.91 
F18 41.24 57.63 24.46 496.71 449.13 47.38 51.50 
F19 44.15 31.48 235.97 419.33 19.50 44.54 54.41 
F20 30.47 19.87 24.94 445.09 450.09 11.09 40.73 




Pure Protein Hela Cell Lysate 
Casp-3 Casp-7 Rhodesian Cruzain Ca
2+ 
Activition TSA Apoptosis 
F22 48.08 50.78 55.55 38.45 449.53 32.33 88.34 
F23 48.44 37.65 28.85 475.06 20.78 15.64 58.70 
F24 70.78 57.56 51.96 541.04 450.18 32.73 71.04 
G01 141.31 143.46 37.54 33.99 43.73 23.52 41.57 
G02 156.01 159.38 49.23 38.24 51.06 23.53 56.27 
G03 125.85 151.32 67.06 44.24 19.61 58.97 26.11 
G04 95.75 51.55 56.08 83.86 54.03 65.38 106.01 
G05 121.03 137.61 49.61 27.57 13.08 57.24 21.29 
G06 60.75 35.58 43.70 56.60 63.16 34.54 91.01 
G07 151.78 150.91 26.19 37.39 25.80 26.19 52.04 
G08 164.53 126.90 30.23 34.33 49.81 55.71 64.79 
G09 164.97 137.81 30.70 30.40 29.73 10.74 65.23 
G10 79.00 50.89 49.57 95.13 49.23 64.60 89.26 
G11 57.27 68.33 36.35 89.21 25.11 54.69 90.53 
G12 44.46 50.44 44.47 93.53 46.51 33.15 94.72 
G13 57.31 44.34 37.82 71.18 33.21 42.88 80.57 
G14 139.92 144.32 19.10 413.38 39.77 11.51 140.18 
G15 143.18 129.30 50.82 28.46 17.33 20.58 43.44 
G16 137.79 120.07 21.73 35.59 50.36 16.65 38.05 
G17 149.65 144.92 41.49 37.98 21.80 16.84 49.91 
G18 154.90 142.35 23.91 46.67 50.01 27.33 155.16 
G19 163.05 160.99 25.94 23.07 22.60 48.29 63.31 
G20 29.46 55.99 415.98 309.81 55.76 57.87 99.72 
G21 154.03 121.28 32.95 38.10 45.22 57.10 54.29 
G22 39.61 86.00 46.65 100.36 47.68 47.02 99.87 
G23 86.65 52.53 51.96 73.33 31.53 58.01 96.91 
G24 68.43 74.47 53.92 56.54 51.86 47.66 90.69 
H01 62.26 30.38 55.37 57.16 20.42 55.47 72.52 
H02 79.94 37.18 52.93 65.47 47.72 47.68 90.20 
H03 93.64 47.37 30.11 40.13 50.13 39.62 103.90 
H04 88.73 30.85 343.86 67.42 77.37 14.46 98.99 
H05 37.42 58.18 61.03 64.25 49.64 46.96 47.68 
H06 20.40 11.53 36.92 59.76 68.63 15.47 30.66 
H07 44.31 37.37 39.67 48.45 17.03 47.67 104.57 
H08 57.68 35.05 52.03 57.63 50.87 11.89 67.95 




Pure Protein Hela Cell Lysate 
Casp-3 Casp-7 Rhodesian Cruzain Ca
2+ 
Activition TSA Apoptosis 
H10 28.75 36.76 51.52 97.10 56.04 39.43 39.01 
H11 54.30 50.04 34.54 54.98 14.61 19.01 64.57 
H12 17.14 50.25 65.23 45.15 49.33 50.62 27.40 
H13 77.62 31.91 63.09 65.32 53.17 15.70 87.88 
H14 77.49 54.28 13.11 61.42 69.72 20.33 87.75 
H15 45.95 13.74 28.07 31.13 31.54 18.30 56.21 
H16 63.21 29.28 245.37 17.50 61.23 14.25 73.47 
H17 35.32 46.78 50.33 32.64 35.62 35.24 45.58 
H18 29.03 56.59 65.12 60.17 53.58 56.34 39.29 
H19 22.36 52.05 39.89 60.41 35.28 64.90 32.62 
H20 51.59 33.73 49.43 54.45 65.08 30.35 61.85 
H21 833.35 850.27 43.57 31.48 32.74 601.47 667.96 
H22 26.44 25.28 444.62 92.99 57.75 29.31 36.70 
H23 400.78 727.27 13.96 33.90 31.84 32.73 121.04 
H24 30.12 47.56 64.44 92.43 48.39 29.19 40.38 
I01 30.48 26.43 64.30 45.92 51.63 41.41 40.74 
I02 45.67 29.41 446.20 50.61 60.09 35.33 55.93 
I03 106.17 50.82 45.99 67.75 25.69 18.75 26.43 
I04 39.05 48.47 48.58 669.57 65.06 18.00 49.31 
I05 17.07 34.84 45.50 45.78 33.55 23.38 27.33 
I06 53.93 16.56 38.83 654.30 48.86 24.03 64.19 
I07 56.41 22.94 45.27 97.98 11.55 30.89 66.67 
I08 92.65 44.27 374.77 439.21 48.83 37.19 102.91 
I09 154.16 72.40 48.00 59.43 33.00 53.66 218.77 
I10 73.45 49.74 81.18 100.17 62.38 46.59 103.71 
I11 33.82 62.95 17.91 48.91 28.93 41.66 44.08 
I12 53.46 56.67 42.68 59.69 48.14 40.18 63.72 
I13 41.73 47.95 39.11 31.12 49.32 58.70 51.99 
I14 36.99 57.95 28.29 502.96 48.80 20.43 47.25 
I15 27.64 26.61 35.27 57.20 48.51 52.09 37.90 
I16 52.15 18.24 540.55 36.87 55.53 57.16 62.41 
I17 29.79 33.43 238.31 42.62 28.17 43.63 40.05 
I18 59.57 57.36 418.66 20.88 65.77 57.46 69.83 
I19 35.36 59.55 31.47 57.37 26.70 45.44 45.62 
I20 45.58 72.86 432.38 694.75 31.02 55.67 55.84 




Pure Protein Hela Cell Lysate 
Casp-3 Casp-7 Rhodesian Cruzain Ca
2+ 
Activition TSA Apoptosis 
I22 412.03 331.13 46.69 33.22 83.16 333.26 91.29 
I23 26.05 15.35 42.37 34.44 26.92 59.26 36.31 
I24 401.91 308.86 50.09 31.42 62.96 31.64 92.17 
J01 47.94 17.68 326.79 437.48 17.50 38.85 58.20 
J02 18.18 19.38 314.57 20.72 60.94 19.24 28.44 
J03 55.75 33.54 427.45 94.58 21.60 52.05 66.01 
J04 21.91 35.91 48.51 37.98 53.40 49.20 32.17 
J05 21.69 27.24 322.91 509.37 13.18 26.90 31.95 
J06 35.54 57.65 215.31 57.87 61.65 27.06 45.80 
J07 26.48 18.63 327.28 372.98 33.49 59.55 36.74 
J08 30.97 44.84 425.29 25.02 49.66 49.76 41.23 
J09 30.34 17.28 22.79 46.98 19.71 46.06 40.60 
J10 50.17 35.19 29.42 67.09 47.88 54.18 60.43 
J11 32.98 50.33 30.10 340.36 13.38 52.91 43.24 
J12 26.42 50.46 340.36 33.68 79.54 50.52 36.68 
J13 52.85 43.24 28.48 54.45 21.02 18.76 63.11 
J14 18.32 45.90 59.08 42.99 61.65 40.71 28.58 
J15 49.54 27.28 30.31 69.52 16.00 46.57 59.80 
J16 58.52 47.41 26.75 27.30 56.11 44.21 68.78 
J17 55.61 21.65 34.64 36.49 36.54 11.41 65.87 
J18 20.81 48.42 49.11 56.23 49.49 50.97 31.07 
J19 34.62 53.04 26.86 52.49 30.70 50.36 44.88 
J20 33.66 49.14 27.59 66.15 54.14 13.96 43.92 
J21 48.38 51.39 61.34 47.52 36.72 37.58 58.64 
J22 50.93 24.79 53.14 37.56 46.42 54.20 61.19 
J23 53.91 23.66 49.87 51.06 21.21 47.35 64.17 
J24 41.55 43.90 53.02 27.46 60.98 59.89 51.81 
K01 51.61 23.28 25.25 51.06 28.14 15.58 61.87 
K02 38.21 34.96 426.32 21.06 65.23 50.22 48.47 
K03 62.55 34.49 51.55 46.53 27.51 52.08 72.81 
K04 38.14 36.42 43.60 42.14 51.89 29.90 48.40 
K05 19.32 40.01 16.16 21.07 27.85 46.62 29.58 
K06 63.08 31.08 23.57 45.79 46.35 20.25 73.34 
K07 86.64 37.11 361.31 22.01 27.99 22.60 96.90 
K08 37.39 50.76 443.55 40.56 43.23 34.45 47.65 




Pure Protein Hela Cell Lysate 
Casp-3 Casp-7 Rhodesian Cruzain Ca
2+ 
Activition TSA Apoptosis 
K10 67.23 56.31 68.09 45.65 53.16 47.69 77.49 
K11 52.01 19.92 59.42 49.12 13.15 47.15 62.27 
K12 47.32 18.43 31.23 59.54 55.72 45.64 57.58 
K13 126.14 52.88 314.69 548.15 13.68 26.51 136.40 
K14 41.44 42.01 22.97 25.89 52.42 20.54 51.70 
K15 54.48 23.68 334.87 680.31 19.93 41.74 64.74 
K16 65.95 34.13 348.03 601.20 55.13 13.64 76.21 
K17 43.46 52.29 421.96 652.03 26.89 53.56 53.72 
K18 51.95 42.49 30.97 53.42 61.89 58.22 62.21 
K19 80.37 39.60 415.38 569.48 16.18 47.74 90.63 
K20 94.82 60.17 20.18 44.81 59.45 46.86 105.08 
K21 23.11 41.26 421.25 617.07 25.49 56.96 33.37 
K22 11.12 14.50 18.42 69.51 67.46 50.28 21.38 
K23 23.83 12.59 51.48 27.64 16.07 53.52 34.09 
K24 50.77 26.76 33.26 25.78 45.88 18.76 61.03 
L01 30.57 43.66 254.87 93.36 48.62 36.15 40.83 
L02 60.95 22.78 67.18 28.55 46.70 40.37 71.21 
L03 52.28 29.01 57.43 10.49 7.66 18.61 62.54 
L04 30.78 58.83 28.55 5.04 35.00 53.09 41.04 
L05 22.58 15.88 95.76 14.88 9.93 18.34 32.84 
L06 31.58 39.85 70.77 69.61 67.59 38.48 41.84 
L07 36.68 32.44 73.27 53.02 29.31 49.63 46.94 
L08 53.87 41.27 69.61 21.67 43.92 48.30 64.13 
L09 57.24 22.19 61.82 64.80 34.81 43.61 67.50 
L10 28.48 46.05 57.32 21.30 44.05 51.07 38.74 
L11 53.06 29.75 64.45 66.20 35.24 30.77 63.32 
L12 69.42 57.91 232.53 55.71 60.37 35.01 79.68 
L13 78.33 22.33 30.24 58.02 31.07 51.11 88.59 
L15 64.58 34.96 29.23 42.88 54.70 21.54 74.84 
L17 73.53 28.93 34.75 55.50 30.07 33.69 83.79 







Table 9.4 Absolute fluorescent intensity [Fluorescent Intensity – Background 
Intensity] of each member of 14-3-3 peptide-small molecule hybrid library at 
designated protein concentration is shown the table below. 
ID 10 µM 7.5 µM 5 µM 1 µM 500 nM 100 nM 
Blank 205.90 248.96 267.28 287.85 308.60 318.16 
Blank 370.55 402.92 434.73 464.05 475.75 477.44 
Blank 310.75 317.93 325.22 363.00 374.52 383.91 
Blank 362.14 402.58 408.09 440.28 486.18 535.28 
Blank 296.50 335.97 365.44 374.55 402.50 427.08 
Blank 231.24 256.30 275.18 305.89 316.25 321.81 
Blank 337.32 378.05 405.32 421.28 469.24 499.66 
Blank 298.65 334.83 379.60 414.03 431.90 459.28 
C-001 206.38 228.18 250.86 287.45 334.92 353.31 
C-002 304.69 346.68 388.29 406.30 455.08 464.97 
C-003 285.49 318.05 360.46 393.83 398.03 422.54 
C-004 396.36 405.28 428.67 454.86 481.01 500.80 
C-005 374.84 417.22 431.86 463.10 508.18 537.44 
C-006 331.26 379.74 426.60 445.88 460.17 509.11 
C-007 29131.08 28844.73 10934.67 6172.54 5454.00 4387.44 
C-008 206.23 207.43 224.14 234.31 284.18 314.86 
C-009 217.88 260.24 283.74 292.09 323.24 350.14 
C-010 30600.77 30387.23 10989.35 5756.76 5027.66 3053.88 
C-011 21648.84 21640.82 10036.67 9063.29 8349.64 5824.48 
C-012 354.70 393.62 419.35 429.54 454.79 499.66 
C-013 277.17 298.51 307.44 324.70 327.21 363.96 
C-014 23531.48 23224.75 8776.70 5665.04 4905.68 3109.09 
C-015 276.29 296.82 345.31 366.12 372.58 417.48 
C-016 30688.79 30191.58 8844.58 8183.01 7341.08 5549.47 
C-017 214.58 220.12 265.13 276.90 284.32 290.37 
C-018 379.20 423.13 426.25 448.34 480.42 495.20 
C-019 301.75 349.29 387.24 406.70 420.83 433.24 
C-020 304.46 308.68 326.80 342.25 391.13 415.72 
C-021 41902.94 41890.87 37203.28 27335.24 9441.76 1901.25 
C-022 233.89 279.07 313.54 331.83 357.75 368.05 
C-023 369.52 413.27 424.22 466.97 484.58 509.60 
C-024 398.96 429.86 442.87 472.07 478.04 510.77 
C-025 295.28 319.43 352.23 375.50 415.88 457.62 
C-026 37278.16 37007.41 10660.39 7936.68 6937.84 4256.64 
C-027 218.48 251.23 261.01 262.44 284.64 304.10 
179	  
	  
ID 10 µM 7.5 µM 5 µM 1 µM 500 nM 100 nM 
C-028 275.37 281.03 326.67 342.66 360.79 391.82 
C-029 247.88 269.26 314.20 319.34 322.02 371.84 
C-030 331.77 331.90 380.22 401.15 433.42 456.37 
C-031 30051.04 29819.94 8734.88 5626.33 4822.66 3445.13 
C-032 37444.13 37191.79 8818.74 8150.43 7430.97 3538.34 
C-033 36527.66 36433.29 19668.21 18781.73 3781.37 3735.68 
C-034 357.43 404.72 451.14 498.40 515.12 547.41 
C-035 249.81 284.63 318.45 335.04 340.31 385.48 
C-036 362.40 377.38 389.21 434.74 473.69 511.90 
C-037 248.27 261.49 273.30 286.50 298.97 312.67 
C-038 265.91 285.94 294.00 335.01 354.99 367.53 
C-039 257.62 263.66 263.87 284.70 299.16 314.33 
C-040 276.89 308.12 348.54 362.35 400.36 424.18 
C-041 263.81 313.59 314.11 348.58 378.36 413.69 
C-042 382.03 408.88 455.19 501.36 514.63 531.93 
C-043 281.94 292.57 335.30 353.88 365.92 379.97 
C-044 217.20 239.89 241.05 243.01 259.08 272.81 
C-045 209.92 239.44 250.78 266.45 280.59 302.65 
C-046 26036.21 25674.11 8875.48 5670.40 4878.92 3457.06 
C-047 252.77 267.10 267.88 316.31 326.80 345.09 
C-048 311.89 331.06 361.50 407.68 431.77 432.47 
C-049 33954.03 33762.17 8970.87 6581.41 5965.89 3523.27 
C-050 298.36 337.02 347.88 371.88 380.36 394.89 
Ctrl- 362.48 380.05 406.06 421.97 458.21 460.25 
Ctrl- 303.22 326.92 371.12 413.82 449.35 487.57 
Ctrl- 296.29 321.31 358.75 378.51 393.35 429.22 
Ctrl+ 56528.49 46433.46 30668.11 18781.33 8781.23 5735.31 
Ctrl+ 59363.17 46802.47 34426.88 21898.79 8924.15 8280.61 
Ctrl+ 56834.18 49512.91 33836.76 21589.64 8971.84 5750.90 
Ctrl+ 60393.83 49095.58 33102.32 21736.59 10988.05 6182.51 
Ctrl+ 60304.75 47126.24 32419.12 20023.20 11084.83 5830.39 
Ctrl+ 56700.60 49261.46 34160.84 20732.41 10051.22 9147.87 
Ctrl+ 59760.71 50094.31 34413.44 19639.18 9041.78 6591.76 
Ctrl+ 60165.48 49105.14 34482.55 19327.15 10667.78 7946.09 
N-001 242.91 245.51 259.42 270.22 281.25 327.71 
N-002 247.43 285.72 328.30 361.22 397.56 446.95 
N-003 293.34 318.55 338.12 352.37 389.41 394.41 
N-004 313.12 360.77 390.18 425.45 460.10 491.02 
180	  
	  
ID 10 µM 7.5 µM 5 µM 1 µM 500 nM 100 nM 
N-005 270.50 289.15 301.09 317.83 341.16 361.88 
N-006 267.99 297.86 320.73 321.02 326.05 339.49 
N-007 248.80 296.74 325.95 343.17 364.30 388.09 
N-008 242.27 290.86 303.51 332.27 372.72 418.48 
N-009 398.86 414.79 446.87 473.27 493.29 530.66 
N-010 282.23 323.18 342.22 356.48 363.33 370.27 
N-011 381.66 395.98 410.66 436.73 462.72 487.03 
N-012 248.64 251.98 294.39 306.96 323.15 350.73 
N-013 275.02 295.73 341.81 346.73 389.19 416.62 
N-014 217.96 258.48 299.64 308.50 309.26 341.54 
N-015 204.50 239.16 275.35 312.99 340.15 365.91 
N-016 290.20 300.55 309.61 328.58 342.50 343.88 
N-017 301.54 320.58 361.68 365.15 397.38 406.85 
N-018 332.06 336.70 337.30 378.54 423.86 449.37 
N-019 359.10 379.11 388.75 394.40 442.11 457.41 
N-020 330.92 332.58 381.91 418.26 450.97 472.68 
N-021 304.42 324.94 363.58 394.62 415.71 421.52 
N-022 217.01 240.42 255.73 301.15 334.94 349.53 
N-023 308.65 352.07 353.48 372.37 378.33 385.28 
N-024 395.23 410.49 453.04 474.99 491.54 534.79 
N-025 290.17 317.91 328.00 363.94 390.38 428.16 
N-026 377.79 401.33 435.24 460.60 475.01 499.70 
N-027 277.62 307.72 313.14 315.39 315.65 359.02 
N-028 261.52 304.73 310.47 357.81 372.86 389.16 
N-029 380.45 390.96 430.01 443.26 479.97 515.76 
N-030 307.56 320.83 350.00 358.12 388.04 392.41 
N-031 345.58 376.59 403.59 444.28 463.43 508.67 
N-032 263.72 264.93 290.53 331.88 358.63 377.30 
N-033 374.10 407.74 457.56 507.34 554.33 596.57 
N-034 317.88 367.72 397.87 424.01 430.25 435.73 
N-035 273.10 296.64 336.78 355.14 377.58 379.14 
N-036 344.64 392.70 415.59 416.25 447.00 466.73 
N-037 207.66 226.70 250.02 271.25 311.75 319.84 
N-038 376.38 413.14 428.33 461.87 489.81 539.57 
N-039 270.10 303.82 316.15 330.55 364.03 388.53 
N-040 221.38 263.81 275.31 304.96 312.08 336.58 
N-041 324.96 364.38 370.64 398.86 440.27 444.13 
N-042 201.59 233.93 276.98 298.00 333.00 365.83 
181	  
	  
ID 10 µM 7.5 µM 5 µM 1 µM 500 nM 100 nM 
N-043 201.67 221.55 231.83 244.00 291.42 296.61 
N-044 250.04 269.14 275.42 285.34 329.72 343.54 
N-045 326.27 368.46 388.09 434.17 467.42 471.90 
N-046 302.90 324.32 338.88 341.11 347.04 370.57 
N-047 317.23 318.02 340.46 382.23 387.21 408.95 
N-048 255.14 262.83 303.92 345.16 364.91 366.28 
N-049 234.01 259.56 261.06 273.96 278.00 313.14 
N-050 365.45 414.07 414.85 457.44 480.20 498.38 
N-051 299.68 309.93 358.77 373.01 377.03 422.25 
N-052 350.96 396.10 406.18 412.93 455.44 490.36 
N-053 283.51 326.89 352.20 382.95 432.76 436.44 
N-054 243.06 284.35 322.27 365.04 400.17 420.03 
N-055 287.12 312.71 353.22 379.86 421.80 454.57 
N-056 347.37 356.66 377.01 389.34 438.27 452.55 
N-057 201.38 234.61 271.09 313.67 351.88 357.74 
N-058 339.48 381.91 398.56 404.61 439.14 455.97 
N-059 310.30 327.47 359.19 393.46 425.76 454.40 
N-060 339.30 363.27 372.93 388.46 417.84 465.12 
N-061 316.88 320.90 345.97 379.78 399.04 400.77 
N-062 259.61 267.00 311.57 314.58 353.11 356.33 
N-063 311.49 326.39 332.69 351.59 381.48 402.35 
N-064 241.35 275.50 283.58 291.69 328.95 356.14 
N-065 215.09 241.30 244.28 266.05 277.72 325.80 
N-066 380.53 393.94 405.88 405.92 407.92 438.15 
N-067 267.99 277.31 308.17 331.86 337.60 359.76 
N-068 286.73 287.90 312.11 314.00 320.21 323.78 
N-069 249.71 274.41 276.02 303.35 312.36 321.22 
N-070 300.08 305.30 354.80 385.89 392.87 399.42 
N-071 276.66 313.92 330.33 349.83 378.55 393.22 
N-072 264.59 295.76 345.74 368.29 400.23 416.42 
N-073 335.64 341.54 367.19 407.83 445.57 492.46 
N-074 213.98 258.34 262.08 306.97 331.58 332.41 
N-075 321.82 333.47 345.12 362.88 385.07 428.41 
N-076 287.31 331.08 344.67 369.36 400.31 405.16 
N-077 294.24 332.15 358.34 391.32 441.07 473.26 
N-078 286.90 289.49 293.20 311.61 354.81 403.41 
N-079 326.84 343.21 360.94 379.45 380.47 395.94 
N-080 218.51 231.83 251.77 297.70 298.80 311.79 
182	  
	  
ID 10 µM 7.5 µM 5 µM 1 µM 500 nM 100 nM 
N-081 263.77 309.92 355.63 397.84 418.40 422.70 
N-082 325.07 351.38 361.26 361.36 364.75 399.13 
N-083 212.03 257.39 270.96 298.35 333.05 340.97 
N-084 276.15 305.41 332.79 358.11 376.82 399.96 
N-085 367.17 376.02 395.50 440.46 486.83 525.50 
N-086 300.87 327.16 367.24 414.95 418.08 464.97 
N-087 256.24 265.81 310.54 333.15 340.19 363.60 
N-088 250.84 298.45 320.31 354.64 389.61 397.32 
N-089 229.02 261.53 278.81 308.52 341.93 389.60 
N-090 247.83 249.23 258.51 295.09 295.74 296.75 
N-091 385.82 435.18 483.07 497.83 544.98 593.27 
N-092 240.58 256.55 276.79 324.17 325.52 370.20 
N-093 363.06 377.56 407.49 445.12 446.82 478.56 
N-094 323.38 356.14 400.54 402.67 431.37 434.23 
N-095 351.86 387.61 406.58 433.37 474.31 503.73 
N-096 382.68 415.46 430.71 440.86 461.60 493.61 
N-097 248.70 290.52 328.44 363.67 363.73 406.75 
N-098 319.32 348.42 375.50 410.33 413.61 417.13 
N-099 367.94 400.95 406.60 429.03 454.40 457.40 
N-100 393.93 404.30 411.03 457.48 477.29 488.63 
N-101 242.18 258.98 300.34 350.00 377.96 381.35 
N-102 396.25 431.29 478.81 528.16 565.76 603.68 
N-103 217.32 264.41 289.93 309.93 316.67 335.92 
N-104 340.68 389.90 433.01 445.09 465.65 511.89 
N-105 371.45 393.69 412.22 423.59 454.29 502.42 
N-106 277.62 306.93 351.33 352.12 377.94 396.25 
N-107 220.13 253.22 257.65 275.64 290.28 323.26 
N-108 307.16 344.47 354.60 385.73 410.84 417.05 
N-109 271.99 319.29 334.18 371.90 394.05 439.62 
N-110 340.76 373.93 418.42 427.62 435.96 446.14 
N-111 41496.07 41213.32 37196.66 27835.69 9715.84 1836.15 
N-112 355.99 393.54 422.12 434.38 439.45 452.75 
N-113 339.73 346.26 395.74 406.34 440.79 451.86 
N-114 225.86 240.77 285.44 326.02 357.64 395.28 
N-115 390.31 407.35 423.01 451.04 481.98 510.88 
N-116 211.72 216.54 245.73 295.11 318.78 319.94 
N-117 388.54 436.19 445.13 459.63 488.41 515.01 
N-118 354.79 376.09 391.36 408.11 455.33 491.92 
183	  
	  
ID 10 µM 7.5 µM 5 µM 1 µM 500 nM 100 nM 
N-119 346.37 353.19 385.99 402.78 430.54 457.90 
N-120 353.18 392.57 413.45 450.54 482.36 504.97 
N-121 237.40 263.90 276.59 281.59 326.59 348.93 
N-122 386.96 393.86 439.43 444.84 446.94 456.26 
N-123 233.94 278.66 299.17 320.54 332.72 345.26 
N-124 398.33 435.30 445.24 476.25 493.10 514.22 
N-125 387.02 414.50 439.13 462.01 503.74 513.61 
N-126 259.09 301.26 306.46 344.82 367.64 380.61 
N-127 320.36 341.63 363.42 388.99 434.02 465.30 
N-128 363.90 381.91 382.07 395.25 424.31 473.04 
N-129 232.66 247.57 279.42 302.96 349.47 377.14 
N-130 230.43 256.10 278.42 294.38 318.60 355.55 
N-131 308.47 347.46 391.97 393.72 410.78 428.02 
N-132 302.69 329.24 373.06 407.12 449.93 472.96 
N-133 380.99 387.24 403.51 418.56 422.43 454.38 
N-134 246.62 274.77 293.29 301.50 348.42 366.88 
N-135 262.69 296.71 298.35 299.88 348.17 396.78 
N-136 267.76 287.10 300.01 324.19 355.43 391.76 
N-137 308.12 310.62 313.07 327.51 336.62 380.85 
N-138 246.06 263.32 296.11 324.54 330.17 338.08 
N-139 205.53 218.72 222.56 245.30 255.34 285.42 
N-140 276.77 287.52 330.87 348.87 367.96 390.30 
N-141 253.75 284.75 306.48 324.06 330.61 379.20 
N-142 330.13 334.52 346.80 379.48 389.05 400.45 
N-143 315.18 348.18 348.88 385.30 404.97 421.49 
N-144 252.18 301.25 313.22 314.60 340.54 356.97 
N-145 203.09 226.02 240.86 258.04 261.75 290.27 
N-146 232.03 233.11 244.76 258.12 266.45 315.19 
N-147 397.55 414.20 436.81 485.75 523.62 537.98 
N-148 201.29 223.48 259.25 287.92 310.12 326.37 
N-149 252.10 280.00 300.90 310.48 338.42 377.19 
N-150 215.84 260.69 261.94 273.06 304.77 332.93 
N-151 267.42 295.11 304.35 308.88 336.42 377.22 
N-152 328.11 367.73 384.38 427.43 451.77 452.06 
N-153 342.47 379.56 405.75 428.22 430.78 444.02 
N-154 316.06 339.77 362.12 402.46 450.17 494.72 
N-155 209.98 251.22 294.85 344.11 366.19 380.57 
N-156 249.38 287.60 329.38 366.67 407.68 417.35 
184	  
	  
ID 10 µM 7.5 µM 5 µM 1 µM 500 nM 100 nM 
N-157 265.91 272.31 304.21 309.81 323.66 359.10 
N-158 242.99 247.81 265.61 273.00 290.33 300.72 
N-159 361.28 402.89 429.71 472.71 514.57 559.88 
N-160 202.97 235.39 275.92 314.06 338.89 365.68 
N-161 361.10 395.60 444.98 461.39 497.46 525.19 
N-162 353.35 367.95 403.45 434.40 468.76 468.79 
N-163 253.01 269.14 273.12 314.07 361.11 392.28 
N-164 359.36 404.49 416.79 454.42 458.52 503.78 
N-165 354.57 384.18 392.51 425.50 442.15 464.05 
N-166 311.60 337.59 369.35 385.24 414.72 445.36 
N-167 353.82 396.63 415.07 464.67 511.47 526.25 
N-168 228.76 234.37 271.73 275.98 278.00 300.51 
N-169 280.73 319.21 320.15 350.54 398.57 411.69 
N-170 250.37 281.89 305.99 322.35 371.21 397.41 
N-171 355.88 357.18 405.08 439.11 441.12 466.73 
N-172 335.56 341.63 365.88 389.04 391.40 407.12 
N-173 301.56 335.52 341.61 373.17 401.59 404.60 
N-174 201.47 224.74 268.27 277.62 312.83 339.69 
N-175 386.17 418.00 445.02 466.91 491.55 498.50 
N-176 381.06 390.04 390.31 416.10 461.57 481.49 
N-177 375.51 391.67 423.36 439.91 487.73 524.09 
N-178 253.71 292.10 339.44 370.85 415.13 429.45 
N-179 360.75 398.76 404.12 438.96 466.71 506.23 
N-180 32491.21 32456.50 25960.59 17364.26 7246.08 2187.08 
N-181 396.08 431.90 444.78 489.41 502.86 515.32 
N-182 364.73 400.52 431.84 441.37 455.37 491.84 
N-183 351.17 386.12 400.31 422.02 448.53 476.85 
N-184 314.07 317.32 350.13 395.41 442.06 486.62 
N-185 318.52 336.85 377.80 387.15 431.14 451.97 
N-186 334.45 344.02 356.46 402.03 439.16 450.20 
N-187 202.62 232.86 273.46 276.78 311.96 320.50 
N-188 302.19 346.89 370.89 379.27 408.74 451.73 
N-189 273.76 317.26 336.59 362.42 405.70 451.59 
N-190 264.98 294.87 332.33 357.10 392.91 420.43 
N-191 384.86 405.70 454.06 475.19 506.58 548.29 
N-192 354.13 393.79 425.53 465.22 476.45 514.54 
N-193 350.84 380.28 419.35 437.51 472.40 500.47 
N-194 384.85 430.58 475.05 510.62 548.70 551.05 
185	  
	  
ID 10 µM 7.5 µM 5 µM 1 µM 500 nM 100 nM 
N-195 255.52 293.36 324.88 361.69 411.44 430.48 
N-196 282.58 324.91 344.41 372.70 384.26 416.70 
N-197 379.73 423.33 432.29 476.37 489.48 509.88 
N-198 229.21 266.80 297.45 299.33 337.13 354.85 
N-199 262.12 277.90 300.73 303.67 319.91 366.92 
N-200 211.81 217.41 218.17 228.15 274.80 299.40 
N-201 239.71 257.18 291.07 315.08 316.31 318.55 
N-202 346.37 359.70 393.75 417.25 423.09 463.07 
N-203 363.48 371.22 406.34 448.61 473.71 487.24 
N-204 232.57 250.92 287.46 313.10 342.99 351.67 
N-205 269.42 284.70 303.56 312.66 340.60 355.01 
N-206 359.41 403.19 443.37 450.44 451.39 467.90 
N-207 326.42 369.95 400.76 438.57 468.17 483.53 
N-208 216.03 255.20 263.50 299.37 306.42 326.39 
N-209 347.25 350.31 360.13 362.46 365.45 406.34 
N-210 355.03 367.16 377.67 403.14 428.30 434.26 
N-211 205.97 239.86 255.42 272.26 314.16 349.51 
N-212 356.93 370.05 395.40 423.40 470.23 482.35 
N-213 344.86 368.22 391.06 408.14 434.00 434.11 
N-214 239.05 259.79 306.13 314.99 358.29 377.68 
N-215 305.49 329.94 333.07 370.80 395.50 398.46 
N-216 300.68 306.06 331.40 334.70 384.65 416.43 
N-217 309.71 323.24 341.90 355.63 358.09 367.50 
N-218 204.44 220.82 226.45 238.20 254.57 301.44 
N-219 212.17 225.60 271.47 296.66 338.77 365.61 
N-220 290.09 293.50 342.04 360.65 404.06 423.95 
N-221 223.59 254.21 264.59 276.11 302.68 324.80 
N-222 340.50 359.74 379.20 426.13 434.06 457.45 
N-223 301.34 320.25 321.33 330.11 359.71 391.27 
N-224 268.74 294.94 318.07 322.28 335.90 371.33 
N-225 315.73 338.10 350.57 367.94 410.63 434.02 
N-226 365.40 383.89 407.92 457.17 457.48 493.60 
N-227 233.16 275.88 309.05 311.99 342.49 344.49 
N-228 212.08 246.40 261.07 261.34 261.60 310.55 
N-229 342.16 382.18 424.95 444.17 449.41 464.07 
N-230 243.38 283.71 323.69 341.00 374.31 394.04 
N-231 39867.70 39474.10 37964.36 29626.71 8709.77 1869.80 
N-232 309.11 321.76 341.93 356.76 361.81 383.36 
186	  
	  
ID 10 µM 7.5 µM 5 µM 1 µM 500 nM 100 nM 
N-233 375.65 407.15 414.65 427.74 429.24 463.90 
N-234 350.71 390.66 436.96 441.06 468.71 469.48 
N-235 248.72 262.92 298.34 306.22 331.69 366.72 
N-236 399.43 441.77 451.19 461.21 506.43 551.03 
N-237 304.88 313.41 349.75 395.66 404.52 414.15 
N-238 200.94 203.72 244.06 274.25 313.92 330.14 
N-239 344.79 388.13 390.48 392.90 426.84 442.23 
N-240 275.36 300.54 313.47 349.75 381.17 428.11 
N-241 261.19 275.70 321.55 364.63 404.69 422.13 
N-242 386.66 389.46 400.59 445.03 483.72 531.75 
N-243 373.00 411.70 451.09 499.46 536.60 544.86 
 
 
9.2 Supplemental Spectra 
9.2.1 LC-MS Profiles of DEVX-CHO Sub-library 
H21. Biotin-G-G-DEVD-CHO 






































































































































































9.2.3 NMR Spectra of Compound (1-1 to 2-6) 
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